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Recent breakthroughs in nanotechnology have paved the way for a new era in cancer 
medicine. Among the myriad of nanotechnology-based systems that have been 
revolutionizing the field of cancer nanomedicine, porous silicon (PSi) nanoparticles have 
recently emerged as a promising nanoplatform, owing to advantageous physicochemical and 
biological properties. Nevertheless, the successful establishment of PSi nanoparticulate 
systems as effective cancer nanomedicines is challenged by several shortcomings associated 
with the instability in biological fluids, the poor tumour targeting efficiency and 
unfavourable pharmacokinetics, the limited capacity to overcome extra and intracellular 
biological barriers, and the ubiquitous and uncontrolled release of the therapeutic payloads. 
This dissertation aimed at designing and developing novel strategies, including the 
surface modification of PSi nanoparticles with biofunctional polymers and the engineering 
of advanced multifunctional PSi-based nanocomposites, in order to overcome some of the 
aforementioned deadlocks, improving the tumour targeting and drug delivery efficiencies, 
and ultimately potentiating the application of PSi nanomaterials in cancer nanomedicine. 
First, the biofunctionalization of PSi nanoparticles with a hyaluronic acid (HA) 
derivative was proven to improve the colloidal and plasma stabilities and to significantly 
enhance the cellular internalization of the nanosystems in breast cancer cells. The HA-
modified PSi nanoplatforms exhibited higher affinity and endocytic activity in the cells 
overexpressing the CD44 receptor, thus evidencing a great potential for further development 
as active targeted drug delivery systems to CD44-overexpressing tumours. 
Next, a bilayered zwitterionic PSi nanocomposite was fabricated by successive 
conjugation of poly(ethyleneimine) and poly(methyl vinyl ether-alt-maleic acid) polymers 
on the surface of PSi nanoparticles. In addition to satisfactory cytocompatibility, and high 
colloidal and plasma stabilities, the designed polymeric surface modification was shown to 
enhance the non-specific cellular association and uptake, and to improve the intracellular 
trafficking of the PSi nanoparticles in breast cancer cells. Moreover, this strategy contributed 
to increase the drug loading of methotrexate (MTX), sustain the release of the drug and 
potentiate the in vitro antiproliferative effect of the MTX-loaded PSi nanocarriers. 
In addition, PSi nanoplatforms were used to engineer multifunctional PSi-based 
nanocomposites, envisioned for cancer therapeutic and theranostic applications. In one 
approach, both sorafenib-loaded PSi and gold nanoparticles were simultaneously 
encapsulated into a self-assembling polymeric nanocomplex. In another study, the same 
nanocomplexes were used to encapsulate DNA-capped PSi nanoparticles, as an innovative 
strategy to bioresponsively deliver hydrophilic and hydrophobic drug molecules into the 
cytosolic compartment of cancer cells. The potential of the fabricated multifunctional PSi-
based nanocomposites stemmed from the versatility to incorporate a combination of 
nanosystems, hydrophilic or hydrophobic drug molecules, and fluorescent dyes within a 
single nanostructure, and the capability to enhance the cellular interactions, endocytosis and 
cytoplasmic delivery of the encapsulated nanoparticles and therapeutics. 
In conclusion, the developed PSi-based nanocomposites exhibited great potential for 
cancer targeting and drug delivery, representing an advanced contribution for the successful 
implementation of PSi nanomaterials as the next generation of cancer nanomedicines. 
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Cancer still stands as a global burden and one of the leading causes of morbidity and 
mortality worldwide. The World Health Organization (WHO) estimated that 32.6 million 
cases, 14.1 million new cancer cases and 8.2 million cancer deaths occurred globally in the 
year 2012.1 The same demographic and epidemiologic report pointed out to lung cancer as 
the most frequent and mortal cancer in both men and women, owing to the high fatality rate, 
followed by breast cancer as the second most common cancer overall. Although breast 
cancer presents a substantially higher incidence in women comparatively to other cancer 
sites, its mortality rate is significantly lower due to the relatively favourable prognosis. 
Colorectal, prostate, stomach and liver cancers complete the list of six cancer types with 
higher incidence, which represent more than 50% of the global burden.1 
In general, cancer defines a group of diseases that progressively evolve from the initial 
genetic mutation of normal cells into tumorigenic cells, which are characterized by a rapid 
and uncontrolled proliferation, ultimately leading to the formation of a malignant tumour. In 
advanced pathological stages, some malignant cells can acquire the capacity to penetrate the 
lymphatic or blood circulation and, consequently, invade and replicate in other organs, 
originating secondary or metastatic tumours.2 The multistage and complex process of tumour 
pathogenesis is highly dependent on the interaction between individual’s factors (i.e., genetic 
factors and ageing), lifestyle factors (e.g., nutrition, tobacco consumption and physical 
activity), and the exposure to external factors, including physical (e.g., ultraviolet and 
ionizing irradiation), chemical (e.g., asbestos, food and water contaminants) and biological 
(e.g., viral, bacterial and parasitic infections) carcinogenic agents. Therefore, modifying or 
avoiding these risk factors can contribute to a significant reduction of the cancer incidence 
and prevalence. In addition, the screening and early diagnosis of cancer can play a 
determinant role on treatment’s response and effectiveness and, consequently, on the patient 
survival rates and reduction of the global burden of cancer.3 
The current clinical treatment of cancer diseases generally relies on local interventions, 
including surgery and radiotherapy, chemotherapy, alternative therapeutic approaches, such 
as targeted therapy and immunotherapy, or a combination of these therapeutic modalities. In 
principle, the administration of potent chemotherapeutic regimens to oncological patients 
can have effective therapeutic outcomes on tumour ablation, by pharmacologically targeting 
the molecular mechanisms and hallmark capabilities of mutant cells involved in the 
tumorigenic process.2 However, the non-specific delivery and ubiquitous biodistribution of 
the chemotherapeutic drugs also induces cytotoxicity to normal cells, consequently resulting 
in severe damages on healthy tissues and organs, and deleterious adverse effects to the 
patients. Another complication arising from multiple chemotherapeutic cycles, which may 
significantly impair the therapeutic efficacy of anticancer drugs, is the development of 
multidrug resistance (MDR) mechanisms by the tumour cells.4,5 A common approach to 
overcome cancer MDR, while maximizing the efficacy and minimizing the off-target side 
effects of chemotherapy, consisting on the combined administration of anticancer drugs with 
complementary mechanisms of action.6,7 In addition, from the perspective of pharmaceutical 
development, the formulation and delivery of chemotherapeutics to the pharmacological 
target in the optimal dose range, can be considerably challenged by the intrinsic 
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physicochemical properties of these drug molecules, particularly when considered for 
combination chemotherapy. On one hand, the majority of drugs currently in clinical use or 
in drug development for cancer treatment are hydrophobic, thus presenting low solubility 
and tendency to aggregate in the aqueous biological fluids and, consequently, requiring the 
use of organic solvents to solubilize them prior to administration.8,9 On the other hand, 
hydrophilic drug molecules, including biomacromolecules (e.g., peptides, proteins and 
nucleic acids), suffer from limited capacity to overcome biological barriers, lability to  
proteolytic and hydrolytic degradation and short circulatory half-life.10 Therefore, there is 
demanding need to develop new therapeutic approaches that circumvent the abovementioned 
inherent limitations of conventional chemotherapeutic drug formulations. 
Recent exciting breakthroughs in nanotechnology have promised to revolutionize the 
current paradigms of cancer therapy and diagnostics, paving the way for a new era in cancer 
medicine.11-14 In fact, a first generation of cancer nanomedicines has already been approved 
for clinical use, while numerous others are currently under clinical or pre-clinical evaluation, 
with successful outcomes expected in a foreseeable future.14,15 In general, the tremendous 
potential of cancer nanomedicine stems from: (1) improving the therapeutic index of 
therapeutics by maximizing the efficacy and/or mitigating the toxicity; (2) refining the 
intrinsic properties of drug molecules, such as solubility, stability, and blood circulation half-
life; (3) enhancing the delivery of the therapeutic drugs and biomacromolecules to the 
intracellular site of action at increased dose; (3) targeting the delivery of therapeutics to 
specific tissues, cells or intracellular compartments; (4) enabling a controlled, sustained 
and/or stimuli-responsive drug release; (5) co-delivering multiple drugs for combination 
therapy with individual spatiotemporal control over the drug release profiles, significantly 
improving the therapeutic efficacy and overcoming MDR; (6) increasing the sensitivity of 
cancer diagnostic and imaging agents; and (7) integrating both drug molecules and imaging 
agents into a single platform for simultaneous therapeutic and diagnostic modalities (i.e., 
theranostics) and/or for the real-time readout of the therapeutic efficacy.13,14 
Over the past few decades, porous silicon (PSi) nanoparticles have been highlighted 
and demonstrating tremendous potential for biomedical applications, with particular focus 
on cancer nanomedicine, owing to the remarkable and unique physicochemical and 
biological features.16-21 In addition to a high biocompatibility and tuneable 
biodegradability,22-24 PSi nanoparticles are characterized by a sponge-like architecture with 
high surface-to-volume ratio, large pore volume and surface area, and controllable pore size 
that allows the high loading of diverse therapeutic drug molecules and biomolecules within 
the porous structure.16,17,25 Moreover, these nanomaterials present high mechanical, 
chemical and thermal stabilities, and surface chemical versatility, enabling the 
straightforward functionalization with biofunctional polymers and biomolecules for 
controlling the release profiles of the therapeutic payloads, targeting specific organs, tissues 
and cells, and/or improving the biological performance.19,26-30 However, the successful 
implementation of PSi nanoparticulate systems as effective nanoplatforms for cancer 
medicine is still hindered by several drawbacks related to (i) the intrinsic instability in 
aqueous environments and biological fluids, (ii) the poor tumour targeting efficiency and 
unfavourable pharmacokinetic (PK) profiles, (iii) the limited capability to overcome extra 
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and intracellular biological barriers, and (iv) the premature and uncontrolled release of the 
therapeutic cargos.  
This dissertation contemplates the design and development of new strategies, 
including the surface modification of PSi nanoparticles with biofunctional polymers and the 
engineering of advanced multifunctional PSi-based nanocomposites, aiming at 
circumventing some of the abovementioned bottlenecks inherent to PSi nanomaterials, 
improving the tumour targeting and drug delivery efficiencies, and ultimately potentiating 
the application of PSi nanoplatforms in cancer nanomedicine. 
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The recent advances in the field of nanotechnology and significant progresses in 
fundamental cancer research have led to an increasing interest from both the academic and 
industrial sectors on developing novel nanotechnology-based tools for cancer biomedical 
applications (Figure 1). As an outcome of this joint effort, a first generation of 
nanomedicines have successfully been approved for clinical use in cancer therapy and 
diagnostics (Table 1).14,15 Furthermore, a vast pipeline of other promising nanotechnology-
based formulations is currently under clinical evaluation for a wide range of cancer 
therapeutic modalities, including non-targeted, targeted, stimuli-responsive and 
combinatorial chemotherapy, hyperthermia, radiotherapy, gene or RNA interference (RNAi) 
therapy and immunotherapy (Table 2).14,15 
 
Figure 1. The design of nanoparticles for cancer biomedical applications. Nanomedicines 
can be modularly assembled from different materials with different physicochemical 
properties and functionalized with a myriad of ligands for cancer targeting, drug delivery 
and diagnostics. Copyright © (2011) The Royal Chemistry Society. Reprinted with 
permission from ref.31. 
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Table 1. Cancer nanomedicines approved for clinical use by one or more regulatory entities. 
Adapted with permission from refs.14,15. 
Product  Nanoplatform Drug Indication Status 
Non-targeted chemotherapy 
Doxil 
Pegylated 
liposome 
Doxorubicin 
HIV-related Kaposi 
sarcoma, ovarian cancer 
and multiple myeloma 
Approved 
by FDA 
DaunoXome Liposome Daunorubicin 
HIV-related Kaposi 
sarcoma 
Approved 
by FDA 
Marqibo Liposome 
Vincristine 
sulphate 
Acute lymphoblastic 
leukaemia  
Approved 
by FDA 
Onivyde or 
MM-398 
Pegylated 
liposome 
Irinotecan 
Post-gemcitabine 
metastatic pancreatic 
cancer 
Approved 
by FDA 
Myocet Liposome Doxorubicin Metastatic breast cancer 
Approved 
in Europe 
and Canada 
Mepact Liposome 
Muramyl 
tripeptide 
phosphatidyl-
ethanolamide 
Nonmetastatic, 
resectable osteosarcoma 
Approved 
in Europe 
Abraxane 
Albumin 
nanoparticle 
Paclitaxel 
Breast, lung and 
pancreatic cancer 
Approved 
by FDA 
SMANCS 
Polymer 
conjugate 
Neocarzinostatin Liver and renal cancer 
Approved 
in Japan 
Genexol-PM Polymeric micelle Paclitaxel 
Breast cancer and 
NSCLC 
Approved 
in Korea 
Protein delivery 
Oncaspar 
Pegylated 
asparaginase 
Asparaginase 
Acute lymphoblastic 
leukaemia 
Approved 
by FDA 
miRNA therapy 
Rexin-G 
Targeting protein 
tagged 
phospholipid 
miRNA-122 
Sarcoma, osteosarcoma, 
pancreatic cancer and 
other solid tumours 
Approved 
in Europe 
Hyperthermia 
NanoTherm 
Iron oxide 
nanoparticle 
NA Glioblastoma 
Approved 
in Europe 
Diagnostics/Imaging 
Feridex 
Dextran-coated 
iron oxide 
nanoparticles 
NA Liver lesion imaging 
Approved 
by FDA 
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Resovist 
Carboxydextran-
coated iron oxide 
nanoparticles 
NA Liver lesion imaging 
Approved 
in Europe  
Endoderm 
Dextran-coated 
iron oxide 
nanoparticles 
NA Liver lesion imaging 
Approved 
by FDA 
and in 
Europe 
Abbreviations: FDA, US Food and Drug Administration; HIV, human immunodeficiency virus; 
miRNA, micro-RNA; NA, not applicable; NSCLC, non-small-cell lung cancer. 
Since the initial clinical approval of Doxil®, a pegylated liposomal formulation of 
doxorubicin (DOX), by the Food and Drug Administration (FDA) in 1995,32 lipid-based 
nanoparticles, particularly liposomes, still represent the major class of nanotherapeutics in 
the market or under clinical evaluation for cancer treatment.33 The attractiveness and 
recognized clinical success of lipid-based nanodrugs reside on their high biocompatibility 
and biodegradability, low immunogenicity, and capability of improving the PK and 
biodistribution of the encapsulated therapeutic agents.34 However, these advantages have 
mainly contributed to improve the toxicological profile and enlarge the therapeutic window 
of the formulated drugs, rather than enhancing the therapeutic efficacy and increasing overall 
patient survival.35 Taking Doxil® as an example, the benefits of this drug-liposome 
formulation, in comparison with the free DOX, arise from prolonging the blood half-life of 
the drug from ~5 min to up to 72 h and, consequently, increasing the tumour accumulation, 
decreasing the volume of distribution nearly to the plasma volume, and reducing the dose-
limiting inherent cardiotoxicity.36-39 
Abraxane® or nab-paclitaxel, consisting of albumin-bound paclitaxel (PTX), was the 
second nanomedicine clinically approved for cancer treatment. Although the albumin-PTX 
nanoconjugate has not shown to significantly affect the PK profile and biodistribution of 
PTX, it has demonstrated an improved therapeutic efficacy in patients with advanced breast 
cancer,40,41 most likely by increasing the drug’s transport from the intravascular space and 
the intratumoral uptake.42 Equally important, this nanoformulation has also revealed to 
significantly decrease the acute adverse effects of the conventional PTX formulations, which 
were typically caused by the toxic organic solvents used for solubilizing the hydrophobic 
drug.42  
Furthermore, polymer-based nanotechnologies, particularly polymeric micelles and 
polymeric nanoparticles, have also been applied for improving the delivery of new and 
potent hydrophobic chemotherapeutics, which clinical use is, however, restricted by their 
poor aqueous solubility or low permeability across biological barriers.43 Genexol-PM®, a 
polymeric micellar nanoformulation of PTX, is a successful example of this new class of 
nanomedicines that has already been introduced in the market.44 Contrarily, other polymeric 
nanoformulations envisioned for non-targeted (e.g., NK-10545 and CRLX-10146) and 
targeted (e.g., BIND-01447) chemotherapy have recently shown unsatisfactory results in 
clinical trials. 
Nanomedicines have also taken their clinical strides as promising platforms for the 
delivery of biomolecules, including proteins,48 antisense oligonucleotides,49 DNA inhibitor 
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oligonucleotides,50 microRNA (miRNA)51 and small interfering RNA (siRNA).52,53 For 
example, Oncaspar®, a pegylated form of asparaginase, has been demonstrated to prolong 
the circulation and retention time of this enzyme, while reducing the proteolysis, renal 
excretion and side effects, such as hypersensitivity.48 Moreover, the first gene therapy 
nanomedicine, consisting of a cancer collagen matrix targeted liposome encapsulating 
miRNA (Regin-G®), has already received clinical approval.51  
 In addition to the organic-based nanomedicines clinically approved for cancer therapy, 
a few inorganic nanosystems have also been introduced in the market. All of these 
nanoformulations are based on superparamagnetic iron oxide nanoparticles (SPIONs), which 
are coated with aminosilane (NanoTherm®) for hyperthermia therapy of solid tumours,54 or 
with carboxydextran (Resovist®) and dextran (Feridex®/Endoderm®) as magnetic resonance 
imaging contrast agents for the diagnostics of liver lesions.55 Furthermore, other inorganic 
nanomaterials, particularly silica-gold core-shell56 and hafnium oxide nanoparticles,57 are 
currently under clinical investigation for cancer hyperthermia and radiotherapy, 
respectively. 
Table 2. Examples of nanomedicines under clinical investigation for cancer treatment. 
Adapted with permission from ref.14. 
Product  Nanoplatform Drug(s)  Indication Status 
Non-targeted chemotherapy 
Lipoplatin 
Pegylated 
liposome 
Cisplatin NSCLC Phase III 
NK-105 Polymeric micelle Paclitaxel 
Metastatic or recurrent 
breast cancer 
Phase III 
EndoTAG-1 Liposome Paclitaxel 
Pancreatic cancer, liver 
metastases, HER2-
negative and triple-
negative breast cancer 
Phase III 
CRLX-101 
Cyclodextrin 
nanoparticle 
Camptothecin 
NSCLC, metastatic 
renal cell carcinoma and 
recurrent ovarian cancer 
Phase II 
Targeted chemotherapy 
MM-302 
HER2- targeting 
liposome 
Doxorubicin 
HER2-positive breast 
cancer 
Phase 
II/III 
BIND-014 
PSMA-targeting 
polymeric 
nanoparticle 
Docetaxel NSCLC and mCRPC Phase II 
MBP-426 
TfR-targeting 
liposome 
Oxaliplatin 
Gastric, oesophageal, 
and gastro-oesophageal 
adenocarcinoma 
Phase I/II 
Anti-EGFR 
immuno-
liposomes 
EGFR-targeting 
liposome 
Doxorubicin Solid tumours Phase I 
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Stimuli-responsive chemotherapy 
ThermoDox 
Heat-activated 
liposome 
Doxorubicin 
Hepatocellular 
carcinoma 
Phase III  
Combinatorial chemotherapy 
CPX-351 or 
Vyxeos 
Liposome 
Cytarabine and 
daunorubicin (5:1) 
High-risk acute myeloid 
leukaemia 
Phase III 
CPX-1 Liposome 
Irinotecan and 
floxuridine (1:1) 
Advanced colorectal 
cancer 
Phase II 
Hyperthermia 
AuroLase 
Silica-gold core-
shell nanoparticle 
NA 
Head and neck cancer, 
and primary and 
metastatic lung cancer 
Pilot 
study 
Radiotherapy 
NBTXR3 
Hafnium oxide 
nanoparticle 
NA 
Adult soft tissue 
sarcoma 
Phase 
II/III 
Gene or RNAi therapy 
SGT53 
TfR-targeting 
liposome 
Plasmid encoding 
normal human 
wild-type p53 DNA 
Recurrent glioblastoma 
and metastatic 
pancreatic cancer 
Phase II 
PNT2258 Liposome 
DNA nucleotide 
against BCL-2 
Relapsed or refractory 
non-Hodgkin lymphoma 
and diffuse large B-cell 
lymphoma 
Phase II 
SNS01-T PEI nanoparticle 
siRNA against 
eIF5A and pDNA 
expressing  
eIF5A-K50R 
Relapsed or refractory 
B-cell malignancies 
Phase I/II 
Atu027 Liposome 
siRNA against 
protein kinase N3 
Advanced and 
metastatic pancreatic 
cancer 
Phase I/II 
Immunotherapy 
Tecetomide Liposome MUC1 antigen NSCLC Phase III 
dHER2 + 
AS15 
Liposome 
Recombinant 
HER2 (dHER2) 
antigen and AS15 
adjuvant 
Metastatic breast cancer Phase I/II 
JVRS-100 Lipid nanoparticle Plasmid DNA 
Relapsed or refractory 
leukaemia 
Phase I 
CYT-6091 
Colloidal gold 
nanoparticle 
TNF Advanced solid tumours Phase I 
Abbreviations: EGFR, epithelial growth factor receptor; eIF5A, eukaryotic initiation factor 5A; 
HER2, human epidermal growth factor receptor type-2; mCRPC, metastatic castration-resistant 
prostate cancer; MUC1, membrane-bound mucin 1; NA, not applicable; NSCLC, non-small-cell lung 
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cancer; PSMA, prostate-specific membrane receptor; RNAi, RNA interference; siRNA, small 
interfering RNA; TfR, transferrin receptor; TNF, tumour necrosis factor. 
In spite of the aforementioned clinical advances in cancer nanomedicine, this field is 
still at an early stage of development and has yet to fulfil the promise to revolutionize the 
future of cancer medicine. Currently, there are still several challenges defying the bench-to-
bedside translation of cancer nanomedicines: (1) the controlled reproducible synthesis of 
nanoplatforms with optimal physicochemical properties; (2) the lack of tumour models that 
replicate the complexity and heterogeneity of human cancers and, consequently, the 
discrepant therapeutic outcomes between preclinical and clinical studies; (3) the scaling-up 
process of innovative and complex nanomedicines, particularly the ones requiring novel 
manufacturing techniques, integrating biological payloads and/or targeting moieties, and 
theranostic/multifunctional nanosystems; and (4) the demanding regulatory guidelines and 
requirements for the clinical approval and commercialization of nanotechnology-based 
therapeutics.14,15  
????????????????????????????????????????????????????????????? 
The complexity and heterogeneity of the human body and, particularly, the tumour 
pathophysiology, together with an incomplete comprehension of the nano-bio interactions, 
represent main hurdles for the establishment of nanomedicines as a new paradigm in cancer 
therapy. Despite considerable efforts on developing nanomedicines for non-invasive 
administration (e.g., oral, pulmonary, nasal and transdermal delivery routes),58-60 most 
cancer nanomedicines are envisioned to be administered systemically. After intravenous 
injection, the nanoparticle-based therapeutics face the challenge to reach and accumulate at 
the targeted tumour site, in order to exert a therapeutic effect. Therefore, the in vivo PK and 
related therapeutic efficacy of newly developed nanomedicines crucially depends on their 
capability to overcome multiple biological barriers. Generally, the passive tumour 
accumulation and localization of nanomedicines is favoured by an increased leakiness of the 
abnormal tumour microvasculature and a defective lymphatic drainage, enabling the 
nanoparticulate systems to extravasate from the blood circulation into the perivascular 
tumour microenvironment (TME) and to be retained within the tumour tissue.61-64 However, 
after intravenous administration, the in vivo fate and tumour accumulation of nanoparticles 
are highly influenced by a multiplicity of biological processes, including the adsorption of 
plasma proteins, the nanoparticles’ opsonisation, clearance and degradation, the 
extravasation and interaction with the TME, the tumour tissue penetration, as well as the 
cellular internalization and intracellular trafficking (Figure 2). In turn, the physicochemical 
properties of nanoparticles, such as the size, morphology, composition, surface charge and 
chemistry, and modification with biofunctional polymers and targeting ligands, can 
significantly impact the aforementioned biological phenomena, thus playing a determinant 
role on the PK profile, therapeutic outcome and safety of the nanomedicines (Figure 2A).14  
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Figure 2. The impact of nanoparticles’ physicochemical properties, chemical composition 
and surface modification with targeting ligands (A) on the biological processes involved in 
the systemic delivery to tumour tissues, including the interaction with plasma proteins (B), 
blood circulation (C), biodistribution (D), extravasation to the tumour microenvironment 
(E), tumour cell targeting and intracellular trafficking (F), and release profile of payloads 
(G). Copyright © (2017) Nature Publishing Group. Adapted and reprinted with permission 
from ref.14. 
??????????????????????????????????????????????????????
Once a nanoparticle enters a biological system, such as the blood, interstitial fluid or 
extracellular matrix (ECM), it is exposed and interacts with a variety of biomolecules, 
particularly proteins, which are tissue or organ specific in terms of their chemical and 
biological composition. These nanoparticle-protein interactions will lead to the formation of 
a protein layer or corona adsorbed onto the nanoparticles’ surface that is constantly 
interacting with other proteins in the surrounding biological environment (Figure 2B).65-69 
The phenomena of protein adsorption and protein corona formation, as well as their 
composition, are highly dependent on the physicochemical properties of the nanomaterials, 
(i.e., size, morphology, chemical composition, and surface chemistry), the composition of 
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biological system (blood, interstitial fluid, TME, intracellular compartment, etc.), the 
pathological state, and other factors such as temperature, pH, dynamic sheer stress, and 
exposure time.69-73  
In turn, the protein corona formation alters the nanoparticle size, surface properties, 
stability, and functionality, thus providing the nanomedicines with a new entity that 
significantly impacts their biocompatibility, PK profile, biodistribution, tumour cellular 
internalization, intracellular trafficking, drug release and, consequently, their safety and 
therapeutic efficacy. For example, the surface adsorption of opsonins can induce the rapid 
recognition and phagocytosis by the mononuclear phagocytic system (MPS),67,74 resulting 
in the clearance of the nanoparticles from the systemic circulation and the accumulation in 
the MPS associated organs (i.e., liver and spleen).75 Contrarily, the surface binding of 
dyopsonins, such as apolipoproteins and albumin, can render stealthy properties to the 
nanoparticles, avoiding the opsonisation by the MPS.76-78  
In addition, the formation of a protein layer on the nanoparticles surface can affect 
their non-specific cellular interactions, uptake and the intracellular trafficking. As an 
example, the cellular internalization of silica nanoparticles revealed to be considerably more 
efficient when the particles were incubated with the cells in serum-free conditions,79 since 
the proteins bound on the nanoparticles surface significantly decreased their adhesion to the 
cellular membrane and, consequently, lowered their cellular uptake.80 However, the 
formation of a protein layer also diminishes the interaction with the cellular milieu, 
attenuating the acute cytotoxic effect of nanomaterials.79 In the case of nanoparticles 
functionalized with targeting ligands, the formation of a protein corona can affect the 
function of conjugated targeting moieties by displacing, altering their orientation, disrupting 
their structure and conformation, or masking their recognition, thus limiting the specific 
interaction and internalization of the nanomedicines by the targeted cancer cells and, 
consequently, impacting their targeting efficiency and biofate.69,81,82 Contrarily, the protein 
corona composition can also be designed for improving the targeting of nanotherapeutics. 
For instance, the adsorption of apolipoprotein E has recently been shown to drive the in vivo 
targeting of siRNA lipoplexes to hepatocytes.83 Similarly, the surface modification of gold 
(Au) nanoparticles with apolipoprotein E and albumin has been demonstrated to prolong 
their blood circulation time, and to significantly increase their translocation into the brain 
and accumulation in the lungs.84 
Furthermore, the protein corona can modify the dissolution rate of nanoparticles and, 
consequently, the release profiles of the therapeutic cargo. This is, for example, the case of 
Abraxane®, which tissue distribution and dissolution rate were affected by the protein corona 
formation and composition, thus also interfering with the tissue distribution of the 
formulated PTX.73,85 
???????????????????????????????????????????????????????????????
Nanomedicines delivered systemically by intravenous injection are immediately subjected 
to rapid clearance from the blood circulation (Figure 2C). Although the eventual clearance 
and biodegradation of nanomedicines are important prerequisites from a toxicological 
perspective, their rapid removal from the bloodstream can result in a primary accumulation 
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in organs like the liver, spleen and kidneys (Figure 2D).13 This unfavourable PK and 
biodistribution between the targeted tumour site and other tissues can not only offset the 
desired therapeutic effect and dramatically impair the therapeutic efficacy of nanomedicines, 
but also induce off-target toxicity.86,87 Therefore, the rational design of nanomedicines that 
enable to circumvent the mechanisms of rapid clearance, to achieve a prolonged circulatory 
half-life and to preferably accumulate at the tumour site, are determinant for the overall 
effectiveness of nanoparticle-based therapeutics and represent some of the main focuses in 
cancer nanomedicine research. 
The MPS and direct renal filtration are the two major physiological mechanisms 
responsible for the clearance of nanoparticles from the systemic circulation.88,89 The MPS, 
also known as reticuloendothelial system (RES), is composed of phagocytic cells, including 
macrophages, monocytes and Kupffer cells that reside in MPS associated organs, such as the 
liver, spleen, lymph nodes and bone marrow, which are responsible for engulfing and 
eliminating external organisms, viruses and particles travelling in the blood circulation.90 
When entering the bloodstream, nanoparticles are immediately opsonized by plasma 
proteins, typically albumin, immunoglobulins, complement proteins and apolipoproteins, 
resulting in the formation of a protein corona onto the nanoparticles’ surface.65,91 The 
opsonization promotes the recognition and phagocytic clearance of the nanoparticles by the 
MPS, through the binding of the adsorbed opsonins to specific receptors expressed on the 
phagocytic cells, followed by enzymatic degradation. The nanoparticles that are not 
degradable by enzymatic breakdown, such as inorganic nanoparticles, will be transported by 
the phagocytes and accumulate in the liver and spleen.92,93 In addition to the association with 
the MPS, the intrinsic physiology of the liver and spleen can contribute for the permanent 
excretion of nanomedicines from the body. In the liver, hepatocytes may endocytose and 
slowly degrade the nanoparticles, subsequently eliminating them in the biliary system.94 In 
turn, nanoparticulate systems with sizes larger than 200 nm and long blood half-lives can be 
physically filtered from the bloodstream through the blood filtration system of the spleen.95 
The clearance of nanomedicines by the MPS is complemented by the renal filtration 
system. The glomerular bed of the kidneys is characterized by a fenestrated capillary 
epithelium with an adjacent basement membrane and an epithelial layer of podocytes, which 
present a combined physiological pore size of approximately 4.5–5 nm.96 Contrarily to the 
active phagocytic role of the MPS, the renal clearance is fundamentally a passive 
mechanism, which is predominantly affected by the particle size rather than the surface 
properties of nanomedicines. Moreover, upon renal filtration, nanoparticles are directly 
excreted from the body in the urine, instead of accumulating in the kidneys.96 
The clearance process and in vivo biofate of nanomedicines is generally influenced by 
their physicochemical properties, particularly the size, shape, surface charge and 
hydrophobicity/hydrophilicity.97,98 In general, spherical nanoparticles with a hydrodynamic 
diameter smaller than 6 nm are rapidly dialysed from the blood circulation through the renal 
filtration system, independently of their surface charge, while the renal clearance of 6–8 nm 
sized nanoparticles significantly depends on their surface properties. Accordingly, positively 
charged nanoparticles smaller than 8 nm have exhibited greater glomerular filtration than 
the negatively charged and neutral counterparts with similar dimensions, due to an increased 
interaction with the anionic moieties of the glomerular capillary wall.88,89,99 In contrary, 
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nanomedicines larger than 8 nm cannot be handled by the kidneys and tend to be cleared by 
the MPS.88 As mentioned above, the phenomena of opsonization and protein corona 
formation play critical roles in the process of MPS clearance. In this regard, ionic and/or 
hydrophobic nanoparticles present a higher propensity to be opsonized and phagocytosed by 
the MPS cells, compared to their neutral and hydrophilic counterparts, which minimally 
interact with the plasma proteins, owing to their sterically stabilized surface.86,87  
Therefore, extensive efforts have been devoted to rationally engineer the surfaces of 
nanomedicines, with the aim of mitigating their opsonization and MPS clearance, prolonging 
their blood half-life and enhancing their tumour accumulation. The most widely explored 
strategy to achieve these goals consists of adsorbing or conjugating polyethylene glycol 
(PEG) or PEG derivatives onto the nanoparticles’ surface, a process also known as 
pegylation.100 The stealth properties of PEG arise from its hydrophilicity, neutral charge and 
steric repulsion, forming a hydrating shell on the nanoparticles’ surface that minimizes the 
interaction with plasma proteins and, consequently, the recognition and internalization by 
the MPS cells. As a result, pegylated nanoparticles normally travel longer in the systemic 
circulation, giving an opportunity to accumulate more efficiently in the tumour tissues.101,102 
Additionally to PEG-based moieties, other hydrophilic polymers, including polyacrylamide, 
poly(vinyl alcohol), poly(N-vinyl-2-pyrrolidone) and polysaccharides, such as dextran, 
heparin, chitosan and hyaluronic acid (HA), have demonstrated similar stealth features and 
provided significant benefits on prolonging the blood half-lives of nanomedicines.75 
Furthermore, alternative biomimetic approaches that inhibit the phagocytic activity of the 
MPS and consequent hepatic and splenic clearances, have recently been exploited. Such 
biologically inspired strategies involve, for example, the surface modification of 
nanoparticulate systems with self-recognizing peptides, such as CD47 peptides,103,104 and 
their coating with membranes derived from haematopoietic cells, including erythrocytes,105 
leukocytes106 and thrombocytes.107,108 
????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
In order to exert the envisioned therapeutic effect and reduce adverse off-target effects, 
cancer nanomedicines need not only to avoid the mechanisms of rapid clearance, as 
mentioned in the previous section, but also to extravasate from the tumour microvasculature 
and accumulate within the tumour tissues (Figure 2E). Since the concept of the “magic 
bullet” was idealized almost one hundred years ago,109 extensive research focus has been 
dedicated to better study and understand the tumour biology and pathophysiology and, 
accordingly, to design new strategies to improve the specific accumulation of cancer 
nanomedicines in malignant tissues.11,110,111 Nowadays, it is well know that therapeutic 
macromolecules and nanoparticles administered intravenously tend to preferably accumulate 
and be retained in tumour lesions, as a combined result of the defective tumour vasculature 
and impaired tumour lymphatic drainage.61,63,112 
During the tumorigenic process, the normal vasculature surrounding the solid tumour 
mass does not comply with the oxygen supply required for the frenetic and uncontrolled 
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proliferation of malignant cells, resulting in a hypoxic TME. In response to the hypoxic cell 
death, cancer cells increase the secretion of vascular epithelial growth factors and pro-
angiogenic signals that promote the continuous development of new blood vessels.2,113 
Contrarily to the vasculature in normal tissues (Figure 3, left panel), the active tumour 
angiogenesis generates an irregular vascular architecture that is characterized by a 
discontinuous and fenestrated endothelium, a disrupted or absent basal membrane and a 
lower count of adjacent perycites (Figure 3, right panel).113-115 The sizes of interendothelial 
fenestrations of the tumour microvasculature typically vary between 100–800 nm, 
depending on the solid tumour, its stage and localization.116 Consequently, the tumour 
vascular walls are significantly more leaky and permeable to active macromolecules and 
nanotherapeutics with appropriate size, allowing their efficient extravasation from the blood 
vessels’ lumen to the tumour interstitium.117,118 Although the particle size is the physical 
parameter driving the passive tumour extravasation and accumulation, the surface properties 
of nanoparticles also play determinant roles in these phenomena, as they greatly impact the 
hydrodynamic radii, stealthiness, blood half-life and clearance of nanomedicines.119 
 
Figure 3. The extravasation of nanoparticles with different sizes and small molecules in 
normal (left) and tumour (right) tissues. The enhanced permeation and retention effect is a 
unique feature of most tumours, allowing nanoparticles of appropriate sizes to preferably 
extravasate and accumulate in cancerous tissues than in normal tissues. Copyright © (2014) 
Wiley-VCH Verlag GmbH & Co. KGaA. Reprinted with permission from ref.13. 
In addition to the enhanced permeation of the tumour microvasculature, tumours 
generally exhibit a defective lymphatic drainage, resulting from the rapid proliferation of 
cancerous and stromal cells, and a condensed ECM (Figure 3, right panel).120 This 
suppressed lymphatic flow reduces significantly the clearance of nanomedicines that 
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extravasate to the tumour perivascular space, thus favouring their accumulation and 
penetration into the tumour tissue.61,112 However, this phenomenon also contributes to an 
increased interstitial fluid pressure (IFP) in the tumour parenchyma, which competes with 
the extravasation pressure for the diffusion of nanotherapeutics through the permeable 
tumour vasculature, and may eventually efflux the extravasated nanoparticles back into the 
systemic circulation.121 The aforementioned pathophysiologic features of the TME are the 
mechanistic fundaments of the enhanced permeation and retention (EPR) effect, originally 
demonstrated by Matsumura and Maeda in 1986,61 and represent the foundation of the 
passive targeting and delivery of nanomedicines to tumours (Figure 4, left panel). 
 
Figure 4. The mechanisms of passive (left) and active (right) targeting of nanoparticles into 
tumours. Abbreviations: IFP, interstitial fluid pressure. Copyright © (2017) Nature 
Publishing Group. Adapted and reprinted with permission from ref.122. 
The majority of clinically approved cancer nanomedicines (Section 2.1) rely on the 
EPR effect as a mechanism for their tumour passive targeting and accumulation. However, 
recent investigations have revealed that the interpretations of the EPR effect over the past 
years are oversimplified and that the passive tumour targeting of nanomedicines is in fact a 
more complex and heterogeneous phenomenon than initially presumed.14 Currently, it is 
clear that the physiology of the tumour microvasculature and microenvironment, and 
associated EPR effect, not only vary considerably between tumour types and patients, but 
are also spatiotemporally heterogeneous throughout the same tumour.13,122 In addition, the 
ubiquitous release of the loaded therapeutic molecules in the tumour tissue can result in 
uptake by unintended cellular targets or in efflux from the tumour interstitium back into the 
bloodstream owing to the increased IFP. These undesired outcomes prevent the therapeutic 
agents from efficiently diffusing within the tumour mass and successfully reaching their 
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pharmacological targets.123,124 All these hurdles contribute to ineffective, non-uniform and 
unpredictable therapeutic responses to passively targeted nanomedicines and can be 
attempted to be circumvented by actively targeting nanomedicines to tumours. 
????????????????????????????????
 
The active tumour targeting of nanomedicines, also named as ligand-mediated tumour 
targeting, involves the surface functionalization of nanoparticulate systems with biologically 
active ligands that specifically recognize and bind to tumour-associated receptors, which are 
(over)expressed on the surface of tumour cells or components of the TME. This strategy can 
not only drive the nanoparticles to selectively accumulate at the targeted tumour tissue, but 
also contribute for an enhanced anchoring and internalization by the targeted cells through 
receptor-mediated endocytosis (Figure 2F), ultimately improving the therapeutic index of 
nanomedicines and their therapeutic payload.12,63,101,125-127  
In order to fully exploit the benefits of active targeting, it is imperative to carefully and 
rationally engineer the actively targeted nanomedicines. The selection of the right targeting 
ligand used to functionalize the surface of the nanoplatforms is of utmost importance to 
efficiently deliver the nanomedicines to the intended cellular target and, consequently, to 
attain the desired therapeutic outcome. For this purpose, a wide repertoire of targeting 
moieties are currently available, including monoclonal antibodies and antibody fragments, 
proteins and peptides (e.g., peptides containing the arginine-glycine-aspartic acid (RGD) 
sequence), nucleic acid ligands (e.g., aptamers), small molecules (e.g., folic acid and 
transferrin) and polysaccharides (e.g., HA).128-130 In addition, different parameters related to 
the nanoparticle design should be considered and optimized, including the intrinsic 
physicochemical properties of the nanocarrier (i.e., the particle size, shape, surface charge 
and hydrophobicity), as well as the avidity of the targeting ligand to the targeted receptor, 
the ligand density and the coupling chemistry used.130,131 Moreover, it is important to 
consider that the specific molecular recognition and ligand-receptor binding of active 
targeting nanovehicles require their availability at the vicinity of the cognate receptors 
present at the targeted cells’ surface. Therefore, nanomedicines that actively target the 
receptors expressed in solid tumours still need to rely on the EPR effect and passive targeting 
to extravasate from the tumour microvasculature and accumulate at the tumour tissue 
(Figure 4, right panel).127,132 Accordingly, the targeting and therapeutic efficiencies of 
actively tumour targeted nanomedicines are significantly impacted by the inherent properties 
of the nanoplatforms and the density of the targeting ligand, as these factors play a 
determinant role on the biological processes of opsonization, MPS-associated clearance, 
systemic half-life and, consequently, the passive accumulation of nanoparticles at the tumour 
site (Sections 2.2.2 and 2.2.3.1).127,130-133  
In an alternative approach to the tumour cell targeting, nanomedicines can be designed 
to actively target non-tumoural cells of the TME.134 Owing to its active involvement in the 
tumorigenic process, the tumour vasculature has been early identified as a potential target 
for cancer nanomedicines.135,136 The active vascular targeting strategy fundamentally 
foresees to promote the tumour extravasation and accumulation of the targeted nanosystems, 
with minimal dependency on the EPR effect.137 In this context, various vascular targeting 
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ligands have been screened for targeting biomarkers that are specific or overexpressed in the 
tumour vascular endothelium and exhibit low or no expression in the normal 
vasculature.137,138  For example, internalizing RGD (iRGD; CRGDK/RGPD/ED), a cyclic 
tumour homing peptide containing the RGD sequence, has been recognized to specifically 
bind the transmembrane ανβ3 and ανβ5 integrins, which are highly overexpressed on the 
surfaces of tumour endothelial cells.139 Upon binding to the tumour angiogenic endothelium, 
the iRGD peptide undergoes proteolytic cleavage, unrevealing a C-terminal motif with 
affinity to neuropilin-1, which mediates the tumour penetration and internalization into 
cancerous cells.136,140 Therefore, the surface modification of nanovectors with iRGD peptide 
has been shown in vivo to efficiently promote the extravasation from the tumour vasculature 
and penetration into the tumour parenchyma, overall resulting in an enhanced intratumoural 
delivery and therapeutic efficiency of the active payload.136,141 In addition to the active 
vascular targeting, a variety of nanoformulations have been designed to target stromal cells 
in the TME,134 such as tumour-associated fibroblasts and macrophages,142,143 as well as 
components of the ECM, including heparan sulphate, chondroitin sulphate and HA.12,144 
In turn, HA, an anionic linear glycosaminoglycan consisting of alternating units of D-
glucuronic acid and N-acetyl-D-glucosamine, has recently been recognized as a potential 
tumour targeting moiety itself, owing to its high binding affinity to the CD44 receptor and 
resultant CD44-mediated endocytosis.145-148 The CD44 biomarker is a type-1 transmembrane 
glycoprotein endogenously expressed at low levels in healthy tissues and is known to be a 
major component of the ECM, playing a key role in diverse physiological events, including 
cell proliferation, differentiation, and migration.149-151 However, this receptor has also shown 
be upregulated in a large number of solid tumours, and a correlation between its 
overexpression and the pathological processes of tumorigenesis and tumour progression, 
invasion, metastasis and drug resistance has already been established.152-157 In addition to 
CD44-binding affinity, biological functions and inherent biocompatibility, biodegradability 
and non-immunogenicity, HA exhibits advantageous physicochemical characteristics, such 
as high aqueous solubility, hydrophilicity and stabilizing properties, and a chemical structure 
that allows further modification in aqueous conditions. All these attractive features render 
this biomaterial with great promise for applications in cancer nanomedicine.145-148 
Accordingly, HA has been extensively used in the design and development of various 
nanoparticulate systems for targeted cancer therapy and diagnostics, including HA-drug 
conjugates, HA-based nanocomplexes and nanogels, HA-decorated inorganic nanoparticles, 
HA-modified lipid-based nanocarriers, and HA-based self-assembling nanoparticles.145-148 
?????????????????????????????????????????????????????????????
Upon extravasation from the tumour microvasculature and accumulation at the tumour site, 
nanomedicines need to efficiently surpass the cell membrane barrier and be internalized by 
the tumour cells, in order to deliver the therapeutic payload to the intracellular 
pharmacological targets and exert an efficacious therapeutic effect. When in close proximity 
to the cells, nanoparticles can interact with the cell membrane through the selective binding 
to membrane-embedded receptors or the non-specific association to the membrane surface 
based on hydrophobic and electrostatic interactions.13,31  
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The initial interaction of the nanoparticulate systems with the surface of the cell 
membrane subsequently triggers their cellular internalization, a process generally known as 
endocytosis.158 There are four major endocytic pathways involved in the cellular uptake of 
nanoparticles, namely clathrin-mediated and claveolin-mediated endocytosis, pinocytosis 
and phagocytosis (Figure 5), which generally differ on the nanoparticle–cell interactions 
established, the properties of the internalized cargo, the size of the resulting endocytic 
vesicles and the intracellular machinery involved in the process at the molecular level.158-160 
The first two endocytic mechanisms predominantly rely on the specific recognition and 
binding of the nanoplatforms to receptors (over)expressed on the cell surface, resulting in 
their receptor-mediated endocytosis.161,162 In this regard, the functionalization of the 
nanomedicines’ surface with targeting ligands not only can significantly contribute to their 
preferential accumulation at the tumour site, as described in the previous section, but also 
play a paramount role on enhancing their cellular internalization via clathrin- and claveolin-
mediated endocytosis.63,125,162 Alternatively, the non-specific adsorption of untargeted 
nanoparticles to the cell membrane through electrostatic and hydrophobic interactions can 
lead to the cellular uptake by pinocytosis. This actin-driven endocytic pathway consists on 
the invagination and pinching off fractions of the cell membrane, creating large endocytic 
vesicles that non-specifically engulf the surrounding extracellular fluid and particles.158-160 
In this case, the nanoparticle–cell interactions and consequent cellular internalization process 
are significantly determined by the physicochemical characteristics of the nanomaterials, 
including size, geometry, aspect ratio, surface charge and surface chemistry.98,163-165 
Therefore, the design and optimization of the nanomedicines is absolutely crucial for 
maximizing their cellular interactions and internalization and, consequently, for the 
intracellular delivery and efficacy of nanotherapeutics.131,133,166 In addition, specialized cells, 
such as macrophages, monocytes and neutrophils, present the capability to detect and engulf 
large particles through phagocytosis.158,167 As previously described in Section 2.2.2, this 
endocytic process represents the main mechanism responsible the clearance of nanoparticles 
by phagocytic cells of the MPS and, therefore, one of the major biological barriers limiting 
the efficient delivery of nanomedicines to tumours.90 
After cellular internalization, nanomedicines are generally confined within endocytic 
vesicles and successively trafficked along the endolysosomal pathway, involving molecular 
motor proteins and cytoskeletal components. During the dynamic and complex process of 
intracellular trafficking, the endocytic vesicles initially transport their nanoparticulate 
contents into early or sorting endosomes, after which they can be either exocytosed from the 
cells, transported to other subcellular organelles or follow the endolysosomal pathway, 
ultimately leading to degradation in the lysosomes (Figure 5).31,162 The maturation of early 
endosomes into later endosomes and lysosomes is accompanied by a rapid acidification of 
the endosomal lumen to pH values of approximately pH 5, thus creating a conductive 
environment for the function of the recruited degradative enzymes responsible for the 
degradation of the lysosomal content.31,162 Therefore, the development of strategies that 
render nanomedicines with the capacity to escape the endolysosomal network is crucial for 
the efficient delivery of the therapeutic payload to the cytoplasmic pharmacological targets, 
with particular relevance for biologic cargos, and represents an active focus of cancer 
nanomedicine research. Some of these strategies are described in the following subsection.?
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Figure 5. The cellular internalization and intracellular trafficking of nanoparticles. Note 
the variation in pH values between the different intracellular compartments. Abbreviations: 
ER, endoplastic reticulum; ERC, endocytic recycling compartment; MTOC, microtubule-
organizing centre; MVB, multivesicular bodies. Copyright © (2014) Wiley-VCH Verlag 
GmbH & Co. KGaA. Reprinted with permission from ref.13. 
????????????????????????????????????????
In order to successfully deliver therapeutic molecules to the cytoplasmic and other 
intracellular compartments and avoid the degradative environment of the lysosomes, 
nanomedicines need to be designed and engineered with the capacity to efficiently evade the 
endolysosomal pathway. Accordingly, different biochemical strategies have been exploited 
to attain this goal, which underlie distinct mechanisms of endolysosomal escape, including 
the pH buffering of the endosomal acidic lumen and the disruption of the endosomal 
membrane by pore formation, fusion or photochemical destabilization.159,168 
One approach to induce the endolysosomal escape of nanomedicines consists on the 
inclusion of polyamine cationic polymers in the nanoformulations, such as the widely 
 20 
investigated poly(ethylenimine) (PEI),169-171 poly(amidoamine) (PAA),172-175 and poly (L-
histidine)-containing polymers176,159,168,177 These polymeric molecules are typically 
characterized by a high density of secondary and tertiary amines and a buffering capacity 
between pH 5.0–7.4, enabling the nanoparticles to escape the acidic endolysosomal 
compartments via the “proton-sponge” effect. 169,178 This mechanism postulates that, during 
the endolysosomal trafficking, the continuous protonation of the polyamine polymers and 
prevention of the endosomal acidification triggers an increased transport of protons mediated 
by the membranal ATPase pump, in order to re-establish the acidic intraendosomal pH. The 
augmented influx of protons and balancing counter-ions subsequently leads to an increased 
osmotic pressure inside the endosomal compartments and, eventually, to the swelling and 
osmolysis of the endosomal membrane (Figure 6).169,178 However, while PAA and 
polyhistidine-based polymers are normally designed to be biocompatible and biodegradable, 
major concerns arise from PEI’s well-known cytotoxicity, non-biodegradability and 
instability in biological buffers, which considerably limit its applicability in 
nanobiomedicine.179,180 
In addition, the endosolysosomal escape of nanovectors can be facilitated through the 
surface functionalization with viral-derived (e.g., human immunodeficiency virus (HIV) 
gp41-derived peptide (HGP),181,182 influenza virus hemagglutinin (HA2) N-terminal 
peptide,183-185 HIV transactivator of transcription (TAT)-derived peptide186-188 and papilloma 
virus L2 minor capsid protein-derived peptide (L240)189,190) or synthetic pH-responsive 
(e.g., glutamic acid-alanine-leucine-alanine (GALA)191-193 and KALA194-196) fusogenic 
peptides.159,168,197 Generally, these membrane-disruptive fusogenic peptides are amphipathic 
molecules that undergo a structure conformational change in response to the acidic 
endosomal pH, acquiring the capability to penetrate or induce the formation of pores in the 
endosomal membrane, causing its destabilization and disruption, and ultimately resulting in 
the cytoplasmic release of the entrapped nanoparticulate systems.159,168,197 
?
Figure 6. Schematic representation of the “proton-sponge” mechanism. The protonation of 
proto-sponge moieties results in an increased influx of protons and counter-ions into the 
endocytic vesicles. The increasing osmotic pressure causes the vesicle to swell and rupture. 
Copyright © (2005) Nature Publishing Group. Reprinted with permission from ref.178. 
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PSi was first reported by Arthur Uhlir Jr. and Ingeborg Uhlir in 1956, at the Bell 
Laboratories,198 but it was only 15 years after that the porous crystalline silicon (Si) structure 
of this material was described.199 Thereafter, considerably growing attention has been drawn 
to PSi, particularly due to the remarkable work of Prof. Leigh Canham, who discovered the 
photoluminescence of highly porous Si wires, owing to the two-dimensional quantum size 
effect200 and, later on, demonstrated the in vitro biocompatibility and bioactive properties of 
PSi.201 These findings are considered the milestones for the following application of PSi 
materials in biomedicine, particularly in the field of drug delivery.16-21 
Over the last decade, PSi nanoparticles have been extensively explored as a nanotool 
for biomedical applications, due to significant advances in their fabrication and surface 
modification methods, the manipulation and fine-tuning of their physicochemical properties, 
as well as the increasing comprehension of their interactions with biological systems.19 In 
this regard, PSi nanoparticles present advantageous physicochemical and biological features, 
including a high surface-to-volume ratio, large surface area (300–1000 m2.g–1) and pore 
volume (0.9 cm3.g–1), high chemical, mechanical and thermal stability, as well as superior 
biocompatibility and biodegradability.16 Additionally, the top-down fabrication method of 
these nanoparticles enables their scaled-up production and an easy control over their particle 
and pore sizes, depending on the fabrication parameters applied.18,202,203 Moreover, the 
surface of PSi nanoparticles can be straightforwardly modified with different functional 
groups, and further functionalized with numerous polymers and biomolecules, in order to 
attain control over the release of therapeutic cargos, target specific organs, tissues and cells, 
or improve the biological performance.27,204,205  
In this section, the methods for fabrication and surface modification of PSi 
nanoparticles will be described, along with aspects related with their biocompatibility and 
biodegradability. Furthermore, some of the latest advances of the biomedical application of 
these nanoplatforms will be reviewed, highlighting their use as targeting and drug delivery 
systems for cancer nanomedicine. 
?????????????????????????????? ???????????????????
PSi is commonly fabricated by an electrochemical anodization method, in which 
monocrystalline Si wafers are electrochemically etched, forming a uniform PSi layer on the 
surface of the bulk Si.16,19,206,207 For this purpose, a Si wafer is introduced between two 
electrolyte cells, with platinum (Pt) electrodes on both sides of the Si wafer. The upper side 
of the Si substrate, acting as the anode, is immersed in a hydrofluoric acid (HF) based 
aqueous or ethanolic electrolyte solution, while the lower side of the Si wafer, working as 
the cathode, is in close contact with a conductive metal anode. When applying an etching 
current between the Pt electrodes, the oxidation and electrochemical etching, occurring at 
the anode, results in the Si dissolution and formation of a PSi layer, exclusively on this side 
of the Si wafer. Oppositely, at the cathode, the proton reduction leads to hydrogen (H2) 
formation and elimination, contributing for the electrolyte penetration into the pores and, 
consequently, the formation of a homogenous PSi layer.16,206  
 22 
The properties of the PSi layer obtained, including the thickness, degree of porosity 
and the pore size and shape, are dependent on the conditions applied in its fabrication. 
Therefore, these parameters, such as the HF concentration and composition of the electrolyte 
solution, the density and voltage of the electrical current, the type, resistivity, doping and 
crystallographic orientation of the Si wafer, temperature, time, and illumination intensity, 
can be finely tuned to reproducibly obtain PSi layers with well-defined structures.19,203,206 
The freshly etched PSi presents an unstable and reactive surface consisting of 
hydrophobic Si hydride terminals (Si-Hx), which are very susceptible to hydrolysis and 
oxidation under open atmospheric conditions, resulting in a more hydrophilic surface and 
affecting its porous structure and optoelectronic properties. The rate and extension of surface 
oxidation is highly influenced by the temperature, relative humidity and composition of the 
atmosphere.16,206 This high reactivity of the surface Si hydride terminals compromises the 
application of native PSi in drug delivery, since it can reduce and, consequently, degrade the 
active payloads adsorbed to the PSi surface.16,207 Therefore, different methodologies, 
including oxidation, hydrosilylation, thermal carbonization, and thermal hydrocarbonization 
are generally applied to stabilize the native PSi surface, before using this material in drug 
delivery and other biomedical applications.206 
Controlled oxidation is one of the most common approaches used for stabilizing the 
native PSi surface, and it can be attained by different methods, such as chemical,208 anodic209 
and thermal oxidation.207 In the last method, the increased temperatures induce the oxidation 
of both the Si-Si backbone and the Si-Hx terminals, forming Si-O-Si, -OySiHx and Si-OH 
bonds,210,211 and rendering thermally oxidized PSi (TOPSi), which is characterised by a 
stable, hydrophilic and biocompatible oxidized surface.212 Although these features can be 
generally considered attractive for the application of TOPSi in drug delivery, its oxidized 
surface may react with certain loaded compounds. Moreover, the insertion of oxygen atoms 
within the Si-Si backbone can results in the expansion of the PSi structure and consequent 
reduction of the pore diameter and volume, as well as on an accelerated dissolution of the 
PSi matrix in aqueous physiological media.28 
Hydrosilylation is another method for stabilizing the surface of PSi, which involves 
the reaction of the surface Si-Hx species with unsaturated compounds containing alkene 
(C=C), alkyne (C≡C), or aldehyde (C=O) bonds, resulting in the formation of Si-C-C, Si-
C=C and Si-C-O bonds, respectively.213-216 These modifications can be achieved by using 
different methods, including Lewis acid catalysed reactions, white light promotion, cathodic 
electrografting or thermal hydrosilylation.16,203 In addition to increasing the stability of the 
PSi surface, the hydrosilylation enables its further functionalization with different molecules 
at the opposite end of the aliphatic chains. 
Thermal carbonization and thermal hydrocarbonization are two alternative surface 
stabilization methods that commonly consist on treating the native PSi surface with 
acetylene at high temperatures. The thermal carbonization involves the flushing of acetylene 
at temperatures above 700 ºC and results on the substitution of the Si-Hx surface ends for 
hydrogen-free Si-C bonds, rendering thermally carbonized PSi (TCPSi), which is 
characterized by a more stable hydrophilic surface.217 In the case of thermal 
hydrocarbonization, the acetylene treatment is carried out at temperatures below 650 ºC, 
forming both Si-C and Si-CH bonds at the PSi surface (Figure 7).218 Similarly to the PSi 
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obtained by thermal hydrosilylation, the surface of thermally hydrocarbonized PSi 
(THCPSi) can be subsequently modified with carboxylic acid functional groups (-COOH), 
by performing a thermal treatment with undecylenic acid (Figure 7).219,220 The resulting 
undecylenic acid modified THCPSi (UnTHCPSi) can be further covalently conjugated with 
a wide variety of polymers, biomacromolecules, fluorescent dyes and other compounds, 
which represents a key feature for the application of these materials in biomedicine.221,222 
 
Figure 7. Schematic illustration of the fabrication method of UnTHCPSi nanoparticles. 
Abbreviations: Si, silicon; THCPSi, thermally hydrocarbonized Psi; UnTHCPSi, 
undecylenic acid thermally hydrocarbonized PSi.  
???????????????????????????????????????????????????
The biocompatibility and biodegradability of any material are highly relevant and decisive 
features for its application in biomedicine. In the case of PSi, the in vitro biocompatibility 
was first reported by Canham in 1995, who correlated the pore morphology of this material 
with its bioactivity.201 Accompanying the increasing interest on the application of PSi for 
biomedical purposes, the biocompatibility of PSi has been extensively investigated, both in 
vitro and in vivo,22,24,212,223-226 along with its inflammatory and immune responses,24,227 and 
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its biofate.224,228-230 Overall, the biocompatibility of PSi materials was revealed to be highly 
dependent on their physicochemical properties, including the size,225 pore size226 and surface 
chemistry.24,227  
The biocompatibility of PSi particles has been extensively evaluated in gastrointestinal 
(GI) tract associated in vitro and in vivo models.22,226,231,232 For example, THCPSi and TOPSi 
nanoparticles were shown not to induce any significant in vitro toxic effect, oxidative stress, 
nor inflammatory response in Caco-2 colon cancer cells or RAW 264.7 mouse leukemic 
monocyte macrophages. Moreover, after in vivo oral administration, 18F-labelled THCPSi 
particles showed not to be absorbed from a subcutaneous deposit and to pass intact through 
the GI tract. When administered intravenously, the same nanoparticles were mainly 
distributed in the liver and spleen, thus indicating a rapid clearance from the blood 
circulation.22 In a more recent study, the in vitro toxicity of TOPSi nanoparticles, with pore 
sizes varying between 17 and 58 nm, and amine functionalized PSi nanoparticles, was 
investigated in a Caco-2/HT-29 cell co-culture. The amine functionalized PSi nanoparticles 
exhibited higher cytotoxicity than the TOPSi counterparts with similar pore size. 
Additionally, an increment in the pore size demonstrated to augment the cytotoxicity of 
TOPSi nanoparticles, as a consequence of the larger pore size itself or the variations in the 
production method applied to increase the pore size of the nanoparticles. For that purpose, 
an annealing step was performed prior to the thermal oxidation of TOPSi nanoparticles, 
which revealed to decrease the density of surface –OH groups, thus also showing a 
correlation between the surface chemistry of PSi nanoparticles and their cytotoxic effect.226  
In addition, the effect of the surface chemistry on the cytotoxicity of PSi nanoparticles 
was assessed in vitro and in vivo in immune and red blood cells (RBCs) based on 
histopathological analysis and biochemical parameters. In general, the in vitro studies 
demonstrated a correlation between the surface chemistry and charge of the PSi 
nanoparticles and their cytotoxic effect, with a higher dependency on the surface charge, 
than on the hydrophilicity/hydrophobicity. In this regard, positively charged and hydrophilic 
3-aminopropyltrietoxysilane modified TCPSi (APSTCPSi) nanoparticles exhibited higher 
levels of ATP depletion, genotoxicity and impact on the RBCs morphology, compared to 
their negatively charged counterparts, among which, the more hydrophobic UnTHCPSi 
showed higher cytotoxicity than TOPSi, TCPSi and THCPSi. After in vivo intravenous 
administration of the different PSi nanoparticles, the histopathological and biochemical 
analyses showed generally biosafe profiles of these nanoparticulate systems. In this respect, 
despite mild histological changes in kidney, liver and spleen, particularly for APSTCPSi and 
UnTHCPSi nanoparticles, no notable changes were observed in the serum levels of 
biochemical and haematological parameters.24  
In a complementary study, the impact of the surface chemistry on the immunological 
response of PSi nanoparticles was investigated by evaluating the immunostimulatory 
responses, namely the dendritic cells (DCs) maturation, T cells proliferation and cytokine 
secretion, induced by a non-toxic concentration of the PSi nanoparticles. The results showed 
that TOPSi and THCPSi nanoparticles induced immunoactivation responses, by enhancing 
the expression of surface co-stimulatory markers of DCs (i.e., CD80, CD83, CD86 and 
MHC-II), and increasing the cytokines mediating T cell differentiation. Contrarily, TCPSi 
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and APSTCPSi nanoparticles did not show any immunostimulatory signs, thus suggesting 
their potential for delivering immunosuppressive molecules.227 
The biocompatibility of PSi micro and nanoparticles was also assessed when studying 
their application in the treatment of myocardial infarction. In this study, 7 and 19 µm sized 
THCPSi microparticles induced a significantly higher activation of inflammatory cytokines 
and fibrosis promoting genes, in comparison to similarly sized TOPSi microparticles and 
110 nm sized nanoparticles. However, none of the tested nanoplatforms affected the cardiac 
function or haematological parameters, therefore demonstrating the high in vivo 
biocompatibility of these nanomaterials in the heart tissue.225 
In addition to the biocompatibility, the biodegradability of materials is of utmost 
importance when envisioning their biomedical application. In this regard, PSi is known to 
degrade in aqueous solutions by oxidative hydrolysis, into orthosilicic acid,23 which has been 
naturally found in numerous tissues16,233 and shown to be biocompatible229,230 and excreted 
by renal clearance.233 The degradation rate of PSi depends on different factors, such as the 
degree of crystallinity,234 the pore size, pore volume, and surface area,235 the surface 
chemistry,236,237 and the pH of the medium.238 An increase in the porosity and surface area 
of PSi and, consequently, the extension of the hydrolysable surface, results in a faster 
degradation.235 Furthermore, the surface chemistry of PSi has an effect on its degradation 
rate, by influencing the hydrophilicity and, consequently, the surface wettability, as well as 
by determining the chemical reactivity to hydrolysis and oxidation.23,236,239 For instance, as 
previously discussed, the surface stabilization of freshly etched PSi by controlled oxidation, 
hydrosilylaytion or hydrocarbonzation, reduces the reactivity towards oxidation and 
hydrolysis, thus enabling a control over PSi’s degradability. Therefore, all these parameters 
should be taken into consideration and fine-tuned, when designing PSi materials with desired 
biodegradability for a specific biomedical application. 
??????????????????????????????????????????????????????????????????????????????????
In order to understand the interactions established at the nano-bio interface, it is of utmost 
importance to comprehend the cellular and intracellular compartments and inherent biologic 
mechanisms, as well as the way these interact and are influenced by the physicochemical 
properties of the interacting nanomaterials.31 Considering the negative surface charge of the 
cell surface rendered by the lipids, proteins, and receptors composing the cell membrane, the 
surface charge of PSi and other nanoparticles is a key feature determining their cellular 
interaction and intracellular trafficking.240 In addition, the extension and mechanisms of 
cellular internalization of nanoparticles are dependent on other parameters, such as the 
concentration, particles size, morphology, surface chemistry, and the exposure time to the 
cells.241,242 
The cellular internalization of PSi nanoparticles occurs predominantly via endocytosis, 
leading to the formation of endocytic vesicles that subsequently fuse with endosomes. These 
primary endosomal compartments can either expel the PSi nanoparticles back to the 
extracellular environment or mature into secondary endosomes, which in turn fuse with 
lysosomes responsible for the degradation of the internalized PSi nanomaterial (Section 
2.2.4).243 Therefore, the therapeutic efficiency of PSi based nanoformulations crucially 
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depends on the capacity of the nanocarriers to evade the endocytic pathway and release the 
therapeutic cargo in the cytoplasm of the cells, especially when considering the delivery of 
biomolecules. In general, the electrostatic interaction of positively charged nanoparticles 
with the negatively charged moieties in the cell membranes favours their cellular association 
and internalization. In addition, cationic nanoparticulate systems can more efficiently escape 
the endolysosomal compartments, when compared to their anionic counterparts.244,245 A 
strategy to circumvent this limitation involves the functionalization of negatively charged 
nanoparticles with positively charged polymers featuring a high density of protonable amine 
groups, which buffers the pH, generates a proton influx and, consequently, increases the 
osmotic pressure inside the endosomes, leading to the disruption of the endosomal 
membrane and escape of the nanoparticles from these compartments (Section 2.2.4.1).168 For 
example, PSi nanoparticles were modified with PEI for complexing and delivering siRNA 
into the cytoplasm of human breast cancer cells, after escaping the endolysosomal 
compartments by exploring the aforementioned mechanism.246 
Although less attention has been drawn to improve the intracellular trafficking and 
endosomolytic properties of the PSi nanoparticles, significant efforts have been done for 
enhancing the cellular interaction and uptake of these nanoplatforms, particularly by 
developing targeted PSi nanoparticles that exhibit cell/tissue specificity and induce the 
cellular internalization by receptor-mediated endocytosis.18 Some of these strategies will be 
further outlined in the following section of this dissertation (Section 2.3.4.2).  
???????????????????????????????????????????????
Since the bioactivity of PSi was first reported in vivo by Canham, significant strides have 
established this material as a promising platform for biomedical purposes,  including the 
development of biosensors,247 implants,248 biomimetic organelles or nanoreactors,249 in vivo 
imaging probes228,230,250,251 and drug delivery systems,16,18 with application in cancer 
therapy252,253 and cancer immunotherapy,254-256 diabetes231,232,257,258 and cardiovascular 
diseases.221,259 This section of the dissertation highlights some of the most recent progresses 
on the application of PSi as a drug delivery and cancer targeting platform, as well as its 
integration in advanced and multifunctional drug delivery systems. In this regard, Table 3 
provides examples of the application of PSi nanoparticles in the cancer biomedical field. 
Table 3. Examples of PSi nanoparticles for cancer biomedical applications. 
PSi 
Surface 
modification 
Drug(s) 
In vitro/In 
vivo model(s) 
Main conclusions Refs 
Cancer drug delivery 
UnTHCPSi 
PSi-PEI-
PMVEMA@
ASHF 
5-fluorouracil 
Celecoxib 
Caco-2 
HT-29 
pH-responsive 
combined drug delivery 
Enhanced drug 
permeability 
In vitro 
antiproliferation effect 
260 
 27 
UnTHCPSi 
HABCD Sorafenib 
MCF-7 
MDA-MB-231 
Improved colloidal and 
plasmatic stabilities 
Sustained drug release 
Enhanced in vitro 
cellular interactions 
and antiproliferation 
effect 
222 
PEI 
MTX 
AS1411 
Methotrexate 
Sorafenib 
MDA-MB-231 
NIH-3T3 
Enhanced in vitro 
cellular uptake and 
combined 
antiproliferation effect 
in nucleolin-positive 
cells 
261 
PEG 
VD11-4-2 
Doxorubicin MCF-7 
pH-dependent drug 
release 
Drug release 
monitoring 
In vitro hypoxia-
induced cancer cell 
targeting and 
antiproliferation effect 
262 
AmQu Doxorubicin 
MCF-7 
DOX/MCF-7R 
pH-responsive drug 
release 
Drug release 
monitoring 
Multidrug resistance 
reversing 
Enhanced in vitro 
cellular interactions 
and antiproliferaion 
effect 
263 
THCPSi 
PSi@MF/H/
MFHF 
Atorvastatin 
Celecoxib 
HT-29 
Multistage pH-
controlled combined 
drug delivery 
In vitro 
antiproliferation effect 
264 
PEG-b-PLA/ 
PEG-b-PHIS 
micelles 
Sorafenib 
RAW 264.7 
PC3MM2 
pH-triggered drug 
release 
In vitro reduced 
macrophage 
interactions 
pH-dependent 
antiproliferation effect 
265 
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TOPSi 
PAE 
Pluronic 
F127 
Doxorubicin 
Paclitaxel 
HeLa 
RAW 264.7 
Sequential pH-
responsive combined 
drug delivery 
Enhanced in vitro 
cellular interactions 
and antiproliferation 
effect 
204 
APSTOPSi 
NIPAm-
DMA-AEM 
Doxorubicin 
HeLa 
Hep2 
3LL tumour 
bearing mice 
Thermal-responsive 
drug release upon IR or 
RF irradiation 
Enhanced in vitro and 
in vivo anticancer 
therapeutic effects 
266 
APSTCPSi NA 
Methotrexate 
Sorafenib 
U87 MG 
EA.hy926 
Dual drug delivery 
In vitro 
antiproliferation effect 
267 
TCPSi 
PSi@AcDex 
CPP 
Methotrexate 
Sorafenib 
Paclitaxel 
MCF-7 
MDA-MB-231 
pH-responsive 
multidrug delivery 
Enhanced cellular 
internalization and in 
vitro antiproliferation 
effect 
268 
Cancer active targeting 
PSi 
MLR2 Ab 
mAb528 Ab 
Rituximab 
Camptothecin 
SH-SY5Y 
U87MG 
U87MG.Δ2–7 
HR1K 
DOHH-2 
Enhanced cellular 
uptake and 
antiproliferative effect 
in antigen-
overexpressing cells 
269 
Anti-CD20 
Ab 
Camptothecin 
AuNCs 
HR1K 
Jurkat 
Enhanced in vitro 
cellular association in 
CD20-expressing cells 
In vitro combined 
chemo and 
hyperthermal 
therapeutic effects 
when exposed to EM 
field 
270 
THCPSi CooP peptide NA 
MDA-MB-231 
MDA-MB-231 
tumour 
bearing mice 
Enhanced in vitro 
cellular association  
Enhanced in vivo 
tumour targeting and 
accumulation in 
MDGI-expressing 
tumours 
271 
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APSTCPSi 
RGD 
iRGD 
Sorafenib EA.hy926 
Enhanced in vitro 
cellular internalization 
and antiproliferation 
effect 
205 
Cancer immunotherapy 
LPSi 
Agonistic 
CD40 mAb 
(FGK45) 
NA 
BMDC 
C57BL/6 
Enhanced CD40-
mediated cellular 
uptake and B cell 
activation 
272 
UnTHCPSi 
Anti-CD326 
Ab 
Sorafenib 
MCF-7 
MDA-MB-231 
Enhanced in vitro 
cellular uptake, ADCC 
activity, cytokine 
release and 
antiproliferation effect 
in CD326-expressing 
cells 
Combined cancer 
chemo-immunotherapy 
273 
TOPSi 
PSi@ 
SpAcDex@ 
CCM 
Trp2 
NA 
KG1 
BDCM 
PBMC 
Cytocompatibility 
Co-stimulatory signal 
induction 
Multistage 
nanovaccines with 
adjuvant properties 
254 
Cancer photodynamic therapy 
PSi 
NA NA 
HeLa 
NIH-3T3 
Photosensitizers for 
singlet oxygen 
generation 
In vitro phototoxicity 
274 
Porphirin NA MCF-7 
Enhanced in vitro 
cellular uptake and 
phototoxicity 
275 
Porphirin 
Mannose 
NA MCF-7 
Enhanced in vitro 
cellular uptake and 
two-photon-induced 
phototoxicity 
276 
Cancer photothermal therapy 
PSi 
NA NA 
CT-26 
CT-26 tumour 
bearing mice 
In vitro and in vivo 
photothermal ablation 
in combination with 
808 nm NIR laser 
277 
DMSO 
stabilization 
NA BXPC-3 
In vitro photothermal 
ablation in combination 
with 808 nm NIR laser 
278 
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PSi Polyaniline Doxorubicin 
4T1 
HUVEC 
4T1 tumour 
bearing mice 
Dual pH/NIR light-
triggered drug release 
In vitro and in vivo 
synergistic chemo-
photothermal 
therapeutic effects 
279 
UnTHCPSi 
PSi-AuNRs 
@Calcium 
alginate nano 
hydrogel 
Afatinib 
Docetaxel 
Erlotinib 
Doxorubicin 
MCF-7 
MCF-7/DOX 
SKBR-3 
SKBR-3/AR 
MDA-MB-231 
NCl-H2087 
Inhibition of multidrug 
resistance 
In vitro synergistic 
multidrug-
photothermal 
antiproliferation effects 
280 
APSTCPSi 
IR820 
Doxorubicin 
Doxorubicin 
MCF-7 
MCF-7/ADR 
Dual pH/NIR light-
triggered drug release 
In vitro synergistic 
chemo-photothermal 
antiproliferation effects 
in drug resistant cells 
281 
Cancer gene or RNAi therapy 
PSi APS MRP1 siRNA T98G 
Effective 
downregulation of 
MRP1 mRNA and 
protein expression 
In vitro cellular 
apoptotic and necrotic 
effects 
282 
Cancer imaging 
LPSi 
PEG NA 
2008-mCherry 
and SKOV3 
tumour 
bearing mice 
In vivo late time-gated 
tumour imaging 
283 
SiO2 shell 
PEG 
iRGD 
NA 
4T1 tumour 
bearing mice 
In vivo time-gated 
tumour imaging 
251 
NA 
HeLa tumour 
bearing mice 
In vivo tumour 
targeting and two-
photon imaging 
284 
THCPSi 
18F-labeling 
SLNC 
NA 
MDA-MB-231 
tumour 
bearing mice 
Improved dispersibility 
In vivo tumour imaging 
285 
UnTHCPSi 
L1-Gd 
Cetuximab 
Rituximab 
NA 
NIH-3T3 
U87 
HR1K 
In vitro cellular 
targeting to antigen-
expressing cells 
MRI contrast agents 
286 
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Cancer theranostics 
LPSi Dextran 
Doxorubicin 
MDA-MB-435 
HeLa 
MDA-MB-435 
tumour 
bearing mice 
Biocompatibility 
Biodegradability 
In vitro 
antiproliferative effect 
and imaging 
In vivo tumour imaging 
230 
NA 
3T3-L1 
CF2Th 
Hep2 
In vitro bioimaging and 
antiproliferation effect 
upon ultrasonic 
irradiation 
287 
UnTHCPSi 
AF488 
111In-labeling 
iRGD 
Sorafenib 
PC3MM2 
PC3MM2 
tumour 
bearing mice 
Enhanced in vivo 
targeted tumour 
accumulation and 
suppression 
In vivo tumour imaging 
250 
Abbreviations: Ab, antibody; AcDex, acetalated dextran; ADCC, antibody-dependent cell-mediated 
Cytotoxicity; AEM, 2-aminoethyl methacrylate hydrochloride; AF488, Alexa Fluor® 488; AmQu, 3-
aminopropoxy-linked quercetin; APCs, antigen presenting cells; APS, 3-aminopropyltrietoxysilane 
APSTCPSi, APS modified TCPSi; APSTOPSi, APS modified TOPSi; ASHF, hydroxypropyl-
methylcellulose acetate succinate; AuNCs, gold nanoclusters; AuNRs, gold nanorods; BMDC, bone 
marrow-derived dendritic cells; CCM, cancer cell membrane; CPP, cell-penetrating peptide; DMA, 
N,N’-dimethylacrylamide; DMSO, dimethyl sulfoxide; DOX, doxorubicin; EM, electromagnetic; 
HABCD, heptakis(6-amino-6-deoxy)-β-cyclodextrin; IR, infrared; iRGD, internalizing RGD; LPSi, 
luminescent PSi; mAb, monoclonal antibody; MDGI, mammary-derived growth inhibitor; 
MF/HF/MFHF, hypromellose acetate succinate; MRI, magnetic resonance imaging; mRNA, 
messenger RNA; MTX, methotrexate; NA, not applicable; NIPAm, N-isopropylacrylamide; NIR, 
near infrared; PAE, poly(beta-amino ester); PBMC, peripheral blood monocytes; PEG, polyethylene 
glycol; PEG-b-PHIS, PEG-block-poly(L-hystidine); PEG-b-PLA, PEG-block-polylactide methyl 
ether; PEI, poly(ethylenimine); PMVEMA, poly(methyl vinyl ether-alt-maleic acid); PSi, porous 
silicon; RF, radiofrequency; RGD, arginine-glycine-aspartic acid sequence; siRNA, small 
interfering RNA; SLNC, solid lipid nanocomposite; SpAcDex, spermine-modified AcDex; TCPSi, 
thermally carbonized PSi; THCPSi, thermally hydrocarbonized PSi; TOPSi, thermally oxidized PSi; 
UnTHCPSi, undecylenic acid modified THCPSi. 
?????????????????????????????????????????
In addition to the superior biocompatibility and suitable biodegradability of PSi particles, 
the unique nanoporous structure, large pore volume and high surface area-to-volume ratio 
of these platforms render them an ideal candidate for drug delivery purposes. Different types 
of therapeutic cargos, including small drug molecules, proteins,231,257,288 peptides232,258,289-292 
and nucleic acids246,293-298 can be efficiently loaded into the porous network of PSi carriers, 
and released in a controlled mode by pore diffusion or upon the dissolution of the PSi matrix. 
19,28,299 The drug loading and release profiles of molecules incorporated into the pores of PSi 
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are governed by the physicochemical properties of the PSi material, such as the pore size 
and volume, surface charge, chemistry, and modification, hydrophobicity/hydrophilicity and 
its degradation rate. In addition, the physicochemical properties of the payload, as well as 
the solvent, method and technical parameters used for drug loading are determinant for the 
efficiency and reproducibility of the loading process and for attaining the intended release 
behaviour.28,203,300,301  
Different methods can be applied for loading active molecules into the pores of PSi 
materials, including immersion, covalent grafting, impregnation and drug entrapment by 
oxidation.28,203 Among these techniques, the immersion method is the most frequently used, 
owing to its straightforwardness, the feasibility to load a wide range of molecules with 
distinct physicochemical properties, and the possibility to be carried out in mild chemical 
conditions and at room temperature, thus being suitable for loading labile compounds, such 
as biomolecules.301 This method consists of the simple immersion of the PSi particles in a 
drug solution and relies on the diffusion of this solution into the porous structure of PSi and 
subsequent physical adsorption of the drug molecules to the pore surface. The phenomenon 
of physical adsorption is driven by the spatial confinement and chemical interactions 
established between the loaded molecules and the PSi pore surface. Therefore, it is highly 
dependent on the physicochemical characteristics of the PSi particles, namely the pore 
size,226,302 surface chemistry and hydrophilicity/hydrophobicity,302 the intrinsic properties of 
the loaded molecules, the surface tension, viscosity and concentration of the drug loading 
solution, the loading time, and the temperature.16,17 Consequently, all these parameters have 
a significant impact on both the drug loading efficiency and reproducibility, and the release 
kinetics of the loaded molecules from the PSi matrix.28 
An alternative and more robust approach for drug loading into PSi carriers involves 
the covalent grafting of the drug molecules to the inner and/or outer surface of the PSi 
materials.267,275,301,303,304 In this case, the release of the active payload from the PSi particles 
only occurs after cleavage of the covalent bonds of the PSi-drug conjugates or degradation 
of the PSi matrix. Therefore, this methodology enables a precise control over the drug 
loading and release kinetics by tuning the type and conditions of the coupling chemistry 
applied and/or the degradation rate of the PSi framework. Although this approach grants 
more reproducible loading and release profiles in comparison to the physical adsorption 
method, the attainable drug loading degree is generally inferior, since it depends on the 
number of functional groups available for drug conjugation at the PSi surface.301 This 
method was applied, for example, for conjugating methotrexate (MTX) to the pore surfaces 
of PSi nanoparticles, resulting in a prolonged release of this anticancer agent for up to 96 h 
and enhanced in vitro antiproliferative effect.267 
In addition, an increased retention of the drug molecules inside the PSi materials and, 
consequently, a sustained drug release can be achieved by oxidizing the surface of the PSi 
pores after drug loading. During the oxidation process, additional oxygen atoms are inserted 
in the PSi matrix, leading to a reduction of the pore volume and an efficient entrapment of 
the active payload inside the PSi pores.25,305 Following this approach, two compounds, 
cobinamide and rhodamine B, were co-loaded with an oxidizing agent, sodium nitrite, inside 
freshly etched PSi films, which were subsequently fractured into PSi microparticles. The 
oxidation-mediated trapping of the model compounds into the PSi material showed, not only 
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to improve the drug loading degree, but also and most importantly, to remarkably sustain the 
drug release by 20-fold, compared to the pre-loading oxidized counterparts.305 
One of the main challenges and focuses in the field of drug delivery, particularly for 
cancer therapy, is associated with the poor aqueous solubility of drugs and consequent 
limited bioavailability. The formulation of poorly water-soluble drugs into PSi particulate 
systems has been demonstrated to significantly increase their dissolution in aqueous 
media.16,299 When loaded in the nanosized pores of PSi particles, the drug molecules are 
spatially confined and restricted from rearranging into three-dimensional crystal lattices, 
thus remaining stable in an amorphous state or forming nanocrystals, which ultimately 
results in a higher dissolution rate, compared to the bulk counterparts.299 This strategy has 
been applied for enhancing the aqueous solubility of a plethora of active compounds, 
including furosemide,299,306,307 griseofluvin,16,308 ibuprofen,302,309 indomethacin,310 
celecoxib,226 itraconazole,311,312 ethionamide,312 saliphenylhalamide,313 sorafenib 
(SFB)205,222 and cisplatin.314 
Despite the above mentioned advantageous features of PSi particles for loading and 
delivering the therapeutic agents, the degradation and off-target uncontrolled release of the 
loaded cargo, owing to the unrestrained access of the release media and biological fluids to 
the open pores of the PSi matrix, are major drawbacks limiting the application of these 
biomaterials for drug delivery. Therefore, different strategies have been explored for 
circumventing this problem and attaining control over the drug release kinetics from the PSi 
particles, including the loading of the drug molecules by covalent grafting or oxidation-
induced trapping previously described in this section, the physical capping of the pore 
apertures,238,307 the chemical grafting of pore gating and stimuli-responsive systems,204,315-
318 or the encapsulation of the PSi particles within other carriers.260,264,268,319-322  
The drug diffusion process from PSi-based drug delivery systems can be modified by 
physically adsorpting or covalently conjugating biocompatible and biodegradable non-
responsive polymers or lipids to the surface of PSi particles. This strategy has been applied, 
for example, by coating the surface of PSi particles with chitosan for prolonging the release 
of insulin and enhancing insulin permeation across an in vitro intestinal monolayer model.231 
In another study, a solid-lipid nanocomposite combining glycerol monostearate and 
phosphatidylcholine was deposited onto the surface of PSi nanoparticles, improving their 
cytocompatibility, colloidal dispersity and in vitro stability in human plasma, and sustaining 
the release of the encapsulated furosemide.307 
Furthermore, the surface of PSi particles can be functionalized with different stimuli-
responsive gate-keeping systems, in order to attain a spatiotemporal control over the drug 
release kinetics. In this regard, a smart PSi-based nanocomposite, envisioned for sequential 
combination cancer therapy, was engineered by combining PSi nanoparticles and a pH-
responsive nanovalve system. This dual-drug delivery nanoplatform was designed by 
covalently conjugating a pH-responsive cationic polymer, poly(β-amino ester), to the 
surface of DOX-loaded PSi nanoparticles, followed by stabilization with PTX-encapsulating 
micelles composed by a PEG and poly(propylene glycol) triblock copolymer. As a result, a 
remarkable synergistic chemotherapeutic effect was achieved in vitro, through an immediate 
release of PTX from the polymeric micelles, followed by a pH-triggered release of DOX 
from the PSi nanoparticles.204 
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Although PSi-based particulate systems have been demonstrating a high promise for drug 
delivery purposes, the biosafety and therapeutic efficiency of PSi-based nanomedicines, 
particularly when considering cancer therapy, is highly dependent on their capacity to 
accumulate in the malignant tissue, specifically attach to the targeted cells and deliver the 
therapeutic cargo in a sufficient concentration at the site of action. Therefore, one of the 
major focuses with respect to the application of PSi nanoparticles in cancer nanomedicine 
has been to develop active targeting strategies to selectively guide these nanovehicles to the 
surface of the cancer cells and trigger the receptor-mediated endocytosis locally. In this 
context, the surface chemical versatility of the PSi nanoparticles represents one of the most 
attractive features, for enabling the surface functionalization with a variety of targeting 
ligands, such as tumour homing peptides,205,271 targeting antibodies,26,30,256,269 and DNA 
aptamers,261 thus tremendously expanding the potential of this nanoplatform for cancer drug 
delivery and therapeutic purposes.  
In this regard, the surface of THCPSi nanoparticles was decorated with a tumour 
homing peptide targeting the mammary-derived growth inhibitor (MDGI) receptor. After 
intravenously administered into nude mice bearing subcutaneous MDGI-expressing 
tumours, the targeted nanoparticles showed an approximate 9-fold higher accumulation at 
the tumour site, in comparison to the non-functionalized particles.271 In another approach, a 
straightforward and efficient method based on copper-free click chemistry was applied to 
covalently conjugate RGD and iRGD tumour penetrating peptides on the surface of 
APSTCPSi nanoparticles for targeting the tumour neovasculature. Both RGD and iRGD 
modified PSi nanocarriers exhibited a significantly enhanced cellular uptake in EA.hy926 
endothelial cells in vitro, when compared to the unmodified APSTCPSi nanoparticles.205 
In addition to tumour homing peptides, the surface of PSi nanocarriers can be 
functionalized with targeting antibodies that are specific to different tumours. For example, 
MLR2, mAb528 and Rituximab antibodies have been successfully conjugated onto the 
surface of PSi nanoparticles to specifically target neuroblastoma, glioblastoma and B 
lymphoma cells, respectively.269 Furthermore, size- and shape-controlled PSi nanodiscs 
were recently fabricated by a new method combining colloidal lithography and metal-
assisted chemical etching, loaded with an anticancer agent, camptothecin, and further 
modified with a MLR2 anti-p75 antibody for targeting the p75NTR neurotrophin receptor 
expressed on the surface of neuroblastoma cells (SH-SY5Y). After antibody 
functionalization, the drug loaded nanodiscs were found to be selectively attached and killed 
the cancer cells.26 Alternatively, the tumour homing of PSi nanovectors can be attained by 
exploring biological targets overexpressed in stroma cells. Accordingly, a Ly6C antibody 
was conjugated on the surface of PSi nanoparticles as a dual targeting to pancreatic tumour 
associated endothelial cells and macrophages. Contrarily to the control nanocarriers, the 
Ly6C antibody decorated PSi nanoparticles exhibited high affinity to the cells expressing 
Ly6C in vitro. Moreover, the targeted nanocarriers were shown to accumulate in the tumour 
associated endothelial cells within 15 minutes, after their intravenous injection in orthotopic 
human pancreatic cancer bearing nude mice. Interestingly, after extravasation through the 
endothelial cell monolayer, the targeted PSi nanoparticles were engulfed by the Ly6C 
expressing tumour associated macrophages. It was demonstrated that, at 4 h after 
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administration, 9.8 ± 2.3% of the Ly6C targeted nanocarriers were accumulated in the 
pancreatic tumours as opposed to 0.5 ± 1.8% of the non-targeted nanoparticles.30 
????????????????????????????????????????????????????????????????????
Taking advantage of the aforementioned attractive properties for drug delivery and tumour 
targeting, PSi-based materials can be used to design and engineer advanced drug delivery 
systems, as well as theranostic tools for the simultaneous therapy and diagnostics of cancer.  
Along with the functionalization by targeting moieties, the surface chemical versatility 
of PSi nanoparticles provides the possibility for radio and fluorescent-labelling, therefore 
enabling to track the in vivo biofate of these targeted nanoparticulate systems.29,221,250,259,271 
For example, UnTHCPSi nanoparticles were dual-labelled with 111In radiolabel for 
monitoring their biofate using live single photon emission computed tomography 
(SPECT/CT) imaging, and Alexa Fluor® 488 (AF488) fluorescent dye for long-term 
biodistribution studies. The dual-labelled PSi nanoparticles were subsequently 
functionalized with an iRGD targeting peptide, generating a targeted and dual-labelled 
multifunctional nanovector for directed cancer theranostics. In this study, the in vivo 
biodistribution of both targeted and non-targeted multifunctional nanovectors was 
investigated, following both intravenous and intratumoural injection in a prostate cancer 
xenograft mice model. While the intravenously administered nanovectors were mainly 
distributed to the liver and spleen of the mice, the intratumourally administered counterparts 
were revealed to accumulate and be retained at the tumour site, even at 26 h post-injection.250 
The PSi nanoparticles have also been applied as a nanoplatform encapsulated within 
various micro- and nano-carriers to form advanced multifunctional drug delivery 
composites.260,264,268,319-322 In this regard, an advanced nanocomposite comprising PSi 
nanoparticles encapsulated into a pH-responsive acetalated dextran (AcDex) polymeric 
matrix was efficiently fabricated by a one-step nanoprecipitation microfluidic technique, for 
combined cancer therapy. A multiplicity of chemotherapeutics possessing distinct 
physicochemical properties, namely SFB, MTX and PTX, were simultaneously and 
efficiently loaded into the PSi@AcDex nanocomposites with precise ratiometric control. In 
order to enhance the intracellular delivery of the active payloads, the formulated 
nanocomposites were surface functionalized with a nona-arginine cell penetrating peptide. 
As a consequence of the enhanced cell penetrating properties and subsequent pH-triggered 
decomposition of the nanoplatforms in the endolysosomal compartments, an efficient 
intracellular release of the combined chemotherapeutic drugs was achieved, resulting in a 
potent concentration-dependent antiproliferative effect on breast cancer cells.268 Similarly, a 
multifunctional nano-in-micro composite, incorporating PSi nanoparticles, gold nanorods 
and magnetic nanoparticles into giant liposomes, was engineered by microfluidics. This 
advanced composite was contemplated for the controlled co-delivery of hydrophilic and 
hydrophobic drugs, as well as DNA nanostructures, while presenting both photothermal and 
magnetic responsiveness.322 
PSi particles have also been successfully used as a vehicle for other nanoparticulate 
drug delivery systems. For instance, nano-in-micro multistage vectors were assembled by 
encapsulating drug-loaded nanocarriers into hemispherical PSi microparticles, which size, 
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shape and surface chemical properties were optimized for attaining a desired in vivo 
biodistribution and enhancing the accumulation at the tumour vasculature.323,324 In a similar 
approach, quasi-hemispherical PSi microparticles modified with a E-selectin thioaptamer 
ligand were explored for delivering PTX-loaded liposomes to the bone marrow 
endothelium.325 Moreover, the same drug was formulated into PEG-block-poly(ε-
caprolactone) micelles subsequently loaded into the pores of PSi particles, delaying the drug 
release and efficiently supressing the tumour growth in mice bearing MDA-MB-468 breast 
cancer cells.326 
In addition to drug nanocarriers, PSi was reported as a suitable platform for 
accommodating a wide range of smaller nanoparticles within its porous structure, including 
carbon nanotubes,327 quantum dots,328 hollow gold nanoshells,329 and SPIONs.330,331 In the 
last example, the incorporation of SPIONs nanoparticles within the PSi carriers considerably 
potentiates its applicability in biomedicine, not only for enabling the magnetically driven 
delivery of therapeutic agents,330 but also for providing the opportunity to integrate both 
therapeutic and magnetic resonance imaging modalities in advanced multifunctional 
theranostic systems.331 
Despite the great promise of PSi nanoparticles for formulating different types of small 
drug molecules and biomolecules, and the remarkable progresses on the development of 
advanced and multifunctional PSi-based drug delivery systems, the successful application 
of these nanocarriers for cancer drug delivery and therapy is still defied by their 
ineffectiveness to deliver the active cargo at sufficient therapeutic concentrations to their site 
of action, mostly owing to their limited non-specific cellular interaction and internalization, 
intracellular trafficking, and lack of specificity for the targeted cancer cells or tissues. 
Therefore, there is still the need for designing innovative PSi-based nanoplatforms that not 
only circumvent these bottlenecks, but also integrate both therapeutic and diagnostic 
modalities, moving towards the development of a new generation of multifunctional PSi-
based nanoformulations with potential application in cancer nanomedicine. 
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???? ???????????????
Despite the recent exciting breakthroughs in the field of cancer nanomedicine, the 
complexity and heterogeneity of both cancer pathophysiology and therapeutic 
nanotechnology still challenge the application and clinical translation of nanoparticulate 
systems, demanding the emergence and optimization of novel and more advanced 
nanoformulations. Over the past decades, PSi nanoparticles have demonstrated great 
potential for drug delivery applications, owing to advantageous physicochemical and 
biological properties, with particular emphasis in cancer nanomedicine. However, major 
deadlocks associated with colloidal and plasmatic instabilities, poor cell-targeting efficiency 
and in vivo PK, limited cellular association, internalization and intracellular trafficking, as 
well as premature and uncontrolled release of the therapeutic cargos, still defy the 
implementation of these nanoparticles as effective anticancer drug delivery systems.  
In this regard, this dissertation outlines several strategies, including the surface 
modification of PSi nanoparticles with biofunctional polymers and the engineering of 
advanced multifunctional PSi-based nanocomposites, with the main aim of circumventing 
some of the aforementioned bottlenecks for the more successful application of this 
nanoplatform in cancer nanomedicine.  
 
The specific objectives of this dissertation are the following: 
 
1.? To investigate the potential of the surface biofunctionalization of PSi 
nanoparticles with an amine-modified hyaluronic acid derivative in order to 
increase the specific cellular interactions and uptake by targeted CD44-
overexpressing breast cancer cells, as well as to improve the colloidal and 
plasmatic stabilities (I). 
 
2.? To evaluate the impact of the surface polymeric modification of PSi 
nanoparticles on the cytocompatibility, non-specific cellular internalization, 
endosomal escape, methotrexate release profile, and in vitro antiproliferative 
effect of the nanocarrier (II). 
 
3.? To fabricate a multifunctional PSi-based nanocomposite encapsulating both 
sorafenib-loaded PSi and Au nanoparticles into a polymeric nanocomplex, 
aiming at improving the cytocompatibility, cellular association and 
internalization, intracellular trafficking, cytoplasmic delivery and 
chemotherapeutic effect of the drug-loaded PSi nanoplatform (III). 
 
4.? To design and develop a multifunctional nano-in-nano composite, consisting of 
DNA-gated PSi nanoparticles encapsulated within polymeric nanocomplexes for 
combined cancer therapeutics or theranostics, and for further evaluation towards 
intracellular bioresponsive dual-drug delivery (IV). 
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???????? ??????
This section summarizes the experimental methods used in this dissertation. The detailed 
description of all the materials, instrumentation and methods used in this work can be found 
in the respective original publications (I−IV). 
?????????????????????????????????????????
???????????????????????????????????????????????????
The UnTHCPSi nanoparticles were fabricated by electrochemically anodizing 
monocrystalline boron-doped p+-type Si 〈100〉 wafers, with resistivity values of 0.01–0.02 
Ω.cm, in a 1:1 (v/v) aqueous HF(38%)-ethanol electrolyte. The multilayer structure was 
formed by applying an etching profile consisting of repeating low/high current density 
pulses, designed to form fracture planes at desired intervals. Hydrogen-terminated free-
standing multilayer PSi films were subsequently lifted off from the substrate by abruptly 
increasing the etching current density to the electropolishing region. The PSi films were then 
dried at 65 ºC for several hours to evaporate the electrolyte.228 In order to improve the PSi 
surface stability and to remove the adsorbed moisture and residual oxygen, the PSi films 
were inserted into a quartz tube under continuous N2 flow (1 L.min−1) for at least 30 min at 
room temperature. In order to render the PSi films a hydrocarbon termination and, 
consequently, improved surface stability towards oxidation, a thermal hydrocarbonization 
treatment was performed by exposing the PSi films to a 1:1 (v/v) N2:acetylene (C2H2) flow 
(1 L.min−1), for 15 min at room temperature, followed by heat treatment at 500 ºC for 15 
min, and cooling back to room temperature under N2 flush.22 For functionalizing the 
THCPSi’s surface with carboxylic groups, the films were immersed into 10-undecylenic acid 
for 16 h at 120 ºC. The resulting UnTHCPSi films were finally wet-milled in a high energy 
ball mill, using 1-decene as milling medium for minimizing surface oxidation, in order to 
obtain the UnTHCPSi nanoparticles.219 
?????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????
An amine modified hyaluronic acid (HA+) was synthesized, prior to conjugation to the 
surface of UnTHCPSi nanoparticles. For this purpose, an aqueous solution of HA sodium 
salt (200 mg, 30 mmol) was sequentially dialyzed for 20 h against 4 L of 0.01 N hydrochloric 
acid (HCl) and Milli-Q water. The acidic form of HA (172 mg, 0.045 mmol of acidic groups) 
was recovered by lyophilisation, and subsequently dissolved in 14 mL of anhydrous 
dimethylsulfoxide (DMSO). The carboxylic groups of HA were activated by adding 80 mg 
(0.70 mmol) of sulfo-N-hydroxysulfosuccinimide (Sulfo-NHS) and 124 µL (109 mg, 0.70 
mmol) of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC), allowing the reaction to 
occur for 60 min at room temperature. Following step, the substitution of the carboxylic 
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groups of HA, was done by addition of NH2-PEG2-NHBoc (223 mg, 0.90 mmol, 2 eq.) and 
N-ethyldiisopropylamine (DIPA) (70 mg, 0.54 mmol, 1.2 eq.) under stirring, after which the 
reaction was set to proceed for 4 days. The resulting HA-PEG2-NHBoc was then precipitated 
in acetone (140 mL), washed three times with the same solvent, filtered, and dried under 
vacuum to remove the residual DMSO. The terminal amine groups of HA-PEG2-NHBoc 
were deprotected by dissolving the polymer (50 mg) in 5 mL of trifluoroacetic acid (TFA) 
at 0°C. After stirring for 20 h at 4 °C, 20 mL of Milli-Q water was added, and the solution 
was neutralized with sodium hydroxide (NaOH). Finally, the sodium salt of HA+ was 
obtained by dialyzing the solution for 20 h against 2 L of 0.1 M NaCL and Milli-Q water, 
followed by lyophilisation.332 
For preparing the UnTHCPSi-amine modified hyaluronic acid (UnHA+) nanoparticles, 
the synthesized HA+ was covalently conjugated to the carboxylic groups of UnTHCPSi 
nanoparticles via EDC/NHS coupling chemistry. In this regard, 1.5 mg of UnTHCPSi 
nanoparticles were dispersed in 4 mL of 10 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) saline buffer (pH 5.2). The precursor carboxylic groups of the UnTHCPSi 
nanoparticles were activated by reacting with 6 mg (0.05 mmol) of N-hydroxysuccinimide 
(NHS) and 8 µL (0.05 mmol) of EDC, under stirring at room temperature and at 800 rpm for 
90 min. After activation, the HA+ was added to the reaction vial at a UnTHCPSi:HA+ ratio 
(w/w) of 1:2, and the nucleophilic substitution was left to occur overnight under the same 
stirring conditions. The excess of reagents was removed by rinsing the modified 
nanoparticles three times with Milli-Q water. Finally, the UnHA+ nanoparticles were re-
dispersed in Hank’s balanced salt solution-4(-2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HBSS−HEPES) buffer (pH 7.4) and stored at 4 ºC until further use. 
???????? ???????????? ??? ?????????????????????? ????????????????? ?????? ??????????
????????????????????????????????
The UnTHCPSi-poly(ethylenimine)-poly(methyl vinyl ether-alt-maleic acid) (UnPP) 
nanoparticles were prepared by successive covalent conjugation of hyperbranched PEI (Mw 
~25,000) and poly(methyl vinyl ether-alt-maleic acid) (PMVE-MA) onto the surface of the 
UnTHCPSi nanoparticles.  
In the first step of UnPP production, the carboxylic groups of UnTHCPSi nanoparticles 
were activated by dispersing 1.5 mg of these nanoparticles in 4 mL of MES saline buffer 
(pH 5.2), followed by the addition of 6 and 7 mg of NHS and EDC, respectively. After 
reacting for 2 h under stirring at room temperature and at 800 rpm, the activated surface of 
UnTHCPSi nanoparticles was exposed to an excess of PEI at an UnTHCPSi:PEI ratio (w/w) 
of 1:10 and left to react overnight, under stirring in the aforementioned conditions. The 
resulting UnP nanoparticles were extensively rinsed with Milli-Q water to remove the 
unreacted reagents and re-suspended in HBSS−HEPES buffer (pH 7.4). 
In the subsequent step, EDC/NHS coupling chemistry was used to conjugate PMVE-
MA to the surface of the previously obtained UnP nanoparticles. For this purpose, 
poly(methyl vinyl ether-alt-maleic anhydrate) (PMVE-MAh; Mw ~216,000) was first 
dissolved in HBSS−HEPES buffer (pH 5.2) and heated for 3 h at 70 ºC, in order to obtain 
the PMVE-MA copolymer. Next, PMVE-MA was activated by EDC/NHS for 2 h, and 
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subsequently added to the UnP nanoparticles dispersed in the same buffer, at a UnP:PMVE-
MA ratio (w/w) of 1:1. The resulting UnPP nanoparticles were washed twice with Milli-Q 
water, by repeated centrifugation for 5 min at 15,000 rpm and re-dispersion for obtaining a 
reagent-free final product. Finally, the nanoparticles were re-suspended in HBSS−HEPES 
buffer (pH 7.4) and stored at 4 ºC until further use. 
????????????????????????????????????????????????????????????????????????
The bioresponsive UnTHCPSi-cystine-acridine-DNA (UnCAD) nanocomposites were 
engineered by biofuntionalizing the surface of UnTHCPSi nanoparticles with cysteine and 
9-aminoacridine as redox responsive inducer and DNA intercalator, respectively, using 
EDC/NHS coupling chemistry. Briefly, 20 µL of EDC and 15 mg of NHS were separately 
dissolved in 4 mL of 10 mM MES saline buffer (pH 5.2). After that, 3 mg of UnTHCPSi 
nanoparticles were dispersed in the EDC solution and tip-sonicated for 20 sec, followed by 
addition of the NHS solution. The reaction vial was left under stirring at room temperature 
for 2 h, for activating the carboxylic groups of the UnTHCPSi nanoparticles, which were 
then purified from the unreacted coupling reagents by centrifugation at 13,000 rpm for 6 
min. Next, 25 mg of cystine was dissolved in 1 mL of HCL, mixed with 7 mL of 0.1 M 
phosphate buffer solution (PBS; pH 9.0), followed by pH adjustment of the final solution to 
9.0. The activated UnTHCPSi nanoparticles were re-suspended in 2 mL of cystine solution 
and left to react for 18 h under stirring at room temperature and at 800 rpm. Due to pH-
dependent cystine solubility, the reaction was performed at a higher pH than the optimal 
range suggested by the manufacture for the nucleophilic substitution of NHS-esters (pH 
7−8). Therefore, an excess of cystine and a longer reaction time were used for compensating 
the slower conjugation kinetics. The resulting UnTHCPSi-cystine (UnC) nanoparticles were 
centrifuged at 13,000 rpm for 6 min, washed twice with 0.1 M PBS (pH 9.0) and once with 
Milli-Q water, and again activated via EDC/NHS chemistry in 10 mM of MES saline buffer 
(pH 5.2), as mentioned above. The activated UnC nanoparticles were purified by 
centrifugation and re-suspended in a 9-aminoacridine solution prepared by dissolving 30 mg 
of this compound in 7 mL of ethanol-PBS (0.1 M, pH 5.2) (3:4 v/v) mixture. The reaction 
was left to occur for an additional 18 h period and the resulting UnTHCPSi-cystine-acridine 
(UnCA) nanoparticles were again centrifuged, washed once with ethanol and twice with 
Milli-Q water. Finally, DNA was anchored at the surface UnCA nanoparticles through 
intercalation with the acridine moieties. For accomplishing the DNA coating, 6 mg of DNA 
was dissolved in 1.5 mL of PBS (pH 7.4), and mixed with the UnCA nanoparticles 
suspended in 3 mL of the same buffer solution. After stirring for 24 h, the UnCAD 
nanoparticles were isolated by centrifugation and washed three times with PBS (pH 7.4). 
DNase free buffers and materials were used in all the steps of DNA intercalation. 
???????????????????????????????????????????????????????
Fluorescently labelled UnTHCPSi, UnHA+, and UnPP nanoparticles were obtained by 
physically adsorbing fluorescein isothiocyanate (FITC) onto their surface (I and II). For that 
purpose, FITC was first dissolved in a 1:5 (v/v) mixture of 0.1 M of HEPES (pH 7.5) and 
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ethanol, and subsequently added to the nanoparticles at a nanoparticles:FITC ratio of 10:1 
(m/m). 
Alternatively, the AF488 fluorescent dye was covalently conjugated to the carboxylic 
groups of UnTHCPSi nanoparticles by EDC/NHS coupling chemistry (III). In this case, 1.5 
mg of UnTHCPSi were dispersed in 4 mL of MES buffer (pH 5.2). After that, 8 µL EDC 
and 6 mg of NHS were added to the nanoparticles suspension, and the activation of the 
precursor carboxylic groups of the UnTHCPSi nanoparticles was allowed to occur for 2 h at 
room temperature, under stirring at 800 rpm. Next, 20 µg of AF488 hydrazine was added to 
the reaction vial at 1:75 (w/w) ratio (AF488:UnTHCPSi nanoparticles), and the conjugation 
was proceeded for additional 2 h at the same stirring conditions. The AF488-labelled 
UnTHCPSi nanoparticles were purified from the excess of coupling reagents and excess of 
AF488 by washing once with 10 mM of HCl and twice with Milli-Q water. 
????????????????????????????????????????????? ?????????????????????????????????
????????????????????????????????????
The L-cysteine-poly(ethylenimine)-poly(methyl vinyl ether-alt-maleic acid) (CPP) 
nanocomplexes composed of three different polyelectrolytes, namely L-cysteine, PEI and 
PMVE-MA, were produced by an ionotropic gelation technique.333-335 In a first step, PMVE-
MAh was dissolved in 0.2× HBSS buffer (pH 5.2) at a concentration of 1.67 mg.mL−1 for, 
at least, 3 h at 70 ºC, to obtain the PMVE-MA copolymer. Additionally, a L-cysteine solution 
(5.0 mg.mL−1) was prepared in acetate buffer (pH 4.0), containing a 1:1 (v/v) ratio mixture 
of 1.7 M of acetic acid and 0.1 M of sodium acetate. PEI was dissolved in Milli-Q water at 
a concentration of 10.0 mg.mL−1. For preparing the CPP nanocomplexes, 500 and 300 µL of 
the L-cysteine and PEI solutions, respectively, were mixed and constantly stirred. Next, 3.4 
mL of the PMVE-MA solution was slowly added to the mixture, under stirring at 800 rpm 
and ultrasonication using a Vibra-cell VCX 750 ultrasonic processor (Sonics, Sonics and 
Materials, Inc., CT, USA) at 30% amplitude, and post stirring for 1 min in the same 
conditions. 
??????????????????????????????????????????????????????????????????
?????????
The UnCPP (III), UnAuCPP (III), and UnCAD@CPP (IV) nanocomposites were 
engineered by nanoencapsulating UnTHCPSi nanoparticles, UnTHCPSi and Au 
nanoparticles, and UnCAD nanoparticles, respectively, into the CPP nanocomplexes. The 
nanoencapsulation was accomplished by resuspending the encapsulates, more precisely 500 
µg of UnTHCPSi and UnCAD nanoparticles, and 20 µg of Au nanoparticles in the PMVE-
MA solution, followed by ultrasonication for 30 sec, prior to addition in the L-cysteine:PEI 
mixture. After that, the fabrication protocol continued, as previously described for the bare 
CPP nanocomplexes (Section 4.1.3). 
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????????????????????????????????????????????????????????????? 
The physical properties of UnTHCPSi nanoparticles were characterized with N2-sorption at 
−196 ºC, using a TriStar 3000 gas sorption apparatus (Micromeritics Inc., GA, USA). The 
specific surface area was calculated from the isotherm using the Brunauer-Emmett-Teller 
(BET) theory,336 and the total pore volume was considered to be the total amount adsorbed 
at a relative pressure p/p0 = 0.97. The average pore diameter was estimated from the values 
of specific surface area and total pore volume obtained, assuming that the pores of the 
UnTHCPSi were cylindrical. 
The average hydrodynamic diameter (Z-average), polydispersity index (PdI) and 
surface zeta (ζ)-potential of the different nanoparticulate systems developed in this thesis 
were analysed by dynamic light scattering (DLS) and electrophoretic light scattering (ELS), 
respectively, using a Zetasizer Nano ZS equipment (Malvern Instruments Ltd., Malvern, 
UK). Prior to the measurements, the nanoparticles were diluted in Milli-Q water to a final 
concentration varying from 25−55 µg.mL−1, and subsequently loaded into disposable 
polystyrene (Sarstedt AG & Co., Nümbrecht, Germany) or disposable folded capillary cells 
(DTS1070; Malvern Instruments Ltd., Malvern, UK) for the size or ζ-potential analyses, 
respectively. All the sample measurements were performed in triplicate. 
The morphology of the nanocarriers was evaluated by transmission electron 
microscopy (TEM), using a Jeol JEM-1400 microscope (Jeol Ltd., Akishima, Tokyo, Japan), 
operating at an acceleration voltage of 80 kV. In this regard, the bare and polymer-
conjugated UnTHCPSi nanoparticles (I−II) were centrifuged, re-dispersed in ethanol at a 
concentration of 10 µg.mL−1, ultrasonicated for 30 sec, dropped onto carbon-coated copper 
TEM grids (150 mesh; Ted PELLA Inc., CA, USA), and allowed to dry overnight at room 
temperature. In the last two works of this thesis (III−IV), the specimens were prepared by 
diluting the nanocomposites suspensions to a final concentration of approximately 5.5 × 102 
µg.mL−1, in which the aforementioned carbon-coated cooper TEM grids were immersed for 
1 min, followed by drying using filter paper and air-drying overnight at room temperature. 
The surface chemical compositions of the bare and polymer-functionalized 
UnTHCPSi nanoparticles (I−II) were investigated by attenuated total reflectance Fourier 
transform infrared (ATR−FTIR) spectroscopy, using a Bruker VERTEX 70 FTIR 
spectrophotometer (Bruker Optics Inc., MA, USA) fitted with a horizontal MIRacle™ single 
reflection ATR accessory (Pike Technologies, WI, USA). All the samples were dried at room 
temperature for 48 h, prior to recording of the ATR-FTIR spectra in the wavenumber region 
between 4000−650 cm−1 with a 4 cm−1 resolution, using OPUS 5.5 software. 
For confirming successful nanoencapsulation of the UnTHCPSi and Au nanoparticles 
into the CPP nanocomplexes, the chemical elements composing these nanoencapsulates, i.e., 
Si and Au, respectively, were identified by energy dispersive X-ray (EDX) microanalysis. 
For this purpose, TEM specimens were prepared following the protocol described above and 
the EDX spectra were recorded using an Oxford INCA 350 EDX microanalysis system 
(Oxford Instruments plc, Oxfordshire, UK) connected to a Hitachi S-4800 field emission 
scanning electron microscope (SEM, Hitachi High-Technologies Corp., Minato-ku, Tokyo, 
Japan), operating at a 30 kV accelerating voltage. 
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?????????????????????????????????????
????????????????? ?????????? ?????????????????
The bare UnTHCPSi and surface-modified UnTHCPSi nanoparticles (II−IV) were loaded 
with different model drug molecules, by an immersion method using highly concentrated 
drug solutions.16 
The anticancer drug MTX was loaded into UnTHCPSi, UnP and UnPP nanoparticles 
by immersing the nanoparticles into a 10 mg.mL−1 concentrated solution of the drug in PBS 
(pH 8.0), at a 20:1 (w/w) ratio (MTX:UnTHCPSi) and under stirring for 2 h at 400 rpm and 
room temperature (II). The MTX-loaded nanoparticles were purified from the unloaded drug 
by centrifugation at 15,000 rpm for 7 min, followed by two washing steps with Milli-Q 
water. 
SFB was loaded within the porous structure of UnTHCPSi nanoparticles, prior to the 
fabrication of UnCPP and UnAuCPP nanocomplexes (Section 4.1.4) (III). In this regard, the 
SFB-loaded UnTHCPSi nanoparticles (SFB@UnTHCPSi) were prepared by redispersing 
the UnTHCPSi nanoparticles in a 5 mg.mL−1 concentrated SFB solution in methanol 
(MeOH) at a 50:1 (w/w) ratio (SFB:UnTHCPSi), followed by ultrasonication for 5 sec and 
stirring for 2 h at 800 rpm and at room temperature. After drug loading, the excess of drug 
solution was removed by centrifugation at 15,000 rpm for 10 min, and the drug molecules 
adsorbed to the nanoparticles surface were removed by washing the drug-loaded 
nanoparticles twice with Milli-Q water. 
The loading of both hydrophilic and hydrophobic molecules within the pores of UnCA 
nanoparticles was performed before DNA capping and nanoencapsulation into the CPP 
nanocomplexes, as described in the Sections 4.1.2.3 and 4.1.4, respectively (IV). For loading 
the hydrophobic chemotherapeutic agent SFB, 3 mg of the UnCA nanoparticles were 
resuspended in 30 mL of a drug solution in acetone (4 mg.mL−1) and left under stirring for 
3 h at room temperature. After drug loading, the nanocarriers were centrifuged and washed 
twice with Milli-Q water. Moreover, for verifying the potential of the developed 
nanosystems to responsively deliver hydrophilic molecules, calcein was loaded into the 
UnCA nanoparticles by immersing 3 mg of the nanoparticles in 30 mL of 10 mM of PBS 
(pH 7.4), containing 0.8 mM of calcein, followed by stirring for 24 h at room temperature to 
allow the calcein molecules to diffuse into the pores of the nanocarriers. In this particular 
case, the DNA capping process was performed in a PBS solution supplemented with 0.8 mM 
of calcein, in order to avoid the release of the cargo during the process. The excess of calcein 
and DNA was then removed from the calcein-loaded UnCAD nanoparticles by 
centrifugation and three washing steps with Milli-Q water. 
The drug loading degree (LD) of the different nanocarriers, calculated as the weight 
percentage of the drug in the nanocarrier, was determined by immersing the drug-loaded 
nanoparticles into a suitable solvent, enabling the complete release of the payloads, followed 
by the quantification with high pressure liquid chromatography (HPLC). The detailed 
description of the protocols used for drug loading measurements and the HPLC experimental 
setups can be found individually in the respective original publications (II−IV). 
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??????????????????????? ????????????????????????????????????????
In addition to SFN loading into the UnTHCPSi nanoparticles, also FITC was encapsulated 
as a model molecule within the CPP matrix of UnCAD@CPP via thiol-isocyanate click 
chemistry,337 for fluorescent labelling of the nanocomposites and as a proof-of-concept for 
co-drug delivery and potential theranostic applications. The highest encapsulation efficiency 
of FITC was optimized by testing different concentration of the fluorescent dye. After 
optimization, 30 µg of FITC was dissolved in 70% ethanol, and subsequently added to 3.4 
mL of PMVE-MA solution containing 500 µg of UnCAD nanoparticles. Next, the 
fluorescent UnCAD@CPP nanocomplexes were prepared, as previously described in the 
Section 4.1.4. 
The encapsulation efficiency of FITC into UnCAD@CPP nanocomposites was 
quantified by an indirect method. For this purpose, the FITC-loaded UnCAD@CPP 
nanocomposites were centrifuged for 5 min at 13,000 rpm, and 200 µL of the supernatant 
was collected into 96-well plates, after which the FITC amount in the supernatant was 
determined using a Varioskan™ Flash Multimode Reader (Thermo Scientific, Thermo 
Fisher Scientific, MA, USA), according to a pre-plotted calibration curve. Furthermore, the 
total amount of FITC (encapsulated and non-encapsulated) was quantified from the 
nanocomposites suspension, using the nanocomposite formulation without FITC as a blank. 
All the experiments were performed in triplicate. 
????????????????????????????????????????????
?????????????????????????????????????????????????
For investigating the in vitro drug release of MTX from UnTHCPSi, UnP and UnPP 
nanoparticles, 250 µg of MTX-loaded nanocarriers were re-dispersed in 20 mL of PBS (pH 
7.4), and stirred for 12 h at 100 rpm and at 37 ºC (II).  
Similarly, the drug release profiles of SFB-loaded UnTHCPSi, UnCPP and UnAuCPP 
nanocomposites were evaluated. For this purpose, the amount of the different 
nanocomposites corresponding to 200 µg of SFB@UnTHCPSi nanoparticles were dispersed 
in 20 mL of 10 mM of HBSS−HEPES (pH 7.4) and 10 mM of HBSS−MES (pH 5.5), and 
left under stirring for 6 h, at 300 rpm and at 37 ºC (III). Owing to the very poor water 
solubility of SFB, the drug release media were supplemented with fetal bovine serum (FBS) 
at the final concentration of 10% (v/v), in order to aid the dissolution of SFB.205 In the case 
of pure SFB dissolution testing, approximately 200 µg of the drug was dispersed in 200 mL 
of the aforementioned drug release media. 
In both studies (II and III), 200 µL aliquots of each sample were withdrawn at 
predetermined timepoints and replaced with equal volume of the corresponding pre-warmed 
media, for maintaining a constant volume of the release media. The sampling aliquots were 
centrifuged for 3 min at 15,000 rpm, and the concentration of the drug release from the 
nanoparticles was quantified in the supernatant by HPLC. In the case of SFB drug release 
testings (III), the sample supernatants were diluted with an equal volume of MeOH, vortexed 
for 30 sec, and again centrifuged in the same conditions prior to the HPLC analysis, in order 
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to precipitate the serum protein constituents of the FBS included in the release media. The 
experimental HPLC setups used in each study can be found individually in the respective 
original publications (II−III). All the experiments described in this section were performed, 
at least, in triplicate. 
?????????????????????????????????????????????????????
The in vitro drug release profiles of SFN-loaded UnTHCPSi, UnCAD and UnCAD@CPP 
nanocomposites were determined by re-dispersing 400 µg of the drug-loaded nanocarriers 
in 40 mL of PBS supplemented with 10% FBS (pH 7.4) for the aforementioned purpose. 
The samples were stirred for 6 h at 150 rpm and at 37 ºC. For evaluating the redox and DNase 
responsiveness of the nanocomposites, in vitro drug release studies were also conducted in 
media containing 10 mM of glutathione (GSH) and 25 U.mL−1 of DNase, respectively. The 
aliquots collected were then centrifuged for 5 min at 13,000 rpm, and the SFB concentration 
in the supernatant was analysed by HPLC, according to the experimental setup described in 
the original publication (IV). 
In addition, for investigating the calcein release from the developed nanocomposites, 
1 mg of calcein-loaded nanoparticles were dispersed in 10 mL of PBS containing 10% FBS 
(pH 7.4), and stirred for 6 h at 150 rpm and at 37 ºC. The amount of calcein released over 
time was monitored by fluorescence spectroscopy (λex = 458 nm and λem = 510 nm). All the 
measurements were performed in triplicate. 
????????????????????????????????????????????????????
The impact of the human plasma proteins on the stability of bare and polymer-functionalized 
UnTHCPSi nanoparticles was investigated. For performing these experiments, 300 µg of 
bare and polymer-conjugated UnTHCPSi nanoparticles were dispersed in 200 µL of PBS 
(pH 7.4) and incubated with 1500 µL of human plasma, under stirring at 800 rpm and at 37 
ºC for 2 h. Sample aliquots (200 µL) were withdrawn after 1, 5, 10, 15, 30, 60, 90, and 120 
min, for measuring the nanoparticles size, PdI and ζ-potential by DLS and ELS, respectively, 
as previously described (Section 4.2), using a Zetasizer Nano ZS equipment (Malvern 
Instruments Ltd., Malvern, UK). At least three independent measurements were performed 
for each experimental setup. Anonymous human plasma samples were obtained from the 
Finnish Red Cross Blood Service, with the permission from the respective institutional 
ethical committee. 
???????????????????????????????????????
???????????????????????????????????????????
Human breast adenocarcinoma cells, namely MDA-MB-231 (I−IV) and MCF-7 (I−II) cell 
lines, were selected for the in vitro cell based studies and obtained from the American Type 
Culture Collection (ATCC, VA, USA). Briefly, the MDA-MB-231 and MCF-7 breast 
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adenocarcinoma cells were cultured in standard Roswell Park Memorial Institute (RPMI) 
1640 medium and Dulbecco’s Modified Eagle’s Medium (DMEM), respectively, both 
supplemented with 10% (v/v) FBS, 1% non-essential amino acids (NEAA), 1% L-glutamine, 
and 1% streptomycin-penicillin (100 IU.mL−1) (all from HyClone, GE Healthcare Life 
Sciences GmbH, UT, USA). The cell cultures were maintained in 75 cm2 culture flasks 
(Corning Inc. Life Sciences, NY, USA) at 37 ºC and at an atmosphere of 95% humidity and 
5% CO2 (BB 16 gas incubator, Heraeus Instruments GmbH, Hanau, Germany). The cell 
culture medium was replaced every other day and subculturing was performed when the 
cells were at 80% of confluency, until the time of the experiments. For subculturing and 
prior to each in vitro study, the cells were harvested with a 0.25% (v/v) trypsin-PBS- 
ethylenediaminetetraacetic acid (EDTA) solution. 
???????????????????????????????????????
????????????????????????????
The in vitro cytotoxicity values of all the developed nanoparticulate systems were assessed 
towards MDA-MB-231 (I−IV) and MCF-7 (I−II) breast cancer cells by measuring the ATP 
activity of the cells after incubation with the different nanoparticles, which was correlated 
to the number of alive cells present in culture. For this purpose, an ATP-based cell viability 
assay was carried out, according to the manufacturer’s specifications and as previously 
described elsewhere.212 Briefly, the cells were harvested, resuspended in their correspondent 
cell culturing medium at the concentration of 1.5–2.0 × 105 cells.mL−1, seeded in 96-well 
plates (Corning Inc. Life Sciences, NY, USA) at a cell density of ~1.5–2.0 × 104 cells per 
well, and allowed to attach overnight at 37 ºC. Thereafter, the cell culture medium was 
removed and the cells were washed twice with pre-warmed 1× HBSS (pH 7.4) (I−II) or 
HBSS−HEPES (pH 7.4) (III−IV) buffers, prior to addition of 100 µL of the various 
nanoparticles resuspended in the same buffer solutions, at concentrations ranging from 12.5 
to 200 µg.mL−1, and incubated for 6 and 24 h at 37 ºC. After incubation, 100 µL of CellTiter-
Glo® reagent assay (Promega Corporation, WI, USA) was added to each well and the 
luminescence was measured using a Varioskan™ Flash Multimode Reader (Thermo 
Scientific, Thermo Fisher Scientific, MA, USA). Positive (1% Triton X-100 solution) and 
negative (1× HBSS (pH 7.4) or HBSS−HEPES (pH 7.4) buffer solutions) controls were 
included in each 96-well plate and treated similarly as described above. All the data sets 
were compared to the negative control, considered as 100% cell viability, and corresponded 
to the average of at least three independent measurements. 
??????????????????????????????
Heparin-stabilized fresh human blood was obtained from anonymous donors from the 
Finnish Red Cross Blood Service and used within 2 h. For isolating the RBCs from the 
serum, 2.5 mL aliquot of blood was gently mixed with 5 mL of Dulbecco’s phosphate 
buffered saline (D-PBS) and centrifuged for 6 min at 2,500 rpm. After that, the RBCs were 
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washed five times with 5 mL of sterile D-PBS solution, and a 5% haematocrit suspension 
was obtained by diluting 1 mL of the RBCs pellet with D-PBS to the final volume of 20 
mL.338 The haemolytic effect of the various nanoparticulate systems was evaluated by adding 
100 µL of the 5% haematocrit to 400 µL of the different nanoparticle suspensions in D-PBS, 
until reaching the final concentrations of 25, 50, 100 and 200 µg.mL−1. The samples were 
vortexed for 5 sec and subsequently incubated at room temperature and static conditions for 
1, 4, 8, 12 and 24 h. After each incubation period, the samples were gently vortexed for 5 
sec and centrifuged for 3 min at 13,000 rpm. Next, 100 µL aliquots of the sample 
supernatants were transferred to a 96-well plate (Corning Inc. Life Sciences, NY, USA), for 
quantifying the haemoglobin absorbance values at 577 nm, with a reference wavelength of 
655 nm, using a Varioskan™ Flash Multimode Reader (Thermo Scientific, Thermo Fisher 
Scientific, MA, USA). D-PBS and Milli-Q water were used as negative and positive controls, 
respectively. The results denote the average of, at least, three independent experiments. 
?????????????????????????????????????????????????????????????????
?????????????????????????????????????????? ?????????????
The cellular association, internalization and intracellular localization of the developed 
nanoparticulate systems was investigated by TEM imaging analysis. Generally, MDA-MB-
231 (I−IV) and MCF-7 (I−II) breast cancer cells were harvested as previously described 
(Section 4.5.1), resuspended in RPMI 1640 and DMEM media, respectively, seeded onto 
13-mm round-shaped coverslips placed at the bottom of 24-well plates (Corning Inc. Life 
Sciences, NY, USA), and allowed to attach overnight at 37 ºC prior to exposure to the 
different nanoparticles. 
In the studies I and II of this thesis, MDA-MB-231 and MCF-7 cells were seeded in 
the 24-well plates at a cell density of 105 cells per well. After attachment and removal of the 
cell culture media, the cells were exposed to 500 µL of bare and polymer-modified 
UnTHCPSi nanoparticles suspensions in HBSS−HEPES buffer (pH 7.4), at the 
concentration of 50 µg.mL−1, for a period of 6 h at 37 ºC. 
In the case of the study III, MDA-MB-231 cells were seeded in the 24-well plates at 
the cell density of 2 × 105 cells per well. Following the overnight attachment, the cell culture 
medium was removed, the cells were washed once with pre-warmed HBSS-HEPES buffer 
(pH 7.4), and exposed to 700 µL of the UnTHCPSi, UnCPP and UnAuCPP nanocomposites 
suspensions in HBSS−HEPES buffer + 10% FBS (pH 7.4), at the concentration equivalent 
to 10 µg.mL−1 of UnTHCPSi, for 3h at 37 ºC.  
In the study IV, MDA-MB-231 cells were seeded in the 24-well plates at a cell density 
of 105 cells per well, followed by incubation for two nights at 37 ºC for allowing the cell 
attachment. After removing the cell culture media, the cells were exposed to 500 µL of the 
UnCAD and UnCAD@CPP nanocomposites suspensions in HBSS−HEPES buffer + 10% 
FBS (pH 7.4), at the concentration equivalent to 20 µg.mL−1 of UnTHCPSi, for 4h at 37 ºC.  
Thereafter, the nanoparticles suspensions were carefully aspirated and the cover slips 
were gently washed twice with HBSS-HEPES buffer (pH 7.4) prior to cell fixation with 
2.5% glutaraldehyde in 0.1 M of PBS buffer (pH 7.4), for 1 h at room temperature. After 
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fixation, the samples were washed twice with HBSS−HEPES buffer (pH 7.4) and sodium 
cacodylate buffer (NaCac) for 3 min, followed by post-fixation with 1% osmium tetroxide 
in 0.1 M NaCac buffer (pH 7.4). The cells were then dehydrated with 30−100% ethanol for 
10 min and embedded in epoxy resin. Ultrathin sections with approximately 60 nm thickness 
were sliced parallel to the coverslips, post-stained with uranyl acetate and lead citrate, and 
finally analysed by TEM. 
???????????????????????????????????????
Before investigating the capability of the HA conjugation on the surface of UnTHCPSi 
nanoparticles to help in targeting to CD44-overexpressing cells, the expression of the CD44 
receptor was evaluated by flow cytometry in MDA-MB-231 and MCF-7 breast cancer cell 
lines, according to a protocol adapted from the manufacturer’s specifications. Briefly, the 
cells were harvested, as described above (Section 4.5.1), and suspended in 1× PBS (pH 7.4), 
at a concentration of 1.5 × 107 cell.mL−1. Next, 50 µL of the cell suspensions were incubated 
with equal volumes of BD Horizon™ PE-CF594 mouse anti-human CD44 antibody (BD 
Biosciences, NJ, USA) stock solutions, with increasing concentrations of 5.0, 10.0, and 20.0 
µg.mL−1, for 45 min at 4 ºC in the dark. After the reaction, the unbound portion of anti-
human CD44 antibody was removed by centrifugation at 1,000 rpm for 5 min and three 
washing steps with 1× PBS (pH 7.4) buffer. The cells were then resuspended in 800 µL of 
1× PBS (pH 7.4), filtered using a 70 µm nylon cell strainer (BD Biosciences, NJ, USA), and 
collected into test tubes. The flow cytometry analysis was then performed using a LSR II 
flow cytometer (BD Biosciences, NJ, USA), with a laser excitation wavelength of 488 nm, 
and a 610/620 nm detector filter. 
In addition, flow cytometry analysis was also performed to quantitatively measure the 
cellular association and internalization of the various nanoplatforms in MDA-MB-231 
(I−IV) and MCF-7 (I−II) breast adenocarcinoma cells. For all the experiments, the cells 
were harvested, as previously described (Section 4.5.1), resuspended in the corresponding 
cell culture media, seeded in 6-well plates (Corning Inc. Life Sciences, NY, USA) and 
incubated overnight at 37 ºC to allow cells attachment to the wells. The attached cells were 
then washed twice with HBSS−HEPES buffer (pH 7.4), before exposing them to the 
different fluorescently labelled nanoparticles. 
In the studies I and II of this thesis, MDA-MB-231 and MCF-7 cells were seeded in 
the 6-well plates at a cell density of 7 × 105 cell per well exposed to FITC-labelled 
UnTHCPSi and UnHA+ nanoparticles (50 and 100 µg.mL−1) (I), as well as FITC-labelled 
UnTHCPSi, UnP and UnPP nanoparticles (50 µg.mL−1) (II), for 6 h at 37 ºC. The cells were 
then detached using 300 µL of 0.25% trypsin–PBS–EDTA solution, centrifuged for 3 min 
at 500 rpm and washed three times with HBSS−HEPES buffer (pH 7.4) in order to remove 
the non-associated nanoparticles. Prior to the flow cytometry analysis, the cells were fixed 
with 2.5% glutaraldehyde in 0.1 M of PBS (pH 7.4) for 30 min and resuspended in 700 µL 
of HBSS-HEPES buffer (pH 7.4). In addition, in the study II, the fluorescence of the 
nanoparticles associated to the surface of the cell membrane was quenched by exposing the 
cells to a 0.005% (v/v) trypan blue (TB) solution before cell fixation, followed by three times 
washing.  
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The same experiments were conducted in the studies III and IV. In this case, 6 × 105 
MDA-MB-231 cells were seeded in the same 6-well plates. After the aforementioned 
attachment and washing, the cells were incubated with 3.5 mL of AF488-labelled 
UnTHCPSi, UnCPP and UnAuCPP nanosuspensions at the concentration equivalent to 10 
µg.mL−1 of UnTHCPSi for 1 and 3 h at 37 ºC (III), as well as with the same volume of FITC-
labelled UnCAD and UnCAD@CPP suspensions at the UnTHCPSi concentration of 20 
µg.mL−1, for 1, 3 and 6 h at 37 ºC (IV). With the aim of removing the unassociated 
nanoparticles, the cells were washed three times with HBSS−HEPES buffer (pH 7.4), 
detached with 3.5 mL of 0.25% trypsin–PBS–EDTA solution and washed again twice with 
the same buffer. Contrarily to the studies I and II, the flow cytometry analyses were carried 
out in alive cells, which were resuspended in 700 µL of HBSS−HEPES (pH 7.4) and kept in 
ice until the time of measurement. All the flow cytometry analyses were performed using a 
LSR II flow cytometer (BD Biosciences, NJ, USA), with a laser excitation wavelength of 
488 nm. A minimum of 10,000 events per sample were recorded using a FACSDiva 
software. The data presented are representative of three independent experiments, and were 
analysed and plotted using Flowjo 7.6 software (Tree Star, OR, USA). 
?????????????????????????????????????????????????????????????????
The intracellular trafficking and endosomolytic properties of the engineered nanoplatforms 
were studied by confocal fluorescence microscopy with MDA-MB-231 (II−IV) and MCF-
7 (II) cells. In all the experiments performed, the cells were harvested, resuspended in the 
suitable cell culture media, seeded in Lab-Tek® 8-chamber slides (Thermo Scientific, 
Thermo Fisher Scientific, MA, USA) and allowed to attach at 37 ºC. Thereafter, the cells 
were exposed to the various fluorescently labelled nanoparticulate systems, and 
subsequently stained for their cellular organelles, as described in detail in this section.  
For the study II of this thesis, MDA-MB-231 and MCF-7 cells were seeded at a density 
of 5 × 104 cells per chamber. After 24 h incubation, the cell medium was removed and 
replaced with 200 µL of FITC-labelled UnTHCPSi, UnP and UnPP nanoparticle suspensions 
in HBSS−HEPES (pH 7.4) at the concentration of 50 µg.mL−1, whereupon the cells were 
incubated for 6 h at 37 ºC. Next, the nanoparticle suspensions were removed and the cells 
were washed three times with HBSS−HEPES buffer (pH 7.4). The acidic organelles of the 
cells were stained with 200 µL of LysoTracker® Blue DND-22 (50 nM; Invitrogen, CA, 
USA) for 30 min at 37 ºC. The cells were washed twice with HBSS−HEPES buffer (pH 7.4) 
and, subsequently, the cell membranes were stained by adding 200 µL of Cell Mask™ Deep 
Red® (3 µg.mL−1; Invitrogen, CA, USA) for 3 min at 37 ºC. Finally, the cells were washed 
twice with HBSS−HEPES buffer (pH 7.4) and fixed using a 2.5% glutaraldehyde solution 
for 20 min.  
In the studies III and IV, 5 × 104 (III) or 4 × 104 (IV) MDA-MB-231 cells were seeded 
in each chamber of the 8-chamber slides and incubated for 48 h at 37 ºC to allow the cell 
adhesion. After removal of the cell culture medium, the cells were carefully rinsed with 
HBSS−HEPES buffer (pH 7.4) and treated with 250 µL of AF488-labeled UnTHCPSi, 
UnCPP and UnAuCPP nanoparticles (III), as well as FITC-labelled UnCAD, 
UnCAD@CPP and CPP nanoparticles (IV) suspensions in HBSS−HEPES (pH 7.4) + 10% 
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FBS, at a concentration corresponding to 20 µg.mL−1 of UnTHCPSi nanoparticles, for 1, 3 
and 6 h (only in study III) at 37 ºC. The nanoparticle suspensions were then removed and 
the unassociated nanoparticles were washed out three times with HBSS−HEPES buffer (pH 
7.4). Thereafter, the staining of the acidic cellular compartments was performed by 
incubation of the cells with 300 µL of 500 nM LysoTracker® Red DND-99 (Invitrogen, CA, 
USA) for 30 min at 37 ºC. In the samples corresponding to the cells exposed to bare CPP 
nanocomplexes (IV), the cell membrane was stained by adding 300 µL of a CellMask™ 
Deep Red® staining solution (5 μg.mL−1; Invitrogen, CA, USA) for 3 min at 37 ºC. The 
excess of tracking agents was removed by washing the cells twice with HBSS−HEPES 
buffer (pH 7.4). The cells were then fixed with 4% paraformaldehyde (PFA), for 15 min, 
and washed again twice with HBSS−HEPES buffer (pH 7.4). Afterwards, the nucleus of the 
cells was stained with 300 µL of 4’,6-diamidino-2-phenylindole (DAPI) for 6 min, followed 
by a final five-time washing step with HBSS−HEPES buffer (pH 7.4).  
Finally, the samples were analysed under an inverted confocal fluorescence 
microscope (Leica SP5 II HCS A, Wetzlar, Germany). The images obtained in the study 
(III) were processed using the ImageJ 1.50i software (National Institutes of Health, MD, 
USA). 
????????????????????????????????????????????????
The in vitro chemotherapeutic effect of MTX and MTX-loaded UnTHCPSi, UnP and UnPP 
nanoparticles was evaluated by measuring the antiproliferative effect on MDA-MB-231 and 
MCF-7 breast cancer cells (II), using the ATP-based cell viability assay described in the 
Section 4.5.2.1. Typically, MDA-MB-231 and MCF-7 cells were harvested, resuspended in 
RPMI 1640 and DMEM media, respectively, seeded in 96-well plates (Corning Inc. Life 
Sciences, NY, USA) at a cell density of 1.5 × 105 cells per well, and allowed to adhere 
overnight at 37 ºC. After that, the cell media was replaced with 100 µL of MTX-loaded 
UnTHCPSi, UnP and UnPP nanoparticle suspensions with different concentrations, and the 
cells were incubated for 6 h at 37 ºC. In addition, cells were similarly treated with pure MTX 
solutions, at concentrations corresponding to the drug-loaded nanoparticles. Moreover, 
HBSS−HEPES buffer (pH 7.4) and 1% Triton X-100 were used as negative and positive 
controls, respectively. After incubation, 100 µL of CellTiter-Glo® reagent assay (Promega 
Corporation, WI, USA) was added to each well and the luminescence was measured using a 
Varioskan™ Flash Multimode Reader (Thermo Scientific, Thermo Fisher Scientific, MA, 
USA).  
The antiproliferative effect of SFB-loaded UnTHCPSi, UnCPP and UnAuCPP 
nanocomposites was also evaluated on MDA-MB-231 breast cancer cells (III), after 6 and 
24 h of cell exposure to the different SFB-loaded nanoparticle suspensions, at the 
concentrations equivalent to 6.25, 12.5, 25, 50 and 100 µg.mL−1 of UnTHCPSi, and 
following the same protocol as described above (Section 4.5.2.1). All the data sets were 
compared to the negative control, considered as 100% cell proliferation, and were performed 
at least in triplicate. 
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?????????????????????????
???? ??????????? ????? ?????????????????? ??? ??????? ????????
??????????????????????????????????????????????
The successful application of nanoparticulate drug delivery systems in cancer therapy is 
highly dependent on their physicochemical and biofunctional characteristics.66 The surface 
properties of nanoparticles, such as surface charge, hydrophobicity, surface chemistry and 
presence of functional groups, can significantly influence their cellular interactions, as well 
as the adsorption of plasma proteins and the protein corona formation, which may ultimately 
impact the biofate and biological performance.67,70,339,340 In addition, the surface 
functionalization of nanoparticles with targeting moieties can significantly improve the 
blood circulation longevity and accumulation at the targeted tumour site, increasing the 
affinity and specificity in tumour cells, enhancing the cellular interactions and intracellular 
penetration.341,342 
In this context, a PSi-based targeting nanosystem was developed by biofunctionalizing 
the surface of UnTHCPSi nanoparticles with an amine-modified HA derivative, aiming at 
increasing the specific cellular interactions and uptake of this nanoplatform by targeting 
CD44-overexpressing cancer cells, and improving the colloidal and plasma stabilities. Both 
bare and HA+-modified UnTHCPSi nanoparticles were characterized, and subsequently 
compared in terms of stability in aqueous medium and human plasma. Furthermore, the 
HA+-mediated targeting of the developed nanosystem was evaluated towards CD44-
overexpressing cells, after assessing the expression levels of the targeted receptor in two 
different breast cancer cell lines. 
?????????????????????????????????????????????????????????????????????
The UnTHCPSi nanoparticles used in this study were initially characterized for their 
physical properties, presenting a specific surface area of 218 ± 3 m2.g−1, a total pore volume 
of 0.63 ± 0.01 cm3.g−1, and an average pore diameter of 12.2 ± 0.4 nm. Additionally, the 
hydrodynamic size, PdI and ζ-potential of both bare and HA+-conjugated UnTHCPSi 
nanoparticles were determined by DLS and ELS, respectively (Figure 8), and their 
morphology was investigated by TEM (Figure 8).  After functionalization, the size of the 
nanoparticles was increased from 208.1 ± 1.6 nm to 228.3 ± 2.6 nm, and the ζ-potential 
altered from −41.6 ± 1.5 mV to −17.7 ± 0.4 mV, possibly owing to the presence of free 
amine groups from the HA+ conjugated on the nanoparticles’ surface. The UnTHCPSi and 
UnHA+ nanosparticles presented PdI values of 0.07 ± 0.01 and 0.09 ± 0.02, respectively, 
therefore indicating high monodispersities of both the nanoparticles suspensions. The results 
obtained suggest a successful conjugation of HA+ onto the UnTHCPSi nanoparticles’ 
surface. 
In addition, the HA+-modified UnTHCPSi nanoparticles showed significantly 
improved colloidal stability, relative to bare counterparts, as evidenced by the similar 
macroscopic appearance of both the nanoparticles suspensions, after re-dispersion in 
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HBSS−HEPES buffer (pH 7.4) and storage at room temperature for 4 h (Figure 8). The 
intrinsic instability of the UnTHCPSi nanoparticles in aqueous environment results from 
their hydrophobic surface and consequent tendency for reducing the interfacial area, leading 
to a reduced dispersibility and aggregation phenomena over time. Contrarily, the conjugation 
of HA+ at the nanoparticles surface contributes for the stabilization in aqueous solutions by 
steric hindrance, due to the solvation of the polymer chains.343-345 
 
Figure 8. (A) TEM images of the UnTHCPSi and UnHA+ nanoparticles with the scale bars 
representing 100 nm. (B) Colloidal stability of UnTHCPSi and UnHA+ nanoparticles, after 
incubation in HEPES buffer (pH 7.4), for 4 h at room temperature. (C−E) Characterization 
of the particle size distribution (C), PdI (D) and ζ-potential (E) of the UnTHCPSi and 
UnHA+ nanoparticles. Bars represent the mean ± s.d. of at least three independent 
experiments (n ≥ 3). (F) FTIR absorbance spectra of HA (a), HA+ (b), UnHA+ (c) and 
UnTHCPSi (d) with relevant features of each spectrum highlighted and numbered for 
clarification. Copyright © (2014) The Royal Society of Chemistry. Adapted and reprinted 
with permission from ref.346. 
 53 
The FTIR spectra of HA, HA+, UnTHCPSi and UnHA+ nanoparticles were obtained 
to first confirm the amine modification of HA and further corroborate the conjugation of the 
resulting HA+ onto the nanoparticles’ surface (Figure 8F). The prominent C−O band at the 
900−1200 cm−1 identifies the carbohydrate chain of HA, which is characteristic of 
polysaccharides. Moreover, the chemical structure of HA features two bands related to the 
amides I and II at ca. 1670 cm−1 (Figure 8F-a1) and 1540 cm−1 (Figure 8F-a3), as well as 
the stretching bands at 1607 cm−1 (Figure 8F-a2) and 1400 cm−1 (Figure 8F-a4), 
corresponding to the carboxylate C=O and C−O stretching vibrations, respectively.347,348 
Next, the HA was modified with NH2-PEG2-NHBoc on the carboxylic acid groups by a 
carbodiimide-mediated reaction. According to the spectrum of the resulting HA+ (Figure 
8F-b), the basic chemical structure of HA was preserved, and the success of the amine-
modification through amide bonding could be confirmed by the emergence of a broad band 
at ca. 1680 cm−1 (Figure 8F-b1) and a band at 1550 cm−1 (Figure 8F-b2). Regarding the 
UnTHCPSi nanoparticles, a broad band between 900 and 1200 cm−1 and a C=O stretching 
at 1715 cm−1 are visible in the corresponding spectra (Figure 8F-d), related to the Si−C 
structure and carboxylic acid groups, respectively. After surface functionalization of the 
UnTHCPSi nanoparticles with HA+, the spectrum of UnHA+ (Figure 8F-c) exhibited the 
formation of an amide I bond, resulting from the covalent conjugation of HA+, recognisable 
by the broad absorption band at 1640 cm−1 (Figure 8F-c1). In addition, the amide II bond 
structure of HA+ corroborates the accomplishment of the chemical conjugation. The FTIR 
results herein confirm the successful synthesis of the HA+ and its subsequent conjugation 
onto the surface of UnTHCPSi nanoparticles, both attained via EDC/NHS coupling 
chemistry. 
Ideally, the nanoparticulate systems that are envisioned to be administered 
intravenously should minimally interact with the plasma proteins, in order to avoid the 
formation of protein corona, which may lead to aggregation, rapid opsonisation by the MPS 
and clearance from the body.271,349 For circumventing this problem, nanoparticles can be, for 
example, functionalized with different polymeric moieties, thus modifying their surface 
properties and minimizing the interaction with plasma proteins.230,350 In this regard, the 
effect of the HA+ functionalization of UnTHCPSi nanoparticles on the protein corona 
formation was evaluated by monitoring and comparing changes in the physicochemical 
properties of both UnTHCPSi and UnHA+, namely their size, PdI and ζ-potential, after 
incubation with human plasma at 37 ºC for 2 h (Figure 9). Immediately after contact with 
human plasma, the size of the bare UnTHCPSi nanoparticles increased from ca. 200 nm to 
ca. 600 nm, suggesting a rapid adsorption of the plasma proteins onto the surface of these 
nanocarriers. Contrarily, no significant variation in the particle size was observed for the 
UnHA+ nanoparticles throughout the incubation period tested (Figure 9A). Additionally, the 
UnHA+ nanosuspension showed to remain relatively monodisperse in human plasma, 
presenting PdI values of ca. 0.2, in contrast with the bare counterparts, the polydispersity 
values of which were increased above 0.5, presumably owing to protein corona formation 
and aggregation of the nanoparticles (data not shown). Moreover, the adsorption of the 
plasma proteins onto the UnTHCPSi nanoparticles surface resulted in an attenuation of the 
ζ-potential values from ca. −42 mV to −15 mV, while the surface charge of the UnHA+ 
remained constant during the experimental period (Figure 9B).   
 54 
 
Figure 9. Effect of the human plasma protein adsorption on the size (A) and ζ-potential (B) 
of the UnTHCPSi and UnHA+ nanoparticles after incubation with human plasma for 120 
min at 37 ºC. Values are represented as mean ± s.d. (n ≥ 3).  Copyright © (2014) The Royal 
Society of Chemistry. Adapted and reprinted with permission from ref.346. 
As evidenced by the minimal variations in the nanoparticles size, PdI and ζ-potential 
of the UnHA+ nanoparticles over time, the HA+ conjugation was revealed to effectively 
minimize the plasma protein adsorption, protein corona formation and particle aggregation, 
as a result of the highly hydrophilic properties, thus significantly improving the stability of 
UnTHCPSi nanoparticles in human plasma. When foreseeing intravenous administration, 
this effect might have a significant contribution for minimizing the opsonisation by the MPS 
and increasing the blood half-life and tumour accumulation of the developed 
nanoformulation.351-353 
??????????????????????????????????????????????????????????????????
Before investigating the impact of the HA+-functionalization of UnTHCPSi nanoparticles 
on the targeting of CD44-overexpressing cells, the CD44 expression was assessed in both 
MDA-MB-231 and MCF-7 breast cancer cells (Figure 10). For this purpose, the cells were 
primarily stained with three different concentrations of PE-CF594-labeled anti-human CD44 
antibody, and subsequently analysed by flow cytometry. The increase in the mean 
fluorescence intensity (MFI) of the stained cells, compared with the respective negative 
controls, showed that both the cell lines studied expressed the CD44 receptor. Furthermore, 
the data presented suggested significantly higher levels of CD44 expression in MDA-MBA-
231 than in MCF-7 cells. As shown in Figure 10, the MFI of MCF-7 cells was increased ca. 
9-fold, independent of the anti-human CD44 antibody concentration used, when compared 
with the negative control, thus suggesting a saturation of the complementary antibody 
binding sites. Contrarily, the fluorescence signal of the MDA-MB-231 cancer cells  was 
successively increased up to ca. 670-fold, with increasing anti-human CD44 
concentration.354  
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Figure 10. Flow cytometry analysis of the CD44 expression in MDA-MB-231 and MCF-7 
breast cancer cells. The cells were incubated with PE-CF594-labeled anti-human CD44 
antibody at the concentrations of 2.5, 5.0 and 10.0 µg.mL−1, for 45 min at 4 ºC. The flow 
cytometry histograms of the stained and unstained (control) cells were obtained, and the 
correspondent mean fluorescence intensity was quantified and subsequently compared for 
evaluating the CD44 expression in both the cell lines. Error bars represent mean ± s.d. (n ≥ 
3). Statistical analysis was performed by means of Student’s t-test, with the level of 
significance set at probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Copyright © 
(2014) The Royal Society of Chemistry. Adapted and reprinted with permission from ref.346. 
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In order to evaluate the effect of HA+ on the cellular association of the nanoplatforms 
with MDA-MB-231 and MCF-7 breast cancer cells through a CD44-mediated targeting 
mechanism, both the cell cultures were incubated with FITC-labelled UnTHCPSi and 
UnHA+ nanosuspensions at the concentrations of 50 and 100 µg.mL−1, for 6 h at 37 ºC, and 
subsequently analysed by flow cytometry (Figure 11). 
Incubation of both the cell lines with bare UnTHCPSi nanosuspension at the lower 
concentration did not result in significant variations of the fluorescence intensity, when 
compared to the respective control samples. In addition, when the nanoparticle concentration 
was increased to 100 µg.mL−1, an increment of the cellular association was observed in a 
similar extension for both the cell lines, meaning that the interaction with the cells was 
unspecific. Contrarily, in the case of UnHA+ nanoparticles, a considerable enhancement of 
the fluorescence intensity was observed, particularly in the CD44-overexpressing MDA-
MB-231 cells, also at the lower nanoparticle concentrations. Moreover, the treatment with 
the highest concentration of the HA+ modified-nanoparticles resulted in a significant 
intensification of the fluorescence signals, in the order of 29.5 and 8.3-fold for MDA-MB-
231, as well as 4.9 and 1.8-fold for MCF-7 cells, relatively to the corresponding negative 
controls and bare counterparts, respectively. 
 
Figure 11. Flow cytometric analysis of the cellular association of UnTHCPSi and UnHA+ 
nanoparticles with MDA-MB-231 and MCF-7 breast cancer cells. The cells were incubated 
with the nanoparticles suspensions at the concentrations of 50 and 100 µg.mL−1, for 6 h at 
37 ºC. Copyright © (2014) The Royal Society of Chemistry. Adapted and reprinted with 
permission from ref.346. 
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Overall, the HA+-functionalization of bare UnTHCPSi nanoparticles considerably 
augmented the cellular interactions of these nanosystems, particularly and more significantly 
with the CD44-overexpressing MDA-MB-231 cells, contrarily to the bare counterparts, 
which evidenced a concentration-dependent and cell type-independent cellular association. 
Therefore, and in agreement with the data presented above for the CD44 expression in both 
the cell lines studied, these results suggested that the conjugated HA+ mediated and enhanced 
cellular association and internalization through a CD44-targeting mechanism. 
?????????????????????? ????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
In addition to the surface functionalization of nanoparticulate systems with targeting 
moieties for enhanced cellular specificity, association and internalization, several strategies 
have been exploited for improving the performance at cellular and intracellular levels.355,356 
An example of such approach consists of the surface conjugation of cell-penetrating peptides 
to enhance the cellular interactions and uptake of nanoparticles, despite several drawbacks, 
including low metabolic stability, possible immunogenicity, and dependency of an effective 
membrane translocation on the amino acid arrangement and orientation upon conjugation to 
the nanoparticles surface.357,358 As an attractive alternative approach, the nanoparticles 
surface can be modified with functional polymers, both for manipulating the intrinsic 
physicochemical properties, such as smoothness, size, shape, surface charge, hydrophilicity, 
polydispersity, and stability, and for improving the non-specific cellular interactions, uptake, 
intracellular trafficking, and drug release profiles, with the ultimate aim of attaining a desired 
therapeutic effect.238,359,360  
Despite the remarkable physicochemical and biological properties of PSi 
nanoparticles, the limited cellular association and internalization, and subsequent incapacity 
to breach out from the endosomal compartments, still stand as major deadlocks defying the 
successful implementation of these nanocarriers as effective anticancer drug delivery 
systems. In this regard, a bilayered zwitterionic nanocomposite was developed by 
successively conjugating PEI and PMVE-MA polymers onto the surface of UnTHCPSi 
nanoparticles. This approach aimed at improving the limited cellular association and 
internalization of the UnTHCPSi nanoparticles, while complementing them with 
endosomolytic properties, through incorporation of free amine groups from the 
hyperbranched PEI disguised by the biocompatible and bioadhesive PMVE-MA polymer. 
The resulting nanoplatform, termed UnPP, was studied in vitro in terms of cytocompatibility, 
cellular interaction and uptake, and capability to induce endosomal escape in breast cancer 
cells. Additionally, the nanosystem was loaded with the chemotherapeutic drug MTX and 
further evaluated for drug release profile and antiproliferative effect in the same in vitro 
model. 
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Despite the potential of cationic polymers, such as PEI, for enhancing the cellular 
internalization and inducing the early escape from endosomal compartments,361,362 these 
materials have previously shown to create overt pores in the cellular membrane and, 
consequently, to disturb the homeostasis of ions and proteins that are essential for the normal 
cell function, eventually leading to an increased cytotoxicity.363,364 Thus, the design and 
development of specific polymer-modified nanostructures with improved intracellular 
trafficking and cytoplasmatic release profiles of the active payloads, while simultaneously 
avoiding cytotoxicity, is essential for their application in cancer nanomedicine. 
Therefore, in order to assess the in vitro cytotoxicity of both the bare and polymer-
modified UnTHCPSi nanoparticles, as well as to understand the importance of the outer 
PMVE-MA polymer layer on the cytocompatibility of the developed nanosystems, the ATP 
activity of both MDA-MB-231 and MCF-7 breast cancer cells was evaluated after exposure 
to different concentrations of the nanoparticles for 6 and 24 h at 37 ºC (Figure 12).24,212 
 
Figure 12. Cell viability of MDA-MB-231 (A and B) and MCF-7 (C and D) breast cancer 
cells, after exposure to UnTHCPSi, UnP and UnPP nanoparticles suspensions at the 
concentrations of 25, 50 and 100 µg.mL−1 for 6 h (A and C) and 24 h (B and D) at 37 ºC. All 
data sets were compared to the negative control (HBSS buffer, pH 7.4). Error bars represent 
mean ± s.d. (n ≥ 3). Statistical analysis was performed by means of one-way ANOVA with 
the level of significance set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001. 
Copyright © (2014) Elsevier B.V. Adapted and reprinted with permission from ref.365. 
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According to Figure 12, the bare UnTHCPSi nanoparticles showed a satisfactory non-
toxic effect in both the cell lines during the incubation period tested, which can be attributed 
to the negative surface charge, low aqueous stability and consequent low cellular interactions 
of these nanosystems. Contrarily, the PEI-modified nanocomposites showed high 
cytotoxicity values in both MDA-MB-231 and MCF-7 cells, in a time and concentration 
dependent manner, particularly for the highest concentration of 100 µg.mL−1, owing to the 
free amine groups of the conjugated PEI polymer.366 The subsequent conjugation of PMVE-
MA onto the surface of UnP, masking the free positive charges of PEI, resulted in a 
significantly improved cytocompatibility of the bilayered UnPP nanocomposites. In 
comparison with the HBSS buffer control, no significant cytotoxic effect of UnPP 
nanoparticles was observed after 6 h of incubation with both the cell lines. However, the cell 
viability was considerably decreased after 24 h to ca. 64% for all the concentrations in MDA-
MB-231 cells, and to ca. 83%, for the concentrations of 50 and 100 µg.mL−1 in MCF-7 cells. 
The results obtained suggested that the UnPP nanocomposites can be considered safe for 
drug delivery applications during short incubation times and at concentrations lower than 
100 µg.mL−1. 
????????????????????????????????????????????????????????
In order to understand the performance of UnTHCPSi nanoparticles and the developed 
polymer-modified nanocomposites at the cellular and intracellular levels, both MDA-MB-
231 and MCF-7 breast cancer cells were exposed to different FITC-labelled nanocarriers at 
the concentration of 50 µg.mL−1, for 6 h at 37 ºC, and subsequently analysed by flow 
cytometry and confocal fluorescence microscopy (Figure 13). 
The flow cytometry experiments were conducted before and after quenching the 
fluorescence of the nanoparticles bound to the cell surface, using a TB solution. The overlap 
of the fluorescence corresponding to the control samples and bare UnTHCPSi nanoparticles 
evidenced a negligible cellular association and internalization of these nanocarriers by both 
MDA-MB-231 (Figure 13A) and MCF-7 (Figure 13B) cells, mainly due to their negative 
surface charge, lack of bioadhesivity and low aqueous stability.344 In contrast, a considerable 
increment in the fluorescence intensity was observed for the cells incubated with UnP and 
UnPP nanocomposites, providing a clear evidence of the high cellular association of the 
polymer-conjugated nanoparticles with both the cell lines. Moreover, only the fluorescence 
values of the cells treated with the polymer-modified nanoparticles were partially quenched 
after the TB treatment, thus demonstrating the cellular internalization of these nanosystems 
after 6 h. The results observed for UnP nanoparticles were in agreement with previous 
reports in the literature demonstrating increased interaction of the positively charged 
nanoparticles with the negatively charged moieties of the cell membrane, followed by their 
internalization.367 In the case of UnPP nanoparticles, the strong cellular association can be 
attributed to the high dispersibility of these nanocomposites and the bioadhesive properties 
of the PMVE-MA polymer conjugated on their surface.368,369 Despite the unfavourable 
interaction between the negative surface charge of UnPP nanoparticles and the cell 
membranes, the results were in line with previous evidence of high cellular uptake of anionic 
nanoparticles by different types of cells.370-373 This can be explained by the non-specific 
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binding of the nanoparticles to the scarce cationic domains on the surface of the cell 
membrane, or other mechanisms attributed to the intrinsic properties of polymers, such as 
cell surface targeting or cell penetration functions.374,375 
 
Figure 13. (A−B) Flow cytometric analysis of MDA-MB-231 (A) and MCF-7 (B) breast 
cancer cells after incubation with FITC-labelled UnTHCPSi, UnP and UnPP nanoparticles 
at the concentration of 50 µg.mL−1 for 6h at 37 ºC. The MDA-MB-231 and MCF-7 cells were 
analysed before and after quenching the extracellular fluorescence using TB, for evaluating 
both the cellular association and internalization of the nanoparticles, respectively. The data 
presented is representative of at least two independent experiments. (C−D) Confocal 
fluorescence microscopy analysis of MDA-MB-231 (C) and MCF-7 (D) cells incubated with 
FITC-labelled UnTHCPSi, UnP and UnPP nanoparticles at the concentration of 50 µg.mL−1 
for 6h at 37 ºC. Cells incubated with HBSS buffer (pH 7.4) were used as control. The images 
correspond to the merged and magnified panels of cells stained for their lysosomes and cell 
membranes, using Lysotracker® Blue DND-22 and Cell Mask™ Deep Red®, shown in red 
and blue pseudo-colours, respectively. The nanoparticles located at the outer surface of the 
cell membrane are presented in green colours. The nanoparticles internalized by the cells 
and co-localized with the acidic endosomal compartments are shown in yellow colour. The 
turquoise colour corresponds to the internalized nanoparticles that are located outside of 
the early endosomes and lysosomes. Copyright © (2014) Elsevier B.V. Adapted and 
reprinted with permission from ref.365. 
Considering the fact that drug loaded nanoparticles entrapped in endosomes and 
lysosomes are subjected to degradation by specific enzymes, the endosomal escape of the 
developed polymer-conjugated nanocomposites is a critical requisite for an effective 
therapeutic outcome.245 Therefore, the intracellular trafficking and endosomal escape of the 
UnTHCPSi, UnP and UnPP nanoparticles were investigated in the MDA-MB-231 and  
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MCF-7 breast cancer cell lines by confocal fluorescence microscopy and simultaneous 
imaging of the FITC-labelled nanoparticles, cell membranes, and the endolysosomal 
compartments of the cells. In accordance to the results previously obtained in the flow 
cytometry experiments, a negligible cellular uptake was observed for the bare UnTHCPSi 
nanoparticles in both the cell lines, while the remarkably enhanced cellular internalization 
of UnP and UnPP nanocomposites was confirmed in both MDA-MB-231 (Figure 13C) and 
MCF-7 (Figure 13D) cells, as elucidated by the turquoise colour in the merged and 
magnified confocal images. Furthermore, it was observed that only a minority of the 
polymer-modified nanoparticles were located inside the acidic endosomal compartments, as 
identified by the overlapped yellow colour, and also that some of the nanoparticles remained 
associated to the outer surface of the cell membrane, predominantly in the MCF-7 cells. 
These observations demonstrated that the polymer-modified nanocomposites were capable 
of efficiently interacting and internalized by the cells, breached out from the endosomal 
compartments and, consequently, localized in the cytoplasm. This phenomenon can be 
plausibly explained by the presence of free amine groups from the hyperbranched PEI layer, 
which were not further conjugated to the outer PMVE-MA layer in UnPP nanoparticles, thus 
inducing endosomal escape via a “proton-sponge” or “endosome buffering” mechanism.376 
Additionally, the endosomal escape of UnPP nanoparticles by the “proton-sponge” effect 
can possibly be amplified as a result of the rapid hydrolysis of the maleic acid amide (MAA) 
bonds, formed by conjugating the carboxyl groups of maleic acid to the amine groups of PEI 
and, consequently, to the dissociation of the PMVE-MA layer in the endosomal acidic 
pH.377,378 Another explanation for the endosomolytic properties of the UnPP nanocomposites 
involves the fusion of the PMVE-MA layer into the lipid bilayer of the acidic compartments, 
leading to its disruption, as previously demonstrated for other specific anionic 
polymers.366,379  
The flow cytometry and confocal fluorescence microscopy results also showed the 
capability of UnP nanocomposites to overpass the cell membranes of MDA-MB-231 cells 
after 6 h of incubation, confirming the fact that the functionalization of the UnTHCPSi 
nanoparticles with PEI efficiently enhanced the cellular association and internalization by 
these cancer cells. In contrast, the cellular uptake of UnP nanoparticles was significantly 
lower in the MCF-7 cells, possibly due to the higher resistance of these cells in comparison 
to MDA-MB-231 cells, as well as to their tendency to form condensed clusters, which 
minimized their interaction with the nanoparticles. 
??????????????????????????????????????????????????????????????????
The bare UnTHCPSi nanoparticles and polymer-modified nanocomposites were loaded with 
the model anticancer agent MTX, a potent drug in breast cancer treatment,380 and the 
different drug loading degrees, before and after polymer conjugation, were investigated. In 
this regard, the presence of both carboxyl and amine groups in the chemical structure of 
MTX increased the probability of interaction with the amine and carboxyl groups of the 
conjugated PEI and PMVE-MA polymers, respectively, thus possibly increasing the loading 
degree of MTX after the polymer-modification of the UnTHCPSi nanoparticles. While the 
bare UnTHCPSi nanoparticles presented a MTX loading degree of 6.4 ± 1.2%, the 
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successive PEI and PMVE-MA conjugations resulted in superior drug loading degrees of 
12.6 ± 0.1% and 14.0 ± 0.5%, respectively. The low MTX loading in the bare UnTHCPSi 
nanoparticles could be attributed to the low affinity and interaction of this hydrophilic drug 
with the intrinsically hydrophobic pores of the nanoparticles. Contrarily, the augmented 
MTX loading degrees observed for the UnP and UnPP nanocomposites suggested that the 
polymeric modification of the UnTHCPSi nanoparticles significantly enhanced the 
interactions with the drug, through establishment of hydrogen and electrostatic bonding 
between the functional groups of the polymers and the active payload.  
Next, the drug release profiles of MTX-loaded UnTHCPSi, UnP and UnPP 
nanoparticles were evaluated in PBS (pH 7.4) over a period of 12 h (Figure 14A). The 
UnTHCPSi nanoparticles showed a burst release of the loaded MTX, within a short period 
of 5 min, owing to the rapid diffusion of the drug from the nanoparticles pores. In contrast, 
the polymeric modification of the UnTHCPSi nanoparticles revealed to sustain the release 
of the active payload, as evidenced by the significantly lower release rates observed for the 
UnP and UnPP nanoparticles, corresponding to a constant drug release up to ca. 95 and 70% 
within the first 3 h, respectively. Thereafter, no significant changes were observed in the 
cumulative drug release throughout the time period tested. A plausible explanation for the 
slower drug release rate from the UnPP nanocomposites, in comparison to the UnP 
counterparts, was the presence of both amine and carboxyl groups from PEI and PMVE-
MA, respectively, which increased the possibility of interactions with the same moieties in 
the MTX structure. These results suggested that the polymer modification of the UnTHCPSi 
nanoparticles surface represents an easy and efficient approach for tuning the release profile 
of active payloads, by capping the porous structure, and establishing hydrogen and 
electrostatic bonding with the loaded drug molecules.238 
To demonstrate that the UnPP nanocomposites can efficiently deliver the anticancer 
payload inside the cells, the antiproliferative effect of MTX-loaded UnTHCPSi and UnPP 
nanoparticles was evaluated in both MDA-MB-231 (Figure 14B) and MCF-7 (Figure 14C) 
breast cancer cells, using an ATP-based activity assay after the exposure to different 
concentrations of drug-loaded nanocarriers for 6 h at 37 ºC. All the data sets were compared 
to the negative control, corresponding to cells incubated in HBSS buffer (pH 7.4) and 
considered as 100% of cell proliferation. The results showed that the free drug and the MTX-
loaded UnTHCPSi nanoparticles presented similar antiproliferative profiles in both the 
cancer cell lines, reducing the cell viability from 90% to less than 35% for MDA-MB-231 
cells, and from 95% to ca. 50% for MCF-7 cells. In turn, the MTX-loaded UnPP 
nanocomposites showed considerably higher cytotoxic effects in both the cell lines tested, 
compared to pure MTX and MTX-loaded UnTHCPSi counterparts. After exposure to the 
MTX-loaded UnPP nanoparticles, the ATP-activity of MDA-MB-231 and MCF-7 cells was 
decreased from 64% to less than 10%, and from 77% to ca. 27%, respectively. The lower 
antiproliferative effect of MTX-loaded UnTHCPSi nanoparticles could be attributed to the 
limited cellular association and uptake of these nanocarriers. In addition, the increased 
cellular internalization of UnPP nanocomposites by MDA-MB-231 cells, relative to MCF-7 
cells, could explain the higher therapeutic efficiency of the MTX-loaded UnPP nanoparticles 
in the former cell line. Considering the intracellular mechanism of action of MTX on 
inhibiting folic acid reductase and DNA synthesis during cellular replication,381,382 the potent 
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therapeutic effect of UnPP nanocomposites could be related with the capability of delivering 
the anticancer payload at higher amounts inside the cells. These results provided a clear 
evidence of the potent therapeutic efficiency of the developed nanoparticulate drug delivery 
systems in breast cancer cells.  
 
Figure 14. (A) Drug release profiles of MTX-loaded UnTHCPSi, UnP and UnPP 
nanoparticles in PBS (pH 7.4) at 37 ºC. (B−C) Proliferation of MDA-MB-231 (B) and MCF-
7 (C) breast cancer cells after exposure to free MTX, MTX@UnTHCPSi and MTX@UnPP 
nanoparticles for 6 h at 37 ºC. In MDA-MB-231 cells, free MTX and MTX@UNTHCPSi 
nanoparticles induced a mild concentration independent reduction on the cell proliferation, 
while the MTX@UnPP nanoparticles showed a potent concentration dependent 
antiproliferative effect. In MCF-7 cells, while the free drug and MTX@UnTHCPSi 
nanoparticles showed to not significantly affect the cell proliferation, the MTX@UnPP 
nanoparticles induced a moderate inhibition of the cell proliferation, independently of the 
concentration tested. Values denote the mean ± s.d. of three independent experiments (n = 
3). Copyright © (2014) Elsevier B.V. Adapted and reprinted with permission from ref.365. 
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???????????????
The surface modification of PSi nanoparticles with functional polymers has been proven to 
circumvent some of the major limitations that have been challenging the establishment of 
this nanoplatform as an effective anticancer drug delivery system. In the previous work, the 
functionalization of the UnTHCPSi nanoparticles with PEI and PMVE-MA showed to 
remarkably enhance the cellular association and endosomal escape and, consequently, 
improve the intracellular delivery and in vitro therapeutic efficacy of the loaded hydrophilic 
anticancer drug, MTX. However, a satisfactory therapeutic efficacy of nanomedicines does 
not only depend on the physicochemical features and biological performance of the 
nanocarrier, but is also affected by the inherent chemical properties of the active payloads, 
such as poor aqueous solubility and low chemical stability. In this regard, PSi nanoparticles 
assume particular relevance for enabling the confinement of hydrophobic drug molecules in 
an amorphous-like form within the porous structure, thus significantly enhancing the 
aqueous solubility of these therapeutics, while preventing their degradation.28,202 
While an extensive research focus has been drawn to the surface functionalization of 
PSi nanoparticles for cancer targeting and therapeutic applications,205,267,271 less attention 
has been paid to the design and engineering of multifunctional PSi@hydrophilic shell 
nanocomposites, mainly owing to methodological impediments and a greater formulation 
complexity. Despite the technical and formulation challenges, the successful development 
of these multifunctional nanosystems holds great promise, stemming from the opportunity 
to modulate the physicochemical and biological properties of the nanoencapsulate, as well 
as to integrate a combination of therapeutic and imaging agents into a nanotheranostic 
system. Therefore, the focus of this third study was to fabricate a multifunctional nano-in-
nanocomplex platform, encapsulating both SFB-loaded UnTHCPSi and Au nanoparticles 
into an electrostatically assembled polymeric nanocomplex composed of a zwitterionic 
amino acid (L-cysteine), a bioadhesive polyanion (PMVE-MA), and an endosomolytic 
polycation (PEI). This innovative nanoformulation was aimed to enhance the cellular 
interactions and intracellular trafficking of the drug-loaded PSi nanocarriers, ultimately 
improving the cytoplasmic delivery and, consequently, the therapeutic efficacy of the loaded 
chemotherapeutic agent. For confirming the applicability of this strategy, the developed 
multifunctional nanosystem was physicochemically characterized and evaluated in vitro for 
cytocompatibility, cellular association and internalization, as well as for endosomolytic, 
cytoplasmic drug delivery and chemotherapeutic properties. 
???????????????????????????????????????
The UnTHCPSi nanoparticles used in this study were physically characterized by a specific 
surface area of 251 ± 16 m2.g−1, a total pore volume of 0.69 ± cm3.g−1 and an average pore 
diameter of 11.1 ± 0.4 nm. The size, PdI and ζ-potential values of the UnTHCPSi 
nanoparticles, CPP nanocomplexes, and UnCPP and UnAuCPP nanocomposites were 
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determined by DLS and ELS, respectively (Table 4). The bare UnTHCPSi nanoparticles 
and the CPP nanocomplexes presented a size of 173.7 ± 3.4 nm and 182.8 ± 0.1 nm, with 
PdI values of 0.10 and 0.14 nm, respectively. The nanoencapsulation of the UnTHCPSi 
nanoparticles into the CPP nanocomplexes resulted in the formation of the UnCPP 
nanocomposites, which exhibited a size of 241.0 ± 4.9 nm and a PdI of 0.18 ± 0.03, and the 
further incorporation of the Au nanoparticles in the formulation originated UnAuCPP 
nanocomposites with 346.2 ± 18.1 nm in diameter and a PdI of 0.24 ± 0.01. The PdI values 
lower than 0.3, for all the nanosuspensions, showed a relative monodispersity of the 
nanoparticles produced. Regarding the surface charge of the developed nanosystems, the 
UnTHCPSi nanoparticles exhibited a negative ζ-potential of −22.2 ± 0.4 mV, owing to their 
surface modification with carboxyl moieties. Oppositely, the CPP nanocomplexes featured 
a very strong positive surface charge of +40.3 ± 1.6 mV, resulting from the free amine groups 
of L-cysteine and hyperbranched PEI polymer. Equally to the CPP nanocomplexes, the 
UnCPP and UnAuCPP nanocomposites presented a positive ζ-potential of +40.1 ± 0.3 mV 
and +38.4 ± 0.3 mV, respectively, thus indicating the successful encapsulation of the 
negatively charged UnTHCPSi and Au nanoparticles into the nanocomplexes. 
Table 4. Physicochemical characterization of the UnTHCPSi, CPP, UnCPP and UnAuCPP 
nanoparticles in terms of size, PdI, ζ-potential, loading degree (LD) and encapsulation 
efficiency (EE) of SFB.a) 
Nanoparticle Size (nm) PdI ζ-potential (mV) LD (%) EE (%) 
UnTHCPSi 173.7 ± 3.4 0.10 ± 0.01 –22.2 ± 0.4 12.3 ± 3.0 ─ 
CPP 182.8 ± 1.0 0.14 ± 0.00 40.3 ± 1.6 ─ ─ 
UnCPP 241.0 ± 4.9 0.18 ± 0.03 40.1 ± 0.3 ─ 99.3 ± 0.1 
UnAuCPP 346.2 ± 18.1 0.24 ± 0.01 38.4 ± 0.3 ─ 99.9 ± 0.0 
a) Values denote the mean ± standard deviation (n ≥ 3). 
For scrutinizing the nanoparticle size and morphology, as well as for verifying the 
nanoencapsulation of UnTHCPSi and Au nanoparticles into the structures of UnCPP and 
UnAuCPP nanocomposites, all the nanoparticulate systems were analysed by TEM (Figure 
15A), where it was possible to visualize the characteristic irregular shape and porous 
structure of the UnTHCPSi nanoparticles. Contrarily, the CPP nanocomplexes showed 
regular spherical structures, and the general particle sizes corroborated the DLS results. 
Additionally, irregular dark contrasted areas, corresponding to UnTHCPSi nanoparticles, 
could be identified within the UnCPP and UnAuCPP nanostructures. Likewise, the TEM 
micrographs of UnAuCPP nanocomposites showed 10 nm spherical Au nanoparticles within 
the polymeric nanocomplexes, highlighted by the green arrows in Figure 15A. 
In order to confirm the chemical composition of the nanostructures observed under 
TEM, particularly regarding the nanostructures identified within the UnCPP and UnAuCPP 
nanocomposites, each of the nanoparticles produced were examined by EDX microanalysis 
(Figure 15B). The spectra of the UnCPP and UnAuCPP nanocomposites clearly exhibited 
the prominent characteristic peak of the Si element at the energy value of 1.74 keV, 
corresponding to the encapsulated UnTHCPSi nanoparticles. In addition, both Au element-
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related peaks could be identified at the energy levels of 2.12 and 9.7 keV in the spectrum of 
UnAuCPP nanocomposites, thus confirming the presence of Au nanoparticles within the 
structure. The described EDX microanalysis corroborated with the physicochemical 
characterization and, therefore, verified the success of the UnTHCPSi and Au nanoparticles 
encapsulation into the UnCPP and UnAuCPP nanocomposites. 
 
Figure 15. Physicochemical characterization of UnTHCPSi, CPP, UnCPP and UnAuCPP 
nanoparticles. (A) TEM images of UnTHCPSi, CPP, UnCPP and UnAuCPP nanoparticles, 
showing the nanoencapsulation of UnTHCPSi and Au nanoparticles into the CPP 
nanocomplexes. Examples of the encapsulated Au nanoparticles are highlighted by the green 
arrows. Scale bars are 100 nm. (B) EDX spectra of UnTHCPSi, CPP, UnCPP and 
UnAuCPP nanoparticles, confirming the presence of Si and Au elements in the composition 
of the UnCPP and UnAuCPP nanocomposites. The peaks corresponding to Cu element drive 
from the TEM grids composition. Copyright © (2017) Future Medicine. Adapted and 
reprinted with permission from ref.383. 
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As previously discussed, major concerns arise from the severe cytotoxicity of PEIs and their 
use in cancer nanomedicine.179,180 Moreover, it is imperative to define a cytocompatible 
concentration range for the developed nanoparticulate systems, prior to their further 
evaluation. Therefore, the cell viability of MDA-MB-231 breast cancer cells was assessed 
by analysing the ATP activity after exposure to the UnTHCPSi, CPP, UnCPP and UnAuCPP 
nanosuspensions at concentrations between 12.5 and 200 µg.mL−1, for 6 and 24 h at 37 ºC 
(Figure 16). 
 
Figure 16. (A−B) In vitro cytotoxicity of UnTHCPSi, CPP, UnCPP and UnAuCPP 
nanoparticles after incubation with MDA-MB-231 breast cancer cells, for 6 h (A) and 24 h 
(B) at 37 ºC. The cell viability was quantified by an ATP-based luminescence assay after 
exposing the cells to the nanoparticle concentrations of 12.5, 25, 50, 100 and 200 µg.mL−1, 
corresponding to the successively darker colours. All the datasets were compared to the 
negative control, corresponding to cells incubated with 10 mM of HBSS−HEPES buffer (pH 
7.4). Error bares denote mean ± s.d. (n ≥ 3). Statistical analysis was performed by means of 
one-way ANOVA with the level of significance set at probabilities of *p < 0.05, **p < 0.01, 
and ***p < 0.001. Copyright © (2017) Future Medicine. Adapted and reprinted with 
permission from ref.383. 
After 6 h of incubation time, the bare UnTHCPSi nanoparticles induced an ATP 
depletion on MDA-MB-231 cells, particularly for the concentrations of 100 and 200 
µg.mL−1, which resulted in a statistically significant decrease in the cell viability to 61.7 ± 
2.5 and 48.6 ± 1.3%, respectively, in comparison with the negative control cells. In contrast, 
for the same exposure period, the CPP, UnCPP and UnAuCPP nanocomplexes showed no 
cytotoxicity in the range of concentrations tested. The cytotoxic effect of UnTHCPSi 
nanoparticles was more clear after 24 h, therefore evidencing a time and concentration-
dependency, while the CPP, UnCPP and UnAuCPP still showed high cytocompatibility 
values, with exception of the 200 µg.mL−1 concentrated nanosuspensions, which decreased 
the cell viability values to ca. 65%. The superior cytocompatibility of the CPP, UnCPP and 
UnAuCPP nanocomposites represented a remarkable attainment, considering the highly 
positive charge of these nanocomplexes, and particularly the well-known cytotoxic 
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properties of the PEI polymer included in these nanoformulations.170,179 The electrostatic 
interaction of the polycationic and cytotoxic PEI with the polyanionic and biocompatible 
PMVE-MA in the CPP nanocomplexes self-assembly process, could possibly reduce the 
cytotoxicity of the former polymer, ultimately resulting in superior cytocompatibility of the 
developed multifunctional nanocomposites.  
?????????????????????????????????????????????????????????????????????
The therapeutic efficiency of the developed multifunctional nanomedicines is highly 
dependent on the capability for overcoming extra- and intracellular barriers, aiming at 
effectively delivering the UnTHCPSi nanoparticles and the therapeutic cargo to the 
cytoplasm of the tumour cells.117 Thus, for investigating the cellular association and 
internalization of UnTHCPSi, UnCPP and UnAuCPP nanoparticulate systems, MDA-MB-
231 breast cancer cells were exposed to the various nanosuspensions at a concentration 
equivalent to 10 µg.mL−1 of UnTHCPSi, for 1 and 3 h at 37 ºC, and subsequent qualitative 
and quantitative analyses were performed by TEM (Figure 17A) and flow cytometry 
(Figure 17B), respectively. In this regard, the presented TEM micrographs were 
representative of MDA-MB-231 cells interacting with the different nanoplatforms, thus 
providing a better understanding on their extra- and intracellular distribution, while the flow 
cytometry analysis enabled the quantification of the cellular association and internalization. 
In agreement with the results presented in the previous study (Section 5.2.2), and according 
to the TEM images (Figure 17A) and corresponding flow cytometry histograms (Figure 
17B), the bare UnTHCPSi nanoparticles showed negligible interactions and endocytosis by 
the cancer cells, which can be possibly explained by the negative surface charge, low 
colloidal stability in aqueous solutions and poor bioadhesiveness of these nanocarriers. In 
contrast, the UnCPP and UnAuCPP nanocomposites did significantly interact with the 
cellular membrane, and were subsequently endocytosed by the cancer cells, as shown in the 
corresponding TEM micrographs. After endocytosis, the nanocomposites exhibited the 
capacity to escape from the endosomal compartments of the cells within a period of 3 h, 
releasing the nanoencapsulated UnTHCPSi nanoparticles in the cytoplasm. These results 
demonstrated the remarkable potential of the CPP nanocomplexes for enhancing the cellular 
association, internalization and endosomolytic capacity of the encapsulated UnTHCPSi 
nanoparticles, releasing these encapsulates into the cytosolic compartment of the cells. The 
improved cellular association and uptake of the UnCPP and UnAuCPP nanocomposites may 
rely on both the positive surface charge of these nanosystems, which enhances and mediates 
the electrostatic interaction with the anionic moieties in the cellular membrane, as well as on 
the intrinsic bioadhesiveness of L-cysteine and PMVE-MA formulating the CPP 
nanocomplexes.369,384 Furthermore, the cationic amine groups and consequent buffering 
properties of the hyperbranched PEI can explain the remarkable capability of the UnCPP 
and UnAuCPP nanocomposites for breaching out from the endosomal compartments, 
probably via the “proton-sponge” mechanism.385 
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Figure 17. Cellular association, internalization, and intracellular distribution of 
UnTHCPSi, UnCPP and UnAuCPP nanoparticles. (A) TEM images and corresponding 
numerically ordered magnifications of ultrathin sections of MDA-MB-231 breast cancer 
cells incubated with the different nanoparticles at the concentration equivalent to 10 
µg.mL−1 of UnTHCPSi, for 3 h at 37 ºC. Cells incubated with 10 mM of HBSS−HEPES 
buffer (pH 7.4) + 10% FBS were used as control. (B) Flow cytometry analysis of the cellular 
association and internalization of UnTHCPSi, UnCPP and UnAuCPP nanoparticles. MDA-
MB-231 cells were incubated with the various nanoparticles at the concentration equivalent 
to 10 µg.mL−1 of UnTHCPSi for 1 and 3 h at 37 ºC. Controls correspond to cells incubated 
with 10 mM of HBSS−HEPES buffer (pH 7.4) + 10% FBS. The UnTHCPSi nanoparticles 
were covalently labelled with Alexa Fluor® 488, prior to encapsulation into the CPP 
nanocomplexes. For evaluating both cellular association and internalization of the 
nanoparticles, the cells were analysed before and after extracellular fluorescence quenching 
with a TB solution, respectively. The results presented are representative of three 
independent experiments. (C) Confocal fluorescence microscopy analysis of MDA-MB-231 
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breast cancer cells, after incubation with UnTHCPSi, UnCPP and UnAuCPP nanoparticles 
at the concentration equivalent to 20 µg.mL−1 of UnTHCPSi, for 1 and 3 h at 37 ºC. Cells 
incubated with 10 mM of HBSS−HEPES buffer (pH 7.4) + 10% FBS were used as controls. 
The UnTHCPSi nanoparticles were covalently labelled with Alexa Fluor® 488, prior to 
encapsulation into the CPP nanocomplexes. The cells were stained with Lysotracker® Red 
DND-99 and DAPI for their acidic endosomal compartments and nucleus, herein 
represented by the red and blue colours, respectively. The green colour denotes the 
nanoparticles interacting at the cells surface or internalized by the cells and evaded from 
the early endosomes and lysosomes, while the nanoparticles co-localized with those 
compartments are shown in yellow colour. Copyright © (2017) Future Medicine. Adapted 
and reprinted with permission from ref.383. 
The TEM analyses were corroborated by the flow cytometry results of the MDA-MB-
231 breast cancer cells exposed to the UnCPP and UnAuCPP multifunctional 
nanocomposites (Figure 17B). In these experiments, a TB solution was used for quenching 
the fluorescence of extracellularly associated nanoparticles. As previously referred to in this 
section, no substantial differences were observed between the fluorescence signals of the 
cells exposed to bare UnTHCPSi nanoparticles and the corresponding negative control 
samples, demonstrating the low cellular interaction and uptake of these nanosystems. 
Contrarily, significantly higher fluorescence intensities were noticed for the cancer cells 
incubated with the UnCPP and UnAuCPP nanocomposites after a 3 h incubation time period, 
representing a solid evidence of the distinguished cellular association properties of these 
nanoplatforms. Interestingly, after the TB quenching, no variation of the fluorescence signal 
was detected, confirming the occurrence of endocytosis and the intracellular localization of 
the UnCPP and UnAuCPP nanocomplexes. 
In order to investigate the capacity of UnCPP and UnAuCPP nanocomplexes to deliver 
the encapsulated UnTHCPSi nanoparticles in the cytoplasm of the cells, and to demonstrate 
the potential of these nanovehicles for cancer therapy, the UnTHCPSi nanoparticles were 
covalently labelled with AF488, and subsequently fabricated to UnCPP and UnAuCPP 
nanocomposites. Next, MDA-MB-231 breast cancer cells were exposed to the different 
nanosuspensions at a concentration equivalent to 20 µg.mL−1 of UnTHCPSi, for 1 and 3 h 
at 37 ºC. Afterwards, the nuclei and endosomal compartments of the cells were stained with 
DAPI and LysoTracker® Red DND-99, respectively, and the samples were analysed by 
confocal fluorescence microscopy (Figure 17C). As previously observed for the TEM and 
flow cytometry analyses, the bare UnTHCPSi nanoparticles were negligibly interacted and 
internalized by the cancer cells. Contrarily, as evidenced in the corresponding merged and 
magnified images presented in Figure 17C, the uptake of the fluorescently-labelled 
UnTHCPSi nanoparticles was significantly higher after the nanoencapsulation into UnCPP 
and UnAuCPP nanocomposites, predominantly after 3 h of incubation. Furthermore, it could 
be inferred that, following endocytosis, the nanocomposites were initially found entrapped 
into the acidic compartments of the cancer cells, as confirmed by the co-localization of the 
fluorescent signals from both the nanoparticles and the endosomes, represented by the 
yellow colour in the merged and magnified confocal panels. Additionally, after 3 h of 
exposure time, a significantly increased endocytosis of the UnCPP and UnAuCPP 
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nanocomposites was observed. The encapsulated UnTHCPSi nanoparticles were 
predominantly found in the cytoplasm of the cells, thus suggesting their endosomal escape, 
elucidated by the emergence of the green fluorescent signal in the overlapped pictures.  
In summary, the results obtained demonstrated the capacity of the CPP nanocomplexes 
to remarkably enhance the cellular interaction and internalization of the UnTHCPSi 
nanoparticles, through the assembly of multifunctional nanocomposites possessing positive 
surface charge and bioadhesive properties. In addition, the CPP nanocomplexes significantly 
improved the intracellular trafficking of the encapsulated UnTHCPSi nanoparticles, 
facilitating their endosomal escape via the “proton-sponge” or “endosome buffering” 
mechanism, and efficiently delivering those to the cytoplasm of the cancer cells.  
???????????????????????????????????????????????????????????????
The therapeutic efficiency and safety profiles of an anticancer drug delivery system depends 
on both the physicochemical properties and biological performance at the extra- and 
intracellular levels, and the ability to effectively deliver the loaded therapeutic agent to the 
cytoplasm of the cancer cells. In this case, the premature drug release of the active cargo 
during circulation of the nanovehicles in the bloodstream, as well as the inefficient protection 
from degradation still remain as bottlenecks encountered in the formulation and application 
of nanomedicines for cancer therapy.386  
SFB was selected as a hydrophobic anticancer drug model,387 and loaded into the pores 
of UnTHCPSi nanoparticles prior to the preparation of the UnCPP and UnAuCPP 
nanocomposites, in order to evaluate the drug loading capacity of the developed nanosystems 
(Table 4). A loading degree of 12.3 ± 3.0% (w/w) was obtained for the SFB@UnTHCPSi 
nanoparticles, and no drug leakage was detected during the nanoencapsulation into the 
UnCPP and UnAuCPP nanocomposites, considering that nearly 100% of the drug amount 
initially loaded into the UnTHCPSi nanoparticles was efficiently encapsulated into the 
assembled nanocomposites.  
After the drug loading, the release profiles of SFB from the different nanocarriers were 
evaluated in HBSS−HEPES (pH 7.4; Figure 18A) and HBSS−MES (pH 5.5; Figure 18B) 
buffer solutions supplemented with 10% FBS for assisting the SFB dissolution, as previously 
reported in the literature.205,264 Approximately 1% of the pure bulk SFB was dissolved in 
both drug release media after 6 h, owing to the extremely low aqueous solubility of the drug. 
Notwithstanding the hydrophobicity, the loading of SFB into the porous matrix of the 
UnTHCPSi nanoparticles resulted in significant improvement of the drug’s dissolution to 
ca. 68 and 43% at pH 7.4 and 5.5, respectively. The enhancement of the SFB’s dissolution, 
and the burst release behaviour exhibited by the SFB@UnTHCPSi nanoparticles resulted 
from the confinement of the drug in amorphous-like form within the porous structure of the 
UnTHCPSi nanoparticles and the inhibition of drug crystallization.311,366 When formulated 
into SFB@UnCPP and SFB@UnAuCPP nanocomposites, the cumulative SFB release  was 
declined to a maximum of ca. 51 and 31% after 6 h, respectively, an effect that was attributed 
to the physical blockage of the UnTHCPSi pores as a consequence of the encapsulation into 
the CPP nanocomplexes, and/or to the electrostatic interactions occurring between the drug 
molecules and the polymeric nanocomplexes. The results presented confirmed the potential 
 72 
of UnTHCPSi nanoparticles for formulating anticancer agents with unfavourable water 
solubility by improving the dissolution rate, and suggested that the developed 
multifunctional nanocomposites could effectively retain the SFB inside their nanostructure, 
avoiding the premature release and, consequently, sustain the release from the UnTHCPSi 
nanoparticles.  
Finally, the in vitro chemotherapeutic effect of the engineered multifunctional 
nanocomposites was investigated by assessing the inhibition of MDA-MB-231 breast cancer 
cells proliferation after 6 h (Figure 18C) and 24 h (Figure 18D) exposure to successively 
increasing concentrations of pure bulk SFB and the various SFB-loaded nanoparticle 
suspensions, all represented in terms of SFB molar concentration. 
?
Figure 18. (A−B) Drug release profiles of pure SFB, SFB@UnTHCPSi, SFB@UnCPP and 
SFB@UnAuCPP in 10 mM of HBSS−HEPES (pH 7.4) + 10% FBS (A) and 10 mM of 
HBSS−MES (pH 5.5) + 10% FBS buffers at 37 ºC. Error bars represent mean ± s.d. (n ≥ 3). 
(C−D) In vitro antiproliferative effect of pure SFB, SFB@UnTHCPSi, SFB@UnCPP and 
SFB@UnAuCPP on MDA-MD-231 breast cancer cells. The cells were exposed to different 
concentrations of the nanoparticles suspended in 10 mM of HBSS−HEPES (pH 7.4) + 10% 
FBS buffer for 6h (C) and 24 h (D) at 37 ºC. The pure SFB samples were prepared by 
suspending the correspondent amount of the bulk drug in 10 mM of HBSS−HEPES (pH 7.4) 
+ 10% FBS buffer, followed by the corresponding dilution with the same solution. All the 
datasets were compared to the negative control, equivalent to the cell viability in 10 mM of 
HBSS−HEPES (pH 7.4) + 10% FBS buffer. Error bars denote mean ± s.d. (n ≥ 3). Copyright 
© (2017) Future Medicine. Adapted and reprinted with permission from ref.383. 
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The pure SFB did not affect the proliferation of MDA-MB-231 cancer cells in the 
experimental conditions and exposure times tested, possibly due to the very low drug 
aqueous solubility, and consequent incapacity to penetrate the cell membranes. Nevertheless, 
the same outcome was observed when formulating SFB into UnTHCPSi nanoparticles. 
Despite enhancing the drug’s dissolution rate, the limited cellular interactions and 
internalization of the UnTHCPSi nanoparticles by cancer cells appeared to be a relevant 
factor limiting the delivery of the chemotherapeutic agent to the intracellular site of action, 
therefore also hindering the antiproliferative effect. In contrast, the SFB@UnCPP and 
SFB@UnAuCPP nanocomposites showed to considerably inhibit the proliferation of the 
breast cancer cells after 24 h, with remarkably low IC50 values of approximately 1.9 and 2.2 
µM, respectively. The superior antiproliferative effect of the nanocomposites could be 
possibly explained by a combination between the attractive physicochemical properties and 
the biological performance of these nanoplatforms. Initially, the high cellular association 
and endocytosis observed for these nanocomposites, as well as their endosomolytic 
properties, enabled the efficient delivery of the nanoencapsulated SFB@UnTHCPSi 
nanoparticles to the cells’ cytoplasm. Thereafter, the enhanced SFB’s dissolution rate, 
resulting from the loading into the UnTHCPSi nanoparticles, played a key role on the 
achieved antiproliferative effect of the malignant cells, even at low concentrations of the 
nanocomposites and SFB. These results provided a robust evidence of the potential of the 
developed UnCPP and UnAuCPP nanocomposites to formulate poorly-water soluble 
anticancer agents and efficiently enhance their cytoplasmic delivery to the targeted cancer 
cells, ultimately improving the chemotherapeutic effect.  
???? ?????????????? ?????????????? ????????? ?????????????
??????? ???????? ?????????????? ???? ???????????????? ????? ?????
??????????????
Despite the attractive and promising features of PSi nanoparticles for cancer nanomedicine, 
particularly when considering the formulation of chemotherapeutic agents with very limited 
aqueous solubility, their successful application in cancer drug delivery is still defied by 
several bottlenecks. Although the previous studies of this thesis have focused on different 
strategies for improving the limited receptor-specific and non-specific cellular interactions, 
cellular uptake and endosomolytic properties of PSi nanoparticles by developing surface-
modified or multistage PSi-based nanocomposites, other challenging drawbacks of these 
nanocarriers include their leaky nature, burst and uncontrolled release of the therapeutic 
cargo, as well as the restraint of loading a single class of drug molecules. For addressing 
these hurdles, numerous strategies have been explored, involving the engineering of surface 
gate capped porous nanoparticles, aiming at developing advanced controlled drug delivery 
systems. In this regard, different biomolecular and supramolecular compounds have been 
anchored on the surface of porous nanoparticles for triggering the release of the active 
payload upon different internal and/or external stimuli, such as changes in the pH, light, 
redox potential, temperature and concentration of certain ions, enzymes or 
biomolecules.266,388-390 However, it is still challenging to engineer a versatile drug delivery 
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platform capable of encapsulating large amounts of various therapeutic/imaging molecules 
without leakage or interference, and of efficiently delivering these active payloads 
intracellularly in a bioresponsive and controlled manner. Therefore, the fourth work of this 
dissertation contemplated the development of an innovative multifunctional nano-in-nano 
platform, idealized for controlled combination drug therapy or for theranostic applications. 
The developed nanocomposite was designed for the triggered and controlled intracellular 
delivery of both hydrophilic and hydrophobic molecules, by simultaneously endorsing 
endosomolytic properties and bioresponsiveness to intracellular reduction gradients through 
chemically defined mechanisms. For materializing this strategy, redox-responsive DNA-
gated UnTHCPSi nanoparticles were encapsulated as a core nanocarrier within the 
previously developed CPP polymeric nanocomplexes. The DNA-capped UnTHCPSi 
nanoparticles were evaluated as redox and DNase responsive nanovehicle for both 
hydrophobic (SFB) and hydrophilic (calcein) model molecules, while being encapsulated 
within the CPP nanocomplexes covalently loaded with FITC via click chemistry, as a model 
drug or imaging agent. In addition, the engineered multifunctional nanocomposites, 
designated here as UnCAD@CPP, were investigated for the intracellular drug release by 
DNA cleavage and redox triggered mechanisms, as well as for the cellular association, 
internalization and capacity to escape the endosomal pathway.  
???????????????????????????? ????????????????????????????
In order to demonstrate the versatility of the developed multifunctional nanocomposites for 
combined drug delivery or theranostic purposes, SFB and calcein were separately loaded as 
hydrophobic and hydrophilic model cargos within the porous structure of the UnTHCPSi 
nanoparticles, as described in the Section 4.3.1. While the loading degree of SFB was 9.3 ± 
0.2% (w/w), a loading value of 29 ± 3 µmol.g−1 was attained for calcein. Despite the 
suitability of UnTHCPSi nanoparticles for loading desirable amounts of both model 
molecules, the direct exposure of the porous matrix to the dissolution medium results in an 
uncontrolled burst release of these payloads. In this case, cystine and 9-aminoacridine were 
consecutively conjugated onto the surface of bare UnTHCPSi nanoparticles, as a redox 
responsive cross-linker and DNA intercalating agent, respectively, prior the loading of the 
active agents. The drug-loaded UnCA nanoparticles were subsequently coated with DNA, 
for controlling the release of the payloads from the nanocarrier through both redox and 
DNase responsive mechanisms. Importantly, a negligible SFB leakage (i.e., <1%) was 
detected during the process of DNA coating, due to the large discrepancy between the 
polarities of the aqueous solution used and the drug molecules. Furthermore, the resulting 
DNA-anchored UnCAD nanoparticles were encapsulated within the CPP nanocomplexes, 
aiming at improving the cell penetrating and endosomolytic properties, as well as enabling 
the application of the assembled UnCAD@CPP nanocomposite for co-drug delivery or 
theranostics purposes. Thus, the sulfhydryl groups of the L-cysteine support the 
straightforward reaction of a wide variety of other functional moieties via thiol-click 
chemistry.391 Here, FITC was used as a model compound to validate the integration into the 
nanocomplexes by a thiol-isothiocyanate click reaction. In addition, the electrostatic 
interaction of isothiocyanate with the amine groups of PEI and L-cysteine contributed to a 
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very efficient and stable encapsulation of these molecules. Therefore, the encapsulation 
efficiency of FITC in both the CPP and UnCAD@CPP nanocomplexes was evaluated and 
compared for different initial amounts of this fluorescent dye (Figure 19A). The results 
showed encapsulation efficiency values above 90% for the initial amounts of FITC lower 
than 45 µg. When the FITC amount was increased to 60 and 90 µg, the encapsulation 
efficiency of the fluorescent dye was significantly decreased to ca. 80 and 60%, respectively. 
Moreover, identical values of the encapsulation efficiency were obtained for both the CPP 
and UnCAD@CPP nanocomplexes, demonstrating that the simultaneous encapsulation of 
both UnCAD and FITC into the CPP nanocomplexes did not interfere with the loading 
efficiency of FITC. 
Next, the release of SFB and calcein from the different nanoparticulate systems was 
investigated under simulated physiological conditions, namely at pH 7.4 and in the presence 
or absence of GSH or DNase. No dissolution of pure SFB was detected in the release 
medium, independently of the presence of GSH or DNase (Figure 19B). The SFB 
dissolution was significantly increased in PBS + 10% FBS (pH 7.4), after the loading into 
the UnTHCPSi nanoparticles (Figure 19B). Despite the enhanced SFB dissolution, the direct 
aperture and exposure of the pores to the release medium prevented the control over the SFB 
release rate from the UnTHCPSi nanoparticles. Therefore, the DNA capping was performed 
for enabling GSH and DNase responsive control over the drug release rate. Consequently, 
no SFB was released from the DNA-anchored UnCAD and UnCAD@CPP nanocomposites, 
after 6 h of incubation in PBS (pH 7.4) lacking the GSH. Contrarily, the SFB release 
occurred after supplementing the release medium with GSH, as a consequence of the cap 
removal through the cleavage of disulphide bond in the cystine chemical structure (Figure 
19C). The slower SFB release rate observed for the UnCAD@CPP nanocomposites, in 
comparison with the UnCAD, could be explained by the slower diffusion of the hydrophilic 
GSH molecules through the CPP polymeric matrix for reducing the disulphide bonds of 
cystine conjugated at the UnCAD surface. Additionally, after being released, some drug 
molecules may have interacted and be retained within the nanocomplex matrix. 
In addition to the GSH responsiveness, the SFB release from the UnCAD and 
UnCAD@CPP nanocomposites could be triggered by the presence of DNase (Figure 19D), 
due to the capability of this enzyme for breaking the DNA structure down to its constituting 
oligonucleotides, thus mediating the drug release. The DNase mediated drug release resulted 
in similar release rates than those corresponding to GSH-triggered drug release, despite the 
slightly higher percentage of SFB released when DNase was present in the medium. This 
phenomenon could be explained by the direct destructive effect of DNase over the DNA 
capping of the UnTHCPSi pores, comparative to the GSH treatment, which in turn resulted 
in the detachment of intact DNA molecules that were still electrostatically interacting with 
the pores surface. Moreover, in the case of UnCAD@CPP nanocomposites, a fraction of the 
DNA coating might have remained at the interface between the UnCAD nanoparticles and 
the CPP nanocomplexes, reducing the SFB release.  
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Figure 19. (A) Encapsulation efficiency of FITC into CPP and UnCAD@CPP 
nanocomplexes, as a function of the initial FITC amount used for loading. (B) Dissolution 
profiles of free SFB and SFB-loaded UnTHCPSi nanoparticles in PBS + 10% FBS (pH 7.4) 
supplemented or not with 10 mM of GSH or 25 U.mL−1 of DNase. (C) GSH-responsive drug 
release profiles of SFB-loaded UnCAD and UnCAD@CPP nanocomposites in PBS + 10% 
FBS (pH 7.4) in the presence or absence of 10 mM of GSH. (D) DNase-responsive drug 
release profiles of SFB-loaded UnCAD and UnCAD@CPP nanocomposites in PBS + 10% 
FBS (pH 7.4), in the presence or absence of 25 U.mL−1 of DNase. (E) GSH-responsive drug 
release profiles of calcein-loaded UnCAD and UnCAD@CPP nanocomposites in PBS + 
10% FBS (pH 7.4) in the presence or absence of 10 mM of GSH. All the error bars represent 
mean ± s.d. (n ≥ 3). Copyright © (2017) Elsevier B.V. Adapted and reprinted with permission 
from ref.392. 
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For confirming the feasibility of loading hydrophilic cargos within the developed 
nanocomposites, in addition to the hydrophobic payloads, the release of calcein was also 
investigated in the presence and absence of GSH (Figure 19E). The calcein loading degree 
and release profiles were determined by fluorescence spectroscopy after developing a linear 
calibration curve for calcein in PBS solution. No fluorescence was detected in the 
supernatant samples after calcein loading into the UnCAD nanoparticles and subsequent 
encapsulation into the CPP nanocomplexes, indicating the absence of compound release 
during this process. Contrarily, the washing steps of bare UnTHCPSi nanoparticles 
performed after calcein loading resulted in more than 95% of calcein release, dropping the 
loaded amount to 3 µmol.g−1. For this reason, the calcein release was not studied for the bare 
UnTHCPSi nanoparticles. In the case of both the UnCAD and UnCAD@CPP 
nanocomposites, no premature calcein release was observed in the absence of GSH, as more 
than 93% of the loaded calcein remained entrapped within the nanoplatforms after the 6 h 
time period tested (Figure 19E). When adding GSH to the release medium, both UnCAD 
and UnCAD@CPP nanocomposites showed remarkable bioresponsive properties by 
sustaining the release of calcein during the same time period.  
Overall, these results demonstrated that the DNA capping of PSi nanoparticles can be 
considered an effective strategy for controlling the intracellular release of different types of 
therapeutic and diagnostic cargos loaded within the PSi pores, through the bioresponsive 
cleavage of disulphide bonds or DNA disintegration. 
???????? ??????????????????????????????????????????????????????
In order to verify the potential of the developed nanocomplexes for the intracellular delivery 
of the encapsulated materials, interactions of bare CPP nanocomplexes with MDA-MB-231 
breast cancer cells were investigated as a function of time, using confocal fluorescence 
microscopy. In Figure 20A, the merged and magnified confocal images corresponding to 
the CPP nanocomplexes demonstrated that these nanoplatforms could extensively interact 
with the cancer cells within 1 h of incubation, and be internalized into the cells over the 
remaining period of time tested. These observations corroborated the results presented in the 
previous study (Section 5.3), and are in line with numerous reports in the literature 
demonstrating the high cellular affinity of nanoparticles containing PEI, owing to the high 
surface positive charge rendered by this polymer.393,394 Furthermore, as previously 
explained, the bioadhesiveness of both PMVE-MA and L-cysteine may importantly 
contribute for the synergistic effects on the superior cellular interactions of the CPP 
nanocomplexes.368,395 
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Figure 20. Time dependent cellular association, internalization, and intracellular 
distribution of CPP, UnCAD and UnCAD@CPP nanoparticles. (A) Confocal fluorescence 
microscopy analysis of MDA-MB-231 breast cancer cells after incubation with CPP 
nanocomplexes at the concentration of 20 µg.mL−1, and UnCAD and UnCAD@CPP 
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nanocomposites at the concentration equivalent to 20 µg.mL−1 of UnTHCPSi for 1, 3 and 6 
h at 37 ºC. Cells incubated with CPP were stained with CellMask™ Deep Red® and DAPI 
for their cell membrane and nucleus, presented in red and blue colours, respectively. FITC-
labelled CPP nanocomplexes located at the cell surface are displayed in green colour, while 
the internalized counterparts are shown in yellow colour. The cells incubated with UnCAD 
and UnCAD@CPP were stained with LysoTracker® Red DND-99 and DAPI for their acidic 
compartments and the nucleus, and are presented in red and blue colours, respectively. The 
cystine of UnCAD was covalently conjugated to NHS-FITC, for fluorescently labelling both 
UnCAD and UnCAD@CPP nanoparticles. The nanocomposites interacting at the cell 
surface or located in the cytosol of the cells can be identified by the green colour, while the 
nanoparticles co-localized with the early endosomes and lysosomes are displayed in yellow 
colour. (B) Flow cytometry of the intracellular localization of the UnCAD and 
UnCAD@CPP nanocomposites in MDA-MB-231 breast cancer cells. The cells were 
incubated with the nanoparticles at the concentration equivalent to 10 µg.mL−1 of 
UnTHCPSi, for 3 h at 37 ºC. Cells incubated with HBSS buffer (pH 7.4) were used as 
controls. For labelling the nanoparticles, the amine groups of cystine in UnCAD were 
covalently conjugated to NHS-FITC. The increased SSC concurrent with enhanced FITC 
fluorescence intensity is representative of an increased intracellular granularity. (C) Flow 
cytometry of the time dependent cellular association of UnCAD and UnCAD@CPP 
nanoparticles with MDA-MB-231 breast cancer cells. The cells were exposed to the 
nanoparticles at the concentration equivalent to 20 µg.mL−1 of UnTHCPSi, for 1, 3 and 6 h 
at 37 ºC. Cells incubated with HBSS buffer (pH 7.4) + 10% FBS were used as controls. The 
cystine of UnCAD was covalently labelled with NHS-FITC fluorescent dye in both UnCAD 
and UnCAD@CPP nanocomposites. The percentage of cell−nanoparticles interactions was 
significantly higher after encapsulation of UnCAD into the CPP nanocomplexes, in a time-
dependent manner. The results presented are representative of three independent 
experiments. Copyright © (2017) Elsevier B.V. Adapted and reprinted with permission from 
ref.392. 
In addition, as supportive evidence of the performance of CPP nanocomplexes to 
deliver the encapsulated bioresponsive UnCAD into the cells, the intracellular granularity of 
MDA-MB-231 breast cancer cells was measured by side scatter (SSC) flow cytometry, after 
3 h of exposure to fluorescently labelled UnCAD and UnCAD@CPP nanocomposites 
(Figure 20B). The performance of this experiment correlated the intracellular granularity 
and cellular uptake depending on the nanoparticle type, size, and the cytosolic dispersity and 
aggregation.396-398 Therefore, this approach could not be considered as conclusive for all 
types of nanoparticulate systems, with preliminary experimental data needed for discerning 
the suitability of SSC analysis for investigating the cellular internalization of nanoparticles. 
The SSC patterns displayed in Figure 20B showed a significant increase in the percentage 
of cells with high SSC, from 18.6% to 55.0%, after encapsulation of the formulation of 
UnCAD nanoparticles into UnCAD@CPP nanocomposites. The observed high localization 
of UnCAD nanoparticles within the intracellular compartments could be considered as an 
important aspect for the design and development of novel advanced multifunctional 
nanosystems with the capability of favourably localizing inside the cells, while 
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simultaneously incorporating different drug molecules, imaging agents, and/or 
biomacromolecules for multiple theranostic purposes. 
The time-dependent association, internalization and cytosolic localization of the 
UnCAD nanoparticles was assessed by flow cytometry before and after encapsulation within 
the CPP nanocomplexes. In this experiment, MDA-MB-231 cells were incubated with 
fluorescently labelled UnCAD and UnCAD@CPP nanoparticles at the concentration 
equivalent to 20 mg.mL−1 for 1, 3 and 6 h at 37 ºC (Figure 20C). The results evidenced 
different time-dependencies on the cellular associations of the UnCAD and UnCAD@CPP 
nanocomplexes. While the percentage of cells interacting with bare UnCAD nanoparticles 
was increased from 37 ± 6% in 1 h to 98 ± 1% after 6 h, the encapsulation within the CPP 
nanocomplexes resulted in over 99% of the cells being associated with the nanocomposites 
immediately within 1 h of exposure. Moreover, when comparing the fluorescence intensity 
of the cells exposed to UnCAD and UnCAD@CPP nanocomposites, after each individual 
incubation timepoint, it was possible to infer that the cellular interaction was significantly 
augmented after the loading of UnCAD nanoparticles into the CPP nanocomplexes. Despite 
the value of this data for understanding the impact of formulating UnCAD into 
UnCAD@CPP nanocomposites, it did not provide comparative information about the 
amount of nanoparticulate systems interacting per cell. Therefore, the MFI of the samples 
was compared for each time point (data not shown), showing that the amount of FITC-
labelled UnCAD nanoparticles interacting with the cancer cells was 9.0 ± 0.6, 3.6 ± 0.1 and 
3.3 ± 0.1 fold higher after 1, 3 and 6 h, respectively, when encapsulated into the CPP 
nanocomplexes. 
Nevertheless, the findings obtained from the flow cytometry experiments did not still 
clarify the localization of the UnCAD nanoparticles within the cell, i.e., whether the 
enhanced fluorescent signal had its origin from the nanoparticles located outside of the 
cellular membrane, inside the acidic compartments or in the cytosol of the cells. Therefore, 
confocal fluorescence microscopy was used for scrutinizing the intracellular trafficking of 
the UnCAD nanoparticles over time, and to further comprehend the impact of the CPP shell 
on their cellular penetration and endosomal escape (Figure 20A). The merged and magnified 
images corresponding to UnCAD nanoparticles showed that these nanocarriers remained 
extensively associated with the outer side of the cell membrane of MDA-MB-231 cells, 
without considerable cellular uptake occurring even after 6 h of incubation, thus indicating 
that the augmented fluorescence signal detected for the UnCAD nanoparticles in the flow 
cytometry tests originated from cell−particle interactions at the cell membrane. In contrast, 
the UnCAD@CPP nanocomposites showed internalization by the cancer cells within 3 h of 
exposure. Interestingly, the UnCAD nanoparticles encapsulated within the CPP 
nanocomplexes were mainly localized inside the endosomal compartments and moderately 
spotted in the cytoplasms of the cells, as evidenced by the yellow and green colours, 
respectively, in the related merged and magnified panels in the Figure 20A. After 6 h, the 
CPP shell of the UnCAD@CPP nanocomposites demonstrated to efficiently breach the 
membrane of the acidic organelles in which they were confined, owing to the cationic amine 
groups of the hyperbranched PEI and consequent “proton-sponge” effect,168,399,400 resulting 
in the release the encapsulated UnCAD nanoparticles in the cytoplasm of the cells. 
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In summary, these finding allowed to conclude that the remarkably improved cellular 
uptake and cytosolic delivery of the developed nanocomposites stemmed from the 
synergistic role of the functional polymers used in the CPP formulation, namely the cell 
membrane binding affinity and intrinsic endosomolytic properties of PEI, as well as the 
bioadhesiveness of L-cysteine and PMVE-MA. Considering the GSH responsiveness of 
these nanocarriers, the higher GSH concentration in reducing intracellular compartments of 
tumour tissues compared to the extracellular environment,401,402 as well as the endosomal 
breaching effect of the CPP nanocomplex shell, it was demonstrated that different 
chemotherapeutic agents can be efficiently delivered to the cytosol of cancer cells when  
simultaneously formulated into the developed multifunctional nanocomposites. 
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In this dissertation, multifunctional PSi-based nanocomposites were designed, developed, 
characterised and investigated in vitro for their biological performance at the cellular level.  
The main aim of this work was to circumvent some of the deadlocks of PSi nanoparticles.  
including colloidal and plasma instabilities, poor cell-targeting efficiency, limited cellular 
association, internalization and intracellular trafficking, as well as premature and 
uncontrolled release of the therapeutic agents, which overall still defy the successful 
application of these nanoplatforms in cancer nanomedicine. 
In the first study, taking advantage of the surface stabilizing properties and CD44 
targeting specificity of HA, an amine-modified HA derivative was synthesised and 
covalently conjugated to the surface of UnTHCPSi nanoparticles. The HA 
biofunctionalization of the PSi nanoparticles was demonstrated to considerably improve the 
colloidal and plasma stability, and to remarkably enhance the cellular interaction and uptake 
by breast cancer cells. Importantly, the developed HA-modified PSi nanoplatforms showed 
a significantly higher affinity to CD44 overexpressing cancer cells, thus providing a clear 
evidence of the capacity to target these cells by a CD44 receptor mediated mechanism. 
The second study reported the development of a bilayered zwitterionic PSi 
nanocomposite with high potential for intracellular drug delivery, by successively 
conjugating PEI and PMVE-MA polymers onto the surface of UnTHCPSi nanoparticles. In 
addition to a satisfactory cytocompatibility profile, the polymer-modified PSi nanoparticles 
showed augmented non-specific cellular association and internalization in the breast cancer 
cells, owing to the biocompatibility and bioadhesivevess of PMVE-MA, as well as improved 
intracellular trafficking. Moreover, the polymeric modification of the PSi nanoparticles 
contributed to increased loading of the anticancer agent MTX, as a consequence of drug 
confinement within the polymeric network, and sustained release, ultimately resulting in a 
potent in vitro antiproliferative effect in breast cancer cells. 
In the third study, a novel PSi-based multifunctional nanocomposite was engineered 
by encapsulating both UnTHCPSi and Au nanoparticles into a self-assembling polymeric 
nanocomplex. This nanoencapsulation strategy not only rendered the PSi nanoparticles with 
superior cytocompatibility, but significantly enhanced the cellular association and 
endocytosis in breast cancer cells. Furthermore, the developed nanocomposites exhibited a 
remarkable endosomolytic effect, enabling the cytoplasmic delivery of the encapsulated PSi 
nanoparticles. In addition, the efficient loading of the chemotherapeutic drug SFB within the 
pores of the encapsulated PSi nanocarriers resulted in a dramatic increase of the drug’s 
aqueous dissolution. Ultimately, the SFB-loaded nanosystems prevented the in vitro 
proliferation of breast cancer cells at very low SFB inhibitory concentrations, thus providing 
a robust evidence of the great promise of these multifunctional nanoplatforms for the 
intracellular delivery of chemotherapeutics. 
In the fourth study, the aforementioned nanocomplexes were used to carry DNA-
anchored UnTHCPSi nanoparticles, as an innovative strategy to fabricate a bioresponsive 
multifunctional PSi-based nanoplatform, envisioned for multidrug delivery or theranostic 
purposes. The potential of the engineered nanocomposites stems from both the versatility to 
load a vast combination of nanoparticulate systems, hydrophilic and hydrophobic drug 
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molecules, as well as fluorescent dyes within the nanostructure, and from the capability to 
efficiently deliver the encapsulated drug-loaded nanoparticles into the cytoplasms of the 
cells, which in turn bioresponsively release the therapeutic cargo in a controlled manner.  
In conclusion, the multifunctional PSi-based nanocomposites engineered and 
evaluated here in vitro have proven to circumvent some of the drawbacks inherent to PSi 
nanoparticles and hold great promise for cancer targeting, (multi)drug delivery, and 
theranostic applications. However, in spite of providing important insights on the 
interactions of the developed nanoparticulate systems at the cellular level, the in vitro models 
used lack the complexity of biological barriers and tumour tissues. Therefore, the full 
realization of the potential of these nanomedicines critically depends on the future evaluation 
of their performance in more complex systems that closely mimic the in vivo scenario of 
human tumours, such as three-dimensional tumour-like spheroids, recently conceptualized 
“organ-on-a-chip” systems, or, preferentially, pre-clinical tumour animal models. In 
addition, from the nanotechnological perspective, it would be extremely exciting and 
challenging to design and engineer a more advanced multifunctional nanoplatform 
integrating the individual attractive features of each of the developed nanocomposites, 
including superior biocompatibility, high stability, active targeting capability, 
controllable/bioresponsive drug release and potential for cancer combined therapeutics 
and/or theranostics. Regardless of these future prospects, this dissertation introduces 
innovative strategies and, overall, represents an advanced and novel contribution for the 
envisioned future implementation of PSi nanoparticles as the next generation of cancer 
nanomedicines. 
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